Pathology In Depth

Library › Endocrine pathology: thyroid, parathyroid, adrenal, paraganglia and pituitary diseases and tumors

Endocrine pathology: thyroid, parathyroid, adrenal, paraganglia and pituitary diseases and tumors

Last reviewed 2026-11-17 by a board-certified pathologist. 201 references.

Non-neoplastic Thyroid Disease: Development, Thyroiditis, Graves Disease and Follicular Nodular Disease

Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), lists tumor-like lesions beside thyroid neoplasms for differential diagnosis. Developmental abnormalities include thyroglossal duct cyst, thyroid dysgenesis and dyshormonogenetic goiter. Thyroid follicular nodular disease (FND; formerly multinodular goiter) is listed among the benign follicular cell-derived lesions without an ICD-O code because its nodules are not regarded as neoplasms (Jung et al. 2022). The CAP Thyroid protocol, version 4.4.0.0, records follicular nodular disease, diffuse hyperplasia (Graves disease), thyroiditis by type and C-cell hyperplasia as optional additional findings in carcinoma resections (CAP 2023).

Related page: Graves Disease and Thyroiditis in Thyroid FNA (thyroiditis and follicular nodular disease on FNA) Related page: Neck Mass FNA and Cystic Neck Lesions (thyroglossal duct cyst and lateral neck cysts on FNA) Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (TSH, free thyroxine, thyroglobulin and thyroid function patterns) Related page: ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System (thyroid peroxidase, thyroglobulin and TSH-receptor antibodies) Related page: Papillary thyroid carcinoma (papillary carcinoma arising in thyroglossal duct cysts, Graves disease and chronic lymphocytic thyroiditis) Related page: Follicular Cell-Derived Thyroid Neoplasms: WHO 2022 Classification, Follicular and Oncocytic Adenoma and Carcinoma, Low-Risk Neoplasms and Invasion Criteria (follicular adenoma, follicular adenoma with papillary architecture and the WHO 2022 classification table) Related page: High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging (C-cell hyperplasia, medullary carcinoma and thyroid lymphoma)

Thyroid embryology and histology

  • Median anlage. The median anlage forms at about 22 days post-conception as a thickened endodermal bud at the foramen cecum on the floor of the tongue. It expands laterally into a bilobed gland and migrates down the neck, connected to the foramen cecum by an epithelial stalk, the thyroglossal duct, which atrophies between 28 and 40 days post-conception (Stoupa et al. 2025).
  • Ultimobranchial bodies. The paired ultimobranchial bodies derive from a more posterior portion of the pharyngeal apparatus and merge with the midline primordium. The merger produces both the thyroid follicles and the parafollicular C cells (Lobo et al. 2026). The two lateral anlagen (ultimobranchial bodies) derive from the ventral recess of the fourth pharyngeal pouch (Stoupa et al. 2025). Lineage tracing has firmly established that C cells are endoderm-derived. They were formerly presumed to arise from the neural crest (Lobo et al. 2026).
  • Thyroid hormone synthesis. NKX2-1, FOXE1 and PAX8 activate SLC5A5 (sodium-iodide symporter), TPO and TG. Thyroid peroxidase oxidizes iodide, iodinates tyrosyl residues of thyroglobulin to monoiodotyrosine and diiodotyrosine and couples them to thyroxine and triiodothyronine. DUOX2 with DUOXA2 generates the hydrogen peroxide for this reaction, and pendrin (SLC26A4) moves iodide into the follicular lumen (Stoupa et al. 2025).
  • Solid cell nests. Solid cell nests are ultimobranchial remnants about 1 mm across, usually in the middle third of the lateral lobes. They consist of non-keratinizing epidermoid cells without intercellular bridges, positive for high and low molecular weight keratins and CEA. Peripheral calcitonin-positive C cells are present in up to 54% of cases. A central lumen lined by mucinous cells and "mixed follicles" lined by both epidermoid and follicular cells can be present (Harach 1988). Solid cell nests were found in 3.3% of 118 completion thyroidectomies (Fuchs et al. 2019). Solid cell nests share p63 positivity and thyroglobulin negativity with sclerosing mucoepidermoid carcinoma with eosinophilia, which is presumed to arise from them (Jung et al. 2022).
  • Calcium oxalate crystals. Birefringent calcium oxalate crystals are present in the colloid of normal thyroid follicles and are rare in parathyroid tissue. Polarized light examination of frozen sections helps separate follicular-patterned parathyroid from thyroid tissue (Wong et al. 2014).

Developmental anomalies of the thyroid

  • Ectopic and lingual thyroid. About 90% of ectopic thyroid tissue occurs at the base of the tongue, and orthotopic thyroid tissue is absent in 70%–80% of patients with lingual thyroid (Patel and Bhatt 2019). Ectopic thyroid tissue is distinguished from metastatic deposits of an orthotopic carcinoma and from other neck masses (Noussios et al. 2011).
  • Thyroglossal duct cyst. In 685 thyroglossal duct remnant cysts, age was bimodal (first and fifth decades; mean 31.3 years) and 76% were infrahyoid. The lining was respiratory and squamous in 51%, respiratory only in 38%, squamous only in 10% and absent in 1%. Thyroid tissue was present in 71% of specimens. Carcinoma was found in 3.2%, all papillary thyroid carcinoma. Recurrence occurred in 3% of patients and followed simple cystectomy far more often than the Sistrunk procedure (Thompson et al. 2016).
  • Lateral aberrant thyroid. Bland thyroid follicles in the capsule of a lateral neck lymph node can coexist with nodal metastases of papillary carcinoma. In one case the intranodal follicles were negative for BRAF VE1 while the primary carcinoma and its overt metastases were positive, suggesting the bland follicles were not metastases. The origin of such benign-appearing intranodal thyroid tissue remains unresolved (Wallace et al. 2022).

Dyshormonogenetic goiter

Dyshormonogenesis is congenital hypothyroidism caused by defective thyroid hormone synthesis in a structurally intact gland. Variants in TG, TPO, SLC26A4, SLC5A5, DUOX2, DUOXA2, IYD and SLC26A7 cause it (Stoupa et al. 2025).

Gene Defect and clinical clue Source
TPO Commonest cause of a total iodide organification defect: release of >90% of accumulated intrathyroidal radioiodine on perchlorate discharge testing Stoupa et al. 2025
DUOX2 and DUOXA2 Partial organification defect; permanent or transient congenital hypothyroidism Stoupa et al. 2025
TG Serum thyroglobulin inappropriately low for the elevated TSH; goiter size variable Stoupa et al. 2025
SLC26A4 (pendrin) Pendred syndrome: congenital sensorineural hearing impairment with enlarged vestibular aqueduct, and diffuse or multinodular goiter with a partial organification defect from about adolescence Stoupa et al. 2025
IYD Normal perchlorate discharge test and raised urinary monoiodotyrosine and diiodotyrosine Stoupa et al. 2025
  • Morphology. In 56 dyshormonogenetic goiters (median age 16 years; 75% before age 24), every gland was enlarged and multinodular, weighing up to 600 g. Nodules were markedly cellular with solid and microfollicular patterns, papillary and insular areas, minimal colloid and marked nuclear atypia. Fibrosis made nodule edges irregular and simulated capsular invasion (Ghossein et al. 1997).
  • Carcinoma mimicry. In 18% of these glands the hyperplasia and atypia led to a mistaken diagnosis of follicular, papillary, medullary or undifferentiated carcinoma. The only other condition with a similar picture is goiter induced by antithyroid drugs (Ghossein et al. 1997).

Thyroid follicular nodular disease (formerly multinodular goiter)

  • Definition. FND is the WHO 2022 term for the multifocal hyperplastic and neoplastic follicular nodules that present clinically as multinodular goiter. The nodules show the histologic findings of nodular hyperplasia. Some are molecularly clonal and resemble adenomas, and encapsulated cellular nodules in FND cannot be separated from follicular adenoma by histology (Jung et al. 2022). The term achieved consensus in the WHO 2022 working group (Baloch et al. 2022). Previous rule (4th edition, 2017): no collective term existed. The WHO 2022 text allows adenomatous nodule, adenomatous hyperplasia, nodular hyperplasia and multinodular goiter as synonyms (Jung et al. 2022).
  • Clonality. In an X-chromosome inactivation study, four of six nodules from multinodular goiters were polyclonal and the two largest were monoclonal, while all six follicular adenomas were monoclonal (Namba et al. 1990). DNA from a multinodular goiter was polyclonal, and three solitary follicular nodules were monoclonal (Hicks et al. 1990).
  • Degenerative changes. Long-standing iodine-deficiency goiters show follicles distended with colloid, fibrosis and calcification (Sande et al. 2023).

Related page: Follicular Cell-Derived Thyroid Neoplasms: WHO 2022 Classification, Follicular and Oncocytic Adenoma and Carcinoma, Low-Risk Neoplasms and Invasion Criteria (follicular adenoma, the solitary encapsulated clonal counterpart, and the encapsulated follicular-patterned lesion table)

Graves disease (diffuse hyperplasia)

  • Pathology and antibodies. In 28 thyroidectomies for Graves disease, severe follicular hyperplasia showed diffuse crowding of small follicles, papillary structures lined by cuboidal cells with round nuclei and scalloping of the colloid. Mild hyperplasia showed little variation in follicle size with scattered thin pseudopapillary projections. The degree of hyperplasia correlated with TSH-receptor antibody levels, while the extent of lymphocytic infiltration, including lymphoid aggregates with germinal centers, correlated with thyroglobulin and thyroid peroxidase antibody levels (Brancatella et al. 2023).
  • Scalloped colloid. Thyroid-stimulating immunoglobulins increased peripheral colloid vacuoles in human thyroid tissue, producing the scalloped colloid of hyperactive glands (Nilsson et al. 1988).
  • Iodide preparation. Preoperative potassium iodide (Lugol solution) was given for 2–3 weeks to increase colloid storage and decrease papillary hyperplasia and vascularity. The histologic evidence for these effects is weak, and the practice is regarded as obsolete (Sande et al. 2023).
  • Antithyroid drug effect. Propylthiouracil produces clear and vesicular change in follicular cells. One case of marked follicular cell pleomorphism after methimazole has been reported, and whether it reflected the drug or the atypia of long-standing hyperthyroidism is unclear (Sande et al. 2023).
  • Radioiodine effect. Radioiodine for hyperthyroidism causes mild acute inflammation and follicular destruction. Long-term effects are severe follicular atrophy, minimal colloid, stromal fibrosis, focal oncocytic metaplasia and random marked nuclear atypia, which can mimic carcinoma on cytology and histology. The changes are diffuse in Graves disease and uneven in toxic nodular goiter (Sande et al. 2023).
  • Carcinoma in Graves disease. In a meta-analysis of 33 surgical series, carcinoma was found in 7% of glands resected for Graves disease (95% CI 4%–12%), without higher odds than in toxic multinodular or toxic uninodular goiter. Of these carcinomas, 88% were papillary and 23% of all carcinomas were solitary papillary microcarcinomas. Patients with coexisting nodules were almost 5 times more likely to have carcinoma (Staniforth et al. 2016).

Related page: Papillary thyroid carcinoma (papillary carcinoma nuclear features that separate it from the papillary hyperplasia of Graves disease)

Chronic lymphocytic (Hashimoto) thyroiditis

  • Spectrum. Hashimoto thyroiditis includes the classic lymphoid goiter, the fibrous variant, the IgG4-related variant, the juvenile form, hashitoxicosis and painless thyroiditis (sporadic or postpartum). All forms show interstitial infiltration by mononuclear cells, mainly lymphocytes. Follicular cells undergo atrophy or oncocytic (formerly Hürthle cell) change. Most forms evolve to hypothyroidism, and the diagnosis rests on thyroid peroxidase and thyroglobulin antibodies with reduced echogenicity on ultrasound (Caturegli et al. 2014).
  • Histology. The parenchyma is effaced by lymphocytes and plasma cells forming lymphoid follicles with activated germinal centers. Fibrous septa accentuate the lobular pattern, fibrosis with follicular atrophy develops in advanced disease, and follicular cells typically undergo oncocytic change (Uccella et al. 2023).
  • IgG4 thyroiditis. Among 105 Hashimoto thyroiditis cases, 28 were IgG4 thyroiditis. Patients were younger, with a lower female-to-male ratio, rapid progression, higher antibody titers, subclinical hypothyroidism and diffuse low echogenicity. Histology showed severe lymphoplasmacytic infiltration, dense stromal fibrosis, follicular cell degeneration, many microfollicles and giant cell or histiocyte infiltration. Predominant interfollicular fibrosis was significantly associated with IgG4 thyroiditis. Interfollicular, interlobular and scar patterns of fibrosis were described, and IgG4 thyroiditis did not completely overlap with the fibrous variant (Li et al. 2012). IgG4 thyroiditis is reported most often in Asian populations (Li et al. 2020).
  • Proposed criteria for IgG4-related thyroid disease. Thyroid enlargement, hypoechoic lesions on ultrasound, elevated serum IgG4 and histology with >20 IgG4-positive plasma cells per high-power field and an IgG4/IgG ratio >30% are the core items. A definitive diagnosis requires all four. A probable diagnosis requires enlargement, hypoechoic lesions and either the histologic item or involvement of other organs (Takeshima et al. 2021). The category includes IgG4-associated Hashimoto thyroiditis, Graves disease and Riedel thyroiditis.
  • Lymphoma risk. Thyroid extranodal marginal zone (MALT) lymphoma arises in a background of Hashimoto thyroiditis, and chronic antigenic stimulation with acquired lymphoid tissue is the proposed mechanism (Teixeira Mendes and Wotherspoon 2017). Diffuse large B-cell lymphoma is the most frequent primary thyroid lymphoma, followed by MALT lymphoma (Pavlidis and Pavlidis 2019).
  • Lithium. Long-term lithium is associated with diffuse lymphocytic thyroiditis with lymphoid follicles, follicular atrophy and variable fibrosis in both hypothyroid and hyperthyroid patients (Sande et al. 2023). A 29-year-old patient on lithium had thyroid antibodies, diffuse goiter, germinal centers and oncocytic cells, and painless thyroiditis and autoimmune thyroiditis were the histologic differential (Shimizu et al. 1997).

Related page: High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging (MALT lymphoma and diffuse large B-cell lymphoma of the thyroid) Related page: Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts (IgG4-related disease tissue thresholds across organs)

Subacute granulomatous (de Quervain) thyroiditis

  • Clinical features. Subacute thyroiditis had an age- and sex-adjusted incidence of 4.9 per 100,000 per year in Olmsted County. Pain was the presenting symptom in 96%. Early transient hypothyroidism was common, permanent hypothyroidism developed in 15%, and recurrence occurred in 4% after 6–21 years (Fatourechi V et al. 2003).
  • Etiology. The disease follows viral infection, including coxsackievirus, adenovirus, mumps virus and echovirus infection, and most patients carry the HLA-B*35 haplotype. Erythrocyte sedimentation rate and C-reactive protein are elevated without leukocytosis, and radioiodine uptake is reduced in the thyrotoxic phase (Toschetti et al. 2025).
  • Gross findings. The gland is asymmetrically enlarged and firm, with a tan-white cut surface and ill-defined nodularity. A localized firm lesion can mimic carcinoma (Prajapati and Hernandez-Prera 2019).
  • Histologic phases. The early phase shows destruction of follicular epithelium, colloid leakage and neutrophil microabscesses, matching the thyrotoxic stage. Lymphocytes, histiocytes and multinucleated giant cells engulfing colloid follow. Interfollicular fibrosis increases in the late phase, matching the hypothyroid stage. Multinucleated giant cells are the histologic hallmark but also occur in other non-neoplastic conditions (Prajapati and Hernandez-Prera 2019).
Giant cell lesion of the thyroid Distribution and morphology Clinical setting Source
Subacute granulomatous thyroiditis Follicle-centered inflammation; giant cells engulfing colloid; early microabscesses; late fibrosis Painful gland after viral illness Prajapati and Hernandez-Prera 2019
Palpation thyroiditis Multifocal; giant cells and macrophages inside isolated follicles Incidental in resections Prajapati and Hernandez-Prera 2019; Carney et al. 1975
Sarcoidosis Interstitial non-necrotizing granulomas without colloid colonization or follicle destruction Systemic disease without thyroid symptoms Prajapati and Hernandez-Prera 2019
Mycobacterial and fungal infection Necrotizing granulomas, caseation, abscesses and acute inflammation; acid-fast or Grocott stains Mainly immunosuppressed patients Prajapati and Hernandez-Prera 2019
Papillary thyroid carcinoma Giant cells in neoplastic follicles or beside papillae; carcinoma nuclear features Painless cold nodule Prajapati and Hernandez-Prera 2019
Type 2 amiodarone-associated thyrotoxicosis Histiocytes and multinucleated cells around disrupted follicles; no lymphocytic infiltrate Amiodarone therapy in a previously normal gland Sande et al. 2023

Other forms of thyroiditis

Entity Clinical setting Pathology Course Source
Postpartum thyroiditis De novo autoimmune thyroid disease, excluding Graves disease, in the first year after delivery; incidence 5.4%; up to 50% of women with first-trimester thyroid antibodies Part of the Hashimoto spectrum (painless lymphocytic thyroiditis) Hyperthyroid then hypothyroid phase in 22%, isolated hypothyroid phase in 48%, isolated thyrotoxicosis in 30%; permanent hypothyroidism in 20%–40% Stagnaro-Green 2012; Caturegli et al. 2014
Painless (silent) sporadic thyroiditis Painless transient thyroid dysfunction Lymphocytic thyroiditis within the Hashimoto spectrum Transient dysfunction; histologic differential of lithium-associated thyroiditis Caturegli et al. 2014; Shimizu et al. 1997
Riedel thyroiditis (invasive fibrous thyroiditis) Women in 81% (mean age 42 years); tobacco use in 76%; tracheal narrowing 48%, dysphagia 33%, vocal cord paralysis 29% Storiform, keloid-like fibrosis extending beyond the capsule; occlusive phlebitis; lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells; no oncocytic change Extracervical fibrosis in 38% (fibrosing mediastinitis, retroperitoneal, orbital, pancreatic); surgical complications in 39%; no disease-specific deaths Fatourechi MM et al. 2011; Dahlgren et al. 2010; Falhammar et al. 2018; Uccella et al. 2023
Acute suppurative thyroiditis Less than 1% of thyroid disease; mostly children aged 5–15 years; pyriform sinus fistula in 21% of one series; esophageal perforation by fish or chicken bones in adults Bacterial abscess (Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae); left lobe more often affected Usually euthyroid; recurrence indicates a possible pyriform sinus fistula Toschetti et al. 2025
Palpation thyroiditis Found in more than 83% of surgically removed thyroids and reproduced by squeezing canine thyroids Multifocal granulomatous folliculitis of single ruptured follicles Little or no clinical importance Carney et al. 1975
Radioiodine effect Prior radioiodine for hyperthyroidism Follicular atrophy, fibrosis, oncocytic metaplasia, random nuclear atypia Hypothyroidism Sande et al. 2023
Type 2 amiodarone-associated thyrotoxicosis Amiodarone (37% iodine by weight) in a normal gland Destructive histiocytic reaction around follicles with colloid release; no lymphocytes Thyrotoxicosis; thyroidectomy when the drug cannot be stopped Sande et al. 2023
Type 1 amiodarone-associated thyrotoxicosis Amiodarone in a nodular gland or Hashimoto thyroiditis Underlying nodular disease or thyroiditis Iodine-induced excess hormone synthesis Sande et al. 2023
Immune checkpoint inhibitor thyroiditis (pembrolizumab) Anti-PD-1 therapy; higher risk with preexisting thyroiditis Diffuse follicular injury with B and T lymphocytes and histiocytes; PD-L1 mainly on histiocytes Thyroiditis and hypothyroidism; rare thyroid storm Sande et al. 2023
Lithium-associated thyroiditis Long-term lithium Atrophic follicles, lymphoid follicles, histiocytes, fibrosis Hypothyroidism more often than hyperthyroidism Sande et al. 2023; Shimizu et al. 1997
  • Riedel thyroiditis and IgG4-related disease. Riedel thyroiditis is regarded as part of the IgG4-related disease spectrum (Dahlgren et al. 2010). Fibrosis extending beyond the capsule can involve the parathyroid glands and cause hypoparathyroidism (Falhammar et al. 2018), which occurred in three of 21 Mayo Clinic patients (Fatourechi MM et al. 2011).
  • Riedel thyroiditis versus the fibrous variant of Hashimoto thyroiditis. Extension of fibrosis outside the thyroid capsule was an inclusion criterion for Riedel thyroiditis in the Mayo Clinic series (Fatourechi MM et al. 2011). In IgG4 thyroiditis, which overlaps only in part with the fibrous variant, fibrosis is predominantly interfollicular and within the gland (Li et al. 2012). Oncocytic change is absent in Riedel thyroiditis, and its presence favors the fibrous variant of Hashimoto thyroiditis (Uccella et al. 2023).

Clinical and histologic comparison of the major forms of thyroiditis

Feature Hashimoto thyroiditis Subacute granulomatous thyroiditis Painless and postpartum thyroiditis Riedel thyroiditis Acute suppurative thyroiditis
Pain Painless Painful in 96% Painless Pain in 24% Painful with fever
Mechanism Autoimmune (thyroid peroxidase and thyroglobulin antibodies) Post-viral; HLA-B*35 Autoimmune IgG4-related fibroinflammatory disease Bacterial infection; pyriform sinus fistula in children
Key histology Lymphoid follicles with germinal centers; oncocytic change; atrophy Follicle-centered giant cells engulfing colloid Lymphocytic thyroiditis Storiform fibrosis beyond the capsule; occlusive phlebitis; no oncocytic change Abscess
Function and complications Hypothyroidism in most Thyrotoxic phase, then transient hypothyroidism; permanent in 15% Thyrotoxic and hypothyroid phases, alone or in sequence Airway narrowing; hypoparathyroidism in 3 of 21 patients Usually euthyroid; abscess and airway risk
Sources Caturegli et al. 2014; Uccella et al. 2023 Fatourechi V et al. 2003; Toschetti et al. 2025; Prajapati and Hernandez-Prera 2019 Stagnaro-Green 2012; Caturegli et al. 2014 Fatourechi MM et al. 2011; Dahlgren et al. 2010; Falhammar et al. 2018; Uccella et al. 2023 Toschetti et al. 2025

Incidental findings in thyroid resections

  • Black thyroid. Minocycline causes a grossly black thyroid. Fine granular black pigment accumulates in colloid and in the apical cytoplasm of follicular cells. It is positive with Masson-Fontana and Schmorl stains, bleaches with potassium permanganate, and is negative with Prussian blue, PAS and Ziehl–Neelsen stains. Nodules can be pigmented or unpigmented independently of the background gland (Sande et al. 2023).
  • Amyloid goiter. Amyloid goiter is diffuse thyroid enlargement by amyloid that is Congo red positive with yellow-green birefringence. Most cases are secondary to chronic inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis and familial Mediterranean fever. All three patients in one series were euthyroid. The usual presentation is thyroid enlargement, sometimes with compressive signs (Laamouri et al. 2025). Medullary thyroid carcinoma also contains amyloid (High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging).
  • Multifocal fibrosing thyroiditis. Multifocal fibrosing thyroiditis consists of multiple superficial scar-like lesions (mean 15.4 per gland; mean size 3.1 mm) with a paucicellular fibrotic center and a cellular periphery with reactive follicular atypia. Of 65 reported cases, 94% were women. It occurs mainly in glands removed for chronic lymphocytic thyroiditis, follicular nodular disease or Graves disease, coexists with papillary carcinoma in 38.5% and mimics papillary carcinoma on ultrasound, cytology and histology (Orsatti et al. 2022).

Related page: Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition (amyloid typing by mass spectrometry)

Follicular Cell-Derived Thyroid Neoplasms: WHO 2022 Classification, Follicular and Oncocytic Adenoma and Carcinoma, Low-Risk Neoplasms and Invasion Criteria

Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), divides follicular cell-derived thyroid neoplasms into benign tumors, low-risk neoplasms and malignant neoplasms (Baloch et al. 2022). Benign tumors are follicular adenoma, follicular adenoma with papillary architecture and oncocytic adenoma. Low-risk neoplasms are noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), thyroid tumors of uncertain malignant potential and hyalinizing trabecular tumor, all with ICD-O behavior code 1. Malignant encapsulated follicular-patterned carcinomas are follicular thyroid carcinoma (FTC), oncocytic carcinoma (OCA; formerly Hürthle cell carcinoma) and invasive encapsulated follicular variant papillary thyroid carcinoma (IEFVPTC) (Jung et al. 2022). The term "Hürthle cell" is discouraged as a misnomer (Baloch et al. 2022). The CAP Thyroid protocol, version 4.4.0.0 (March 2023), applies to malignant follicular cell-derived neoplasms. It is not required for thyroid tumors of uncertain malignant potential, hyalinizing trabecular tumor or NIFTP, and low-risk neoplasms are not required to be staged (CAP 2023).

Related page: Papillary thyroid carcinoma (PTC subtypes, the nuclear score, the NIFTP criteria list and its revision, IEFVPTC, AJCC 8th edition staging of differentiated thyroid carcinoma) Related page: Papillary Thyroid Carcinoma: Imaging, Treatment and Follow-up (molecular testing of indeterminate nodules, extent of surgery, ATA 2025 risk of recurrence tiers and RAI) Related page: Papillary Thyroid Carcinoma (Cytology) Related page: Follicular Neoplasm (Bethesda IV) (Bethesda IV and histologic outcomes after lobectomy) Related page: The Bethesda System for Reporting Thyroid Cytopathology Related page: Atypia of Undetermined Significance (Thyroid) Related page: Thyroid Molecular Testing (ThyroSeq, Afirma and the meaning of each alteration) Related page: Non-neoplastic Thyroid Disease: Development, Thyroiditis, Graves Disease and Follicular Nodular Disease (follicular nodular disease, formerly multinodular goiter; Graves disease) Related page: High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging (poorly differentiated and differentiated high-grade carcinoma, anaplastic and medullary carcinoma, cribriform-morular thyroid carcinoma, thyroblastoma and staging of non-PTC carcinomas) Related page: Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes (MEN syndromes)

WHO 2022 classification of thyroid tumors with the 2017 rule beside each change

Category (WHO 2022) Entities Change from WHO 2017 (4th edition) Source
Developmental abnormalities Thyroglossal duct cyst; other congenital thyroid abnormalities Tumor-like lesions newly listed; WHO 2017 listed only neoplasms with ICD-O codes Jung et al. 2022
Benign follicular cell-derived tumors Thyroid follicular nodular disease (FND); follicular adenoma; follicular adenoma with papillary architecture; oncocytic adenoma FND was a new term with no 2017 equivalent; hyperfunctioning adenoma and follicular adenoma with papillary hyperplasia were variants of follicular adenoma; oncocytic adenoma was Hürthle cell adenoma Jung et al. 2022
Low-risk follicular cell-derived neoplasms NIFTP (subcentimeter and oncocytic subtypes); follicular tumor of uncertain malignant potential (FT-UMP); well-differentiated tumor of uncertain malignant potential (WDT-UMP); hyalinizing trabecular tumor Subcentimeter and oncocytic NIFTP were not defined Jung et al. 2022
Malignant follicular cell-derived neoplasms FTC; IEFVPTC; PTC; OCA IEFVPTC was a subtype of PTC; papillary microcarcinoma was a variant of PTC; OCA was Hürthle cell carcinoma Jung et al. 2022
Follicular-derived carcinomas, high-grade Poorly differentiated thyroid carcinoma (PDTC); differentiated high-grade thyroid carcinoma (DHGTC) No high-grade category; DHGTC was a differentiated carcinoma with high-grade features Jung et al. 2022
Anaplastic follicular cell-derived carcinoma Anaplastic thyroid carcinoma, including the squamous cell carcinoma pattern Squamous cell carcinoma of the thyroid was a separate entity Jung et al. 2022
Thyroid C-cell-derived carcinoma Medullary thyroid carcinoma Grading by mitotic count, necrosis and Ki-67 introduced Jung et al. 2022
Mixed medullary and follicular cell-derived carcinomas Mixed medullary-follicular and mixed medullary-papillary carcinoma Placed in a separate section Baloch et al. 2022
Salivary gland-type carcinomas Mucoepidermoid carcinoma; secretory carcinoma Secretory carcinoma was formerly mammary analogue secretory carcinoma; sclerosing mucoepidermoid carcinoma with eosinophilia was a salivary gland-type carcinoma Jung et al. 2022
Thyroid tumors of uncertain histogenesis Sclerosing mucoepidermoid carcinoma with eosinophilia; cribriform-morular thyroid carcinoma Cribriform-morular carcinoma was a variant of PTC Jung et al. 2022
Thymic tumors within the thyroid Thymoma family; intrathyroidal thymic carcinoma; spindle epithelial tumor with thymus-like elements New grouping; diagnostic criteria unchanged Jung et al. 2022
Embryonal thyroid neoplasms Thyroblastoma (DICER1) Renamed from malignant teratoma Jung et al. 2022
  • Terminology. "Subtype" replaces "variant" for histologic subclasses, and "variant" is reserved for genetic alterations. Mitoses are counted per 2 mm² in a hotspot (previously per 10 high-power fields), and gene fusions are written with a double colon (previously a hyphen or slash) (Jung et al. 2022).
  • Non-thyroid chapters. Mesenchymal and stromal tumors, hematolymphoid tumors, germ cell tumors and metastases moved from the thyroid chapter to standalone chapters that cover all endocrine organs (Jung et al. 2022).

BRAF-like and RAS-like molecular groups of follicular cell-derived neoplasms

  • BRAF-like group. PTCs with many morphologic subtypes form the BRAF-like malignancies (Baloch et al. 2022). The BRAF V600E-like profile includes BRAF V600E and fusions of BRAF, RET and NTRK1/NTRK3, with papillary or infiltrative growth and florid nuclear atypia (Jung et al. 2022).
  • RAS-like group. IEFVPTC and FTC are the RAS-like malignancies (Baloch et al. 2022). The RAS-like profile includes NRAS, HRAS, KRAS, EIF1AX, EZH1, DICER1 and PTEN mutations, BRAF K601E and fusions involving PPARG and THADA. Encapsulated tumors with a predominant follicular pattern generally have a RAS-like profile (Jung et al. 2022).
  • Non-BRAF-like, non-RAS-like group. In a three-group scheme, PAX8::PPARG and mutations of EIF1AX, EZH1, IDH1, SOS1, SPOP, DICER1 and PTEN form a non-BRAF-like, non-RAS-like group (Jung et al. 2022).
  • Progression. BRAF-like and RAS-like carcinomas can acquire further alterations and progress to high-grade carcinoma (Jung et al. 2022).

Follicular adenoma

  • Definition. Follicular adenoma is a benign encapsulated follicular cell-derived neoplasm without capsular or vascular invasion and without the nuclear features of PTC. Separation from FTC depends on invasion of the capsule or vessels (CAP 2023).
  • Distinction from follicular nodular disease. FND can contain encapsulated cellular nodules that resemble follicular adenoma and cannot be separated from it on histologic features (Jung et al. 2022).
  • Genetics. In 88 follicular and Hürthle cell tumors, 48% of follicular adenomas had RAS mutations, 4% had PAX8::PPARG and 48% had neither (Nikiforova et al. 2003).
  • Follicular adenoma with papillary hyperplasia. A follicular adenoma with papillary growth that is not hyperfunctioning is classified as follicular adenoma with papillary hyperplasia within follicular adenoma (Jung et al. 2022).
  • Signet-ring cell change. In 7 thyroidectomies with signet ring cells, the tumors were 4 follicular adenomas, 2 NIFTPs and 1 secretory carcinoma with ETV6::NTRK3. One adenoma carried a PTEN mutation (Farhat et al. 2017).
  • Subtypes listed in WHO 2017. Hyperfunctioning adenoma, follicular adenoma with papillary hyperplasia, lipoadenoma, follicular adenoma with bizarre nuclei, signet-ring cell, clear cell, spindle cell and black follicular adenoma were variants of follicular adenoma in WHO 2017 (Bai et al. 2020).
  • Lipoadenoma (adenolipoma). Thyroid lipoadenoma has adipocytes intermixed between edematous follicles and is associated with PTEN hamartoma tumor syndrome. Thyroglobulin, TTF-1 and PAX8 confirm follicular origin and separate it from parathyroid lipoadenoma and lipid-rich follicular tumors (Cameselle-Teijeiro et al. 2020).

Follicular adenoma with papillary architecture (hyperfunctioning adenoma)

  • Definition and 2017 rule. Follicular adenoma with papillary architecture is a separate type in WHO 2022. It is generally an autonomous hyperfunctioning nodule with intrafollicular papillary growth. Previous rule (WHO 2017): hyperfunctioning (toxic) adenoma was a variant of follicular adenoma (Jung et al. 2022).
  • Genetics. These adenomas harbor activating mutations in TSHR, GNAS or EZH1, whereas conventional follicular adenomas usually harbor RAS mutations (Jung et al. 2022).
  • Mimic of PTC. The papillae have broad edematous cores and lack PTC-type nuclei (Jung et al. 2022).

Oncocytic adenoma and oncocytic carcinoma

  • Definition. Oncocytic adenoma and oncocytic carcinoma are follicular cell-derived neoplasms composed of ≥75% oncocytic cells that lack the nuclear features of PTC and lack high-grade features (necrosis and ≥5 mitoses per 2 mm²) (Baloch et al. 2022). The ≥75% thyroid threshold is the WHO 2022 definition as cited in ATA 2025 (Ringel et al. 2025). Capsular or vascular invasion separates the carcinoma from the adenoma. Oncocytic tumors with PTC nuclei are oncocytic PTCs (Baloch et al. 2022). Previous rule (WHO 2017): these tumors were named Hürthle cell adenoma and Hürthle cell carcinoma (Jung et al. 2022). WHO 2017 first recognized them as a distinct entity. Earlier classifications treated them as variants of follicular adenoma and FTC (Bai et al. 2020).
  • Oncocyte. An oncocyte is an enlarged polygonal cell with abundant granular eosinophilic cytoplasm, a round nucleus with even chromatin and a prominent nucleolus. Oncocytic carcinoma accounts for about 3% of differentiated thyroid carcinoma (DTC) and is now regarded as a third form of DTC (Ringel et al. 2025).
  • Invasion criteria. As in FTC, capsular or vascular invasion in an encapsulated oncocytic neoplasm establishes carcinoma. OCA is subtyped as minimally invasive, encapsulated angioinvasive or widely invasive (Ringel et al. 2025; CAP 2023).
  • Genetics. Whole-exome sequencing of Hürthle cell carcinomas showed recurrent mutations in DAXX, TP53, NRAS, NF1, CDKN1A, ARHGAP35 and the TERT promoter. Mitochondrial DNA carried recurrent homoplasmic mutations in complex I subunits. Widespread chromosomal loss produced near-haploid content in a large fraction of tumors and was maintained in metastases (Gopal et al. 2018). In 56 primary tumors, whole-chromosome duplications of chromosomes 5 and 7 and widespread loss of heterozygosity from haploidization and copy-neutral uniparental disomy were found (Ganly et al. 2018). Hürthle cell tumors infrequently carry RAS mutations or PAX8::PPARG (Nikiforova et al. 2003).
  • Clinical behavior. Oncocytic carcinomas are often not radioiodine avid despite thyroglobulin secretion and TSH receptor expression (Ringel et al. 2025). In 173 oncocytic carcinomas, minimally invasive tumors had no clinical recurrence or death. Recurrence was 17% in oncocytic carcinoma and 8% in FTC in a comparison of 126 and 252 patients (Ringel et al. 2025).
  • Infarction after FNA. Of 257 Hürthle cell tumors with matched FNA and resection, 8 showed extensive (≥80%) infarction or necrosis. Infarcted tumors were smaller than noninfarcted ones and carried the mitochondrial DNA common deletion less often (25% versus 72.7%) (Conti et al. 2017).
  • Oncocytic NIFTP and oncocytic PDTC. Oncocytic NIFTP requires ≥75% oncocytic cells (Jung et al. 2022; CAP 2023). Oncocytic poorly differentiated thyroid carcinoma is a CAP histologic type (CAP 2023).

Low-risk follicular cell-derived neoplasms

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features

  • Renaming in 2016. An international panel of 24 thyroid pathologists reviewed 109 noninvasive encapsulated follicular variant PTCs followed for 10 to 26 years and 101 invasive ones. All 109 patients with noninvasive tumors, 67 treated by lobectomy alone without radioactive iodine, were alive without disease at a median of 13 years. Adverse events occurred in 12 of 101 (12%) invasive tumors, including 5 distant metastases and 2 deaths. The noninvasive tumor was renamed NIFTP (Nikiforov et al. 2016).
  • Sampling. Complete submission of the tumor periphery is required in all encapsulated or well-demarcated nodules (CAP 2023).
  • Management. NIFTP, FT-UMP and hyalinizing trabecular tumor have a very low malignant potential, and completion thyroidectomy, lymphadenectomy or radioactive iodine are not advised routinely (Ringel et al. 2025).
  • Frequency. NIFTP comprised 2.2% and 2.6% of SEER-22 cases in 2018 and 2019 (CAP 2023) and 2.1%–9.6% of follicular cell-derived neoplasms in published series (Ringel et al. 2025).

Thyroid tumors of uncertain malignant potential

  • Definitions. Williams proposed WDT-UMP for an encapsulated tumor of well-differentiated follicular cells with well or partially developed PTC-type nuclei and questionable capsular or vascular invasion. The WHO 4th edition (2017) grid crossed PTC-type nuclei with invasion. A tumor without PTC-type nuclei and with questionable invasion is FT-UMP. A tumor with PTC-type nuclei and questionable invasion is WDT-UMP. A tumor with questionable PTC-type nuclei and definite invasion is well-differentiated carcinoma, not otherwise specified (Kakudo et al. 2018). WHO 2022 made no change to the diagnostic criteria of the low-risk neoplasms (Jung et al. 2022).
  • Observer variation. Eleven thyroid pathologists reviewing 20 encapsulated follicular neoplasms agreed poorly on questionable capsular invasion (κ = 0.186) and only fairly on a diagnosis of malignancy (κ = 0.545). Nine of 11 used FT-UMP, the term proposed in the WHO 2017 classification, for questionable invasion (Zhu et al. 2020).
  • Atypical follicular adenoma. "Atypical adenoma" is applied to a noninvasive follicular neoplasm with atypical features (indefinite capsular or vascular invasion, necrosis, solid growth or increased mitoses) and was used as a synonym of FT-UMP in a comparison of 31 atypical adenomas with 18 nonmetastatic and 38 metastatic FTCs. TERT promoter mutations were present in 10% of atypical adenomas, 25% of nonmetastatic FTCs and 50% of metastatic FTCs. The combination of solid growth with increased mitoses, necrosis and TERT promoter mutation occurred only in carcinomas (Cracolici et al. 2020).
  • Bizarre cells in atypical adenoma. In 2 atypical adenomas, the bizarre cells carried a TP53 codon 273 mutation that was absent from the bland follicular cells and from 6 typical adenomas and 6 FTCs (Tzen et al. 2003).
  • WDT-UMP outcome. In 30 WDT-UMPs, HBME-1, cytokeratin 19 and galectin-3 were positive in 40.0%, 33.3% and 36.7%. BRAF V600E was absent, CCDC6::RET (RET/PTC1) was found in 2 (6.7%), and none of 20 followed patients recurred at a mean of 80 months (Liu et al. 2011).

Hyalinizing trabecular tumor

  • Morphology. Hyalinizing trabecular tumor is encapsulated with trabecular growth and prominent intratrabecular and perivascular hyaline material that is PAS positive and Congo red negative. Tumor cells are polygonal to columnar with nuclear grooves and pseudoinclusions. Cytoplasmic "yellow bodies" are frequent, and mitoses and psammoma bodies are rare (Liu et al. 2017).
  • Immunohistochemistry. Tumor cells express thyroglobulin, TTF-1 and CD56 and are negative for calcitonin, cytokeratin 19 and HBME-1. The MIB-1 antibody gives membranous and cytoplasmic staining, whereas Ki-67 clone SP6 gives nuclear staining in <1% of cells (Liu et al. 2017).
  • Genetics. PAX8::GLIS3 was found in 13 of 14 (93%) and PAX8::GLIS1 in 1 of 14 (7%) hyalinizing trabecular tumors. The fusions upregulate extracellular matrix genes and cause collagen IV deposition, which accounts for the hyalinization. No PAX8::GLIS3 and one PAX8::GLIS1 were found in 220 PTCs. Among 10,165 indeterminate FNA samples, 8 (0.1%) carried PAX8::GLIS3, and all 5 resected fusion-positive nodules were hyalinizing trabecular tumors (Nikiforova et al. 2019).
  • Misdiagnosis as PTC. The shared nuclear features with PTC cause false-positive cytology (Nikiforova et al. 2019), and the tumor is often misdiagnosed on FNA and frozen section (Liu et al. 2017).

Follicular thyroid carcinoma

  • Definition. FTC is an encapsulated follicular-patterned carcinoma without the nuclear features of PTC, defined by capsular invasion, vascular invasion (limited or extensive) or wide invasion of the thyroid beyond the capsule (Ringel et al. 2025). FTC and IEFVPTC are the RAS-like follicular-patterned carcinomas, separated by subtle nuclear atypia that is subject to interobserver variability (CAP 2023).
  • Subtypes. WHO 2022 subtypes FTC, OCA and IEFVPTC as minimally invasive (capsular invasion only, irrespective of the number of foci), encapsulated angioinvasive (any number of involved vessels without widely invasive growth) and widely invasive (CAP 2023). Even a single focus of angioinvasion places a tumor in the encapsulated angioinvasive subtype (CAP 2023). Widely invasive tumors show grossly apparent invasion of thyroid or soft tissue, loss of encapsulation and multiple fronts of satellite invasion and are usually accompanied by extrathyroidal extension and extensive vascular invasion (CAP 2023). Extensive vascular invasion alone does not make a tumor widely invasive (Jung et al. 2022).
  • Previous rule (ATA 2015). FTCs were traditionally divided into minimally invasive (encapsulated with microscopic capsular or vascular invasion) and widely invasive. Newer schemes placed angioinvasive tumors in a separate category because capsular-only tumors have a mortality <5% and angioinvasive tumors 5%–30%, depending on the number of invaded vessels (Haugen et al. 2016).
  • Genetics. In conventional FTC, 49% had RAS mutations, 36% PAX8::PPARG and 3% both. PAX8::PPARG-positive carcinomas occurred in younger patients, were smaller and were almost always overtly invasive. RAS-mutant carcinomas were minimally or overtly invasive (Nikiforova et al. 2003). Other drivers are EIF1AX and PIK3CA mutations and PTEN loss. DICER1 mutations are prevalent in FTC. BRAF V600E and RET fusions are typically absent (Ringel et al. 2025).
  • TERT promoter. TERT promoter mutations were found in 17.1% of FTCs, 7.5% of PTCs, 29.0% of PDTCs and 33.3% of anaplastic carcinomas. In FTC they were associated with disease-specific mortality (P < .001) (Melo et al. 2014).
  • Spread. FTC spreads mainly by the hematogenous route and PTC mainly by lymphatics (CAP 2023). Among 30 patients with distant metastases from thyroid carcinoma (19 papillary, 3 follicular, 3 Hürthle cell and 5 with focal anaplasia), sites were lung in 26, bone in 11 and brain in 1 (Clark et al. 2005).
  • Size. FTC larger than 3.5 cm is associated with a worse prognosis (CAP 2023).
  • Ki-67. A Ki-67 labeling index above 5% may be a risk factor in FTC, and routine Ki-67 in differentiated carcinoma requires further validation (CAP 2023).
  • High-grade features. All encapsulated tumors are examined for high-grade features and dedifferentiation. FTC with ≥5 mitoses per 2 mm² or tumor necrosis is classified as a high-grade follicular cell-derived carcinoma (CAP 2023; Jung et al. 2022).

Capsular and vascular invasion criteria in encapsulated follicular-patterned thyroid tumors

Criterion Counts as invasion Does not count, or mimics Source
Capsular invasion No consensus definition; some authorities require complete transgression of the capsule and others do not Changes from a previous biopsy can confound the interpretation CAP 2023
Location of invaded vessels Vessels in the capsule or outside the capsule Vessels within the tumor nodule parenchyma Haugen et al. 2016; CAP 2023
Rigid (unequivocal) vascular invasion Tumor through a vessel wall with fibrin thrombus; tumor juxtaposed to the vessel wall with thrombus; tumor fragments intermingled with organized thrombus and adherent to the wall Free-floating irregular fragments (artifactual displacement); tumor bulging into and indenting a vessel wall; endothelialized tumor floating in an intracapsular vessel (tangential section) CAP 2023
Contentious vascular invasion Endothelialized deposit juxtaposed to the vessel wall without thrombus is equivocal The same deposit can represent organization of a tumor thrombus CAP 2023
Traditional (2015) definition Direct extension into the lumen, or an intraluminal aggregate attached to the wall and covered by endothelium Rigid criteria add fibrin thrombus attached to the tumor cells Haugen et al. 2016
Lymphatic invasion Tumor in lymphatic spaces; psammoma bodies alone in lymphatics are reported as lymphatic invasion Lymphatic and blood vessel invasion are distinguished; "lymphovascular invasion" is discouraged in endocrine neoplasms CAP 2023
  • Ancillary stains. CD31 (vascular endothelium) and podoplanin (D2-40, lymphatic endothelium) separate capillary-sized blood vessels from lymphatics. CD61 highlights platelets admixed with tumor cells at sites of angioinvasion (CAP 2023).

  • Deeper levels. Endothelialized tumor in an intracapsular vessel prompts deeper levels, at least 3, to exclude definitive vascular invasion (CAP 2023). Multiple levels from individual blocks also assist in assessing capsular invasion (CAP 2023).

  • Evidence for the rigid criteria. Among 4000 carcinomas of follicular epithelial derivation, tumor through a vessel wall with adherent thrombus was found in 118 (3%). Of 98 with follow-up, 35% developed distant metastases, including about one-third of angioinvasive well-differentiated carcinomas and one-half of angioinvasive poorly differentiated carcinomas at a mean of 5.3 years (Mete and Asa 2011). Metastasizing angioinvasive carcinomas in that series mostly had a single focus and never more than 2 foci of vascular invasion (CAP 2023).

  • Other endocrine organs. WHO 2022 endorsed the rigid criteria for parathyroid carcinoma and adrenal cortical carcinoma, and validation in follicular cell-derived carcinomas is still recommended (CAP 2023).

  • Chan criteria. Capsular invasion is full-thickness penetration of the capsule, with or without a "mushroom" of protruding tumor or a newly formed thin fibrous covering over the protruding tumor. Blood vessel invasion is an endovascular tumor plug protruding into the lumen, covered by endothelium or associated with fibrin, with or without attachment to the wall. Intratumoral and subcapsular vessels do not qualify. The ICCR endorses these criteria (Mansour et al. 2025).

  • Reproducibility. In an e-learning study of 69 challenging encapsulated follicular-patterned lesions, among the 211 pathologists who scored every lesion, interobserver agreement across five categories (certain or doubtful capsular invasion, certain or doubtful vascular invasion, no invasion) was slight before training (combined κ = 0.199). Agreement for certain vascular invasion against the other four categories rose from κ = 0.330 to 0.423 after a training lecture and was maintained at 3 months (Mansour et al. 2025).

  • Polar sections. Adding vertical cuts at the upper and lower poles to transverse serial sectioning nearly doubled the odds of detecting capsular invasion (odds ratio 1.91). Capsular or vascular invasion was found in the added polar cuts in 23% of tumors sampled this way, and detection of vascular invasion did not change (Oh et al. 2019).

  • Capsular invasion alone. Among 65 FTCs followed for a median of 11 years, none of the 20 tumors with capsular invasion alone produced distant metastasis or cancer death. Tumors with vascular invasion had 10-year rates of 19% for distant metastasis and 28% for cause-specific mortality (van Heerden et al. 1992).

Number of invaded vessels

  • CAP 4.4.0.0. Historically, fewer than 4 vessels was focal and 4 or more was extensive angioinvasion. WHO 2022 questioned the validity of this cutoff, and the CAP protocol asks for the extent of angioinvasion as the number of vessels involved (CAP 2023). Jung et al. 2022 describe WHO 2022 as dividing encapsulated angioinvasive tumors into limited (<4 foci) and extensive (4 or more foci) vascular invasion.
  • ATA 2025. Vascular invasion, particularly extensive vascular invasion in FTC or OCA, is associated with an increased risk of distant metastasis and may warrant completion thyroidectomy (Ringel et al. 2025). In 276 low-grade encapsulated DTCs, recurrence was 1% with focal (<4 vessels) and 26% with extensive vascular invasion. In 523 FTCs, the hazard ratio for distant metastasis was 2.5 with <4 vessels and 8.03 with ≥4 vessels. In a meta-analysis of the FTC subgroup, extensive (≥4 foci) vascular invasion raised the odds of distant recurrence (OR 26.38) (Ringel et al. 2025).
  • Previous rule (ATA 2015). The number of invaded blood vessels (fewer than 4, or 4 or more) was to be stated in the pathology report. FTC with extensive vascular invasion was ATA high risk (the ATA 2015 risk table wording is ">4 foci of vascular invasion") because new distant metastases develop in up to 30%–55%. Encapsulated minimally invasive FTC with a small number of foci confined to intracapsular vessels had a recurrence rate of about 0%–5%, and FTC with capsular invasion only had 0%–7% (Haugen et al. 2016).

Encapsulated follicular-patterned thyroid lesions

Lesion PTC-type nuclei Capsular invasion Vascular invasion Usual molecular class Source
Follicular adenoma Absent Absent Absent RAS; PAX8::PPARG in 4% Nikiforova et al. 2003; Jung et al. 2022
Follicular adenoma with papillary architecture Absent; intrafollicular papillae with edematous cores Absent Absent TSHR, GNAS or EZH1 Jung et al. 2022
Oncocytic adenoma Absent; ≥75% oncocytic cells Absent Absent RAS and PAX8::PPARG infrequent in Hürthle cell tumors Ringel et al. 2025; Nikiforova et al. 2003
NIFTP (criteria in Papillary thyroid carcinoma) Present Absent Absent RAS-like Nikiforov et al. 2016; Jung et al. 2022
FT-UMP Absent Questionable Questionable RAS-like follicular pattern Kakudo et al. 2018; Jung et al. 2022
WDT-UMP Present or questionable Questionable Questionable BRAF V600E absent in 30 cases Kakudo et al. 2018; Liu et al. 2011
Minimally invasive FTC or OCA Absent Present Absent RAS or PAX8::PPARG in FTC CAP 2023; Nikiforova et al. 2003
Encapsulated angioinvasive FTC or OCA Absent Present or absent Present, any number of vessels RAS or PAX8::PPARG in FTC CAP 2023; Jung et al. 2022
Widely invasive FTC or OCA Absent Gross invasion with lost encapsulation Often extensive TERT promoter mutations associated with mortality CAP 2023; Melo et al. 2014
IEFVPTC (subtypes in Papillary thyroid carcinoma) Present Present in minimally invasive Present in encapsulated angioinvasive RAS-like CAP 2023; Jung et al. 2022

Frozen section in thyroid surgery

  • Follicular lesions. In a meta-analysis of 46 studies of frozen section for nodules with Bethesda IV cytology, sensitivity was 43% and specificity 100%, and routine use was discouraged (Grisales and Sanabria 2020). For follicular lesions, FNA was more sensitive and frozen section more specific with a higher positive predictive value. For nonfollicular lesions the two methods performed almost identically (Peng and Wang 2008).
  • Frozen section in classic PTC. Frozen section is most helpful when the diagnosis is classic PTC and has low impact for follicular variant PTC and FTC. It can confirm malignancy during lobectomy and allow conversion to total thyroidectomy (Haugen et al. 2016).
  • Parathyroid tissue. A devascularized or removed parathyroid gland is autotransplanted into muscle after frozen section of a portion confirms benign parathyroid tissue (Ringel et al. 2025).

Familial and syndromic follicular cell-derived thyroid neoplasia

Familial non-medullary thyroid carcinoma (FNMTC) is syndromic when DTC is one of a constellation of tumors and non-syndromic when DTC is the single or prevailing inherited malignancy (Ringel et al. 2025). WHO 2022 describes syndromic and non-syndromic familial thyroid disease in its familial tumor syndrome chapter (Nosé et al. 2022).

Related page: Papillary thyroid carcinoma (familial PTC and the two groups of familial non-medullary thyroid carcinoma)

Syndrome (gene) Thyroid histology and cancer risk Other features Source
PTEN hamartoma tumor syndrome, Cowden syndrome (PTEN) Numerous sharply delineated, often encapsulated cellular nodules; FTC overrepresented with PTEN mutation; PTC; lifetime thyroid cancer risk 3%–10% Breast and endometrial cancer, goiter, macrocephaly Haugen et al. 2016; Ngeow et al. 2011; Ringel et al. 2025
Familial adenomatous polyposis (APC) Cribriform-morular thyroid carcinoma (in High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging); PTC; lifetime thyroid cancer risk up to 12% Colon polyposis, congenital hypertrophy of the retinal pigment epithelium, desmoids Ringel et al. 2025
DICER1 tumor predisposition (DICER1) Multinodular goiter; PTC, FTC and PDTC; thyroblastoma (in High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging); odds ratio 9.2 for DTC Pleuropulmonary blastoma, cystic nephroma, ovarian sex cord-stromal tumors Rutter et al. 2016; Ringel et al. 2025
Carney complex (PRKAR1A) FTC and PTC Pigmented skin lesions, myxomas, schwannomas, endocrine tumors Ringel et al. 2025
Werner syndrome (WRN) FTC and PTC Premature aging, cataracts, diabetes mellitus, other cancers Ringel et al. 2025
  • Cowden syndrome thyroid pattern. In 2723 Cowden and Cowden-like patients, all 6 diagnosed with thyroid cancer before age 18 years carried pathogenic PTEN mutations (Ngeow et al. 2011).
  • Oncocytic carcinoma. OCA was formerly included with FTC and is likely associated with the same hereditary predispositions (Ringel et al. 2025).
  • Germline testing. ATA 2025 conditionally recommends germline testing when DTC occurs with features of PTEN hamartoma tumor syndrome, and consideration of DICER1 testing in families with pediatric DTC. A pathologic diagnosis of cribriform-morular thyroid carcinoma is a conditional indication for APC testing, and histologic subtypes associated with familial syndromes (cribriform-morular carcinoma with familial adenomatous polyposis, PTEN hamartoma tumor syndrome-associated FTC or PTC) are identified and reported as a good practice statement (Ringel et al. 2025).

High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging

Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), groups high-grade follicular cell-derived carcinomas without anaplastic histology into one tumor type with two subtypes: poorly differentiated thyroid carcinoma (PDTC) and the new differentiated high-grade thyroid carcinoma (DHGTC). Both show increased mitotic activity and tumor necrosis and behave similarly. Anaplastic thyroid carcinoma (ATC) remains the most undifferentiated form. Medullary thyroid carcinoma (MTC), derived from C cells, keeps a separate section with a new grading system, and mixed medullary and follicular cell-derived carcinomas have their own section (Baloch et al. 2022). The CAP Thyroid protocol, version 4.4.0.0 (March 2023), applies to all malignant follicular cell-derived carcinomas, MTC, mixed carcinomas, salivary gland-type carcinomas, thymic tumors within the thyroid, thyroblastoma and tumors of uncertain cytogenesis. It does not apply to lymphoma, sarcoma, struma ovarii-derived carcinoma or metastases to the thyroid (CAP 2023).

Related page: Papillary thyroid carcinoma (PTC subtypes, NIFTP criteria, AJCC 8th edition T, N and M definitions and stage groups for differentiated thyroid carcinoma, CAP elements for PTC) Related page: Papillary Thyroid Carcinoma: Imaging, Treatment and Follow-up (ATA 2025 risk tiers, radioactive iodine and molecular testing of indeterminate nodules) Related page: Follicular Cell-Derived Thyroid Neoplasms: WHO 2022 Classification, Follicular and Oncocytic Adenoma and Carcinoma, Low-Risk Neoplasms and Invasion Criteria (WHO 2022 thyroid classification table, follicular and oncocytic carcinoma, capsular and vascular invasion criteria) Related page: Non-neoplastic Thyroid Disease: Development, Thyroiditis, Graves Disease and Follicular Nodular Disease (Hashimoto thyroiditis, the background of thyroid lymphoma; solid cell nests) Related page: Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes (MEN2A and MEN2B definitions and RET codon risk categories) Related page: Medullary Thyroid Carcinoma (Cytology) (MTC on fine-needle aspiration and calcitonin in washout fluid) Related page: Lymphoma, Metastases and Undifferentiated Malignancies in Thyroid FNA (lymphoma, ATC and metastases on FNA) Related page: Diagnostic Enzymes and Serum Tumor Markers (serum calcitonin and CEA as tumor markers) Related page: Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms (pheochromocytoma in MEN2, paraganglioma as a mimic of MTC and the classification of neuroendocrine neoplasms)

WHO 2022 changes for high-grade, medullary and rare thyroid tumors

Entity WHO 5th edition (2022) Previous rule, WHO 4th edition (2017) Source
High-grade follicular cell-derived carcinoma New tumor type "follicular-derived carcinomas, high-grade" with two subtypes, PDTC and DHGTC No combined high-grade tumor type Jung et al. 2022
DHGTC New subtype: PTC, FTC or oncocytic carcinoma with ≥5 mitoses per 2 mm² and/or tumor necrosis Differentiated thyroid carcinoma (PTC, FTC or oncocytic carcinoma) with high-grade features, without a separate name Jung et al. 2022
PDTC Diagnostic criteria unchanged (Turin) Turin criteria Jung et al. 2022
MTC Grading by mitotic count, tumor necrosis and Ki-67 index (high grade versus low grade) No grading system Jung et al. 2022; Xu et al. 2022
Cribriform-morular thyroid carcinoma (CMTC) Thyroid tumor of uncertain histogenesis Cribriform-morular variant of PTC Jung et al. 2022
Sclerosing mucoepidermoid carcinoma with eosinophilia (SMECE) Thyroid tumor of uncertain histogenesis Grouped with the salivary gland-type carcinomas Jung et al. 2022
Thyroblastoma New name for an embryonal tumor with DICER1 mutation Malignant teratoma (carcinosarcoma with DICER1 mutation) Jung et al. 2022
  • Grading by least differentiated component. Tumors with mixed histologic patterns are classified by the least differentiated component and the highest grade. A PDTC or DHGTC diagnosis requires the absence of an anaplastic component (Jung et al. 2022).
  • Counting method. Mitoses are counted in the region with the highest activity (hotspot) and expressed per 2 mm², roughly 10 high-power fields (Jung et al. 2022).
  • AJCC grade. The CAP protocol does not endorse the generic four-tier AJCC grade for thyroid carcinomas (CAP 2023).

Poorly differentiated thyroid carcinoma: Turin criteria

The Turin consensus (83 tumors from Europe, Japan and the United States, reviewed by 12 thyroid pathologists) defines PDTC by all of the following (Volante et al. 2007):

  1. A solid, trabecular or insular growth pattern.
  2. Absence of the conventional nuclear features of papillary carcinoma.
  3. At least one of convoluted nuclei, mitotic activity ≥3 per 10 high-power fields or tumor necrosis.
  • 2022 expression of the mitotic criterion. The WHO 5th edition expresses the PDTC threshold as ≥3 mitoses per 2 mm². An FTC with solid or trabecular areas and ≥3 mitoses per 2 mm² in those areas is classified as PDTC (Jung et al. 2022).
  • Historical names and subtypes. PDTC was historically called insular or trabecular carcinoma. The CAP protocol lists PDTC NOS and oncocytic PDTC (CAP 2023).
  • Extent needed. A PDTC component of as little as 10% of a differentiated carcinoma confers aggressive behavior (CAP 2023).
  • Encapsulation. Encapsulated PDTCs without capsular or vascular invasion on adequate sampling appear to have a more favorable prognosis than unencapsulated tumors (CAP 2023).
  • Ki-67. Ki-67 is not required for the diagnosis. Most PDTCs have a Ki-67 index of 10%–30%, and ATCs tend to be higher (CAP 2023; Jung et al. 2022).
  • CMTC exception. High-grade features in cribriform-morular thyroid carcinoma do not make it a PDTC (CAP 2023).

Differentiated high-grade thyroid carcinoma

  • Definition. DHGTC is a PTC, FTC, oncocytic carcinoma or invasive encapsulated follicular variant PTC with ≥5 mitoses per 2 mm² and/or tumor necrosis, without solid, trabecular or insular growth meeting PDTC criteria and without anaplastic histology (Jung et al. 2022; CAP 2023).
  • Follicular carcinoma rule. An FTC without solid or trabecular growth and with ≥5 mitoses per 2 mm² is classified as DHGTC (Jung et al. 2022).
  • NIFTP-like tumors with mitoses. A noninvasive tumor with NIFTP features and ≥5 mitoses per 2 mm² is classified as DHGTC (noninvasive high-grade follicular variant PTC) (Jung et al. 2022).
  • CAP reporting. The CAP protocol reports the parent tumor with a high-grade prefix, for example high-grade tall cell PTC or high-grade widely invasive FTC, or DHGTC NOS (CAP 2023).
  • Behavior. DHGTCs present at more advanced stage and have lower radioactive iodine avidity than well-differentiated carcinomas. Their overall prognosis is similar to PDTC defined by the Turin criteria (Jung et al. 2022; Juhlin et al. 2023).
  • Outcome in a large series. In 364 high-grade non-anaplastic carcinomas (200 Turin PDTC and 164 high-grade tumors not meeting Turin criteria), disease-specific survival at 3, 5, 10 and 20 years was 89%, 76%, 60% and 35%. Survival was similar in the two groups. Turin PDTC had more radioactive iodine avidity, more RAS mutations, fewer BRAF V600E mutations and a higher propensity for distant metastasis. Older age, male sex, extensive necrosis and lack of encapsulation predicted death from disease (Xu et al. 2022b).
  • PTC with high-grade features. In 15 PTCs with high-grade features compared with 47 PDTCs, the PTCs had more pT4 disease (53% versus 13%), more nodal metastases (73% versus 38%), worse disease-specific survival and more BRAF V600E mutations (42% versus 3%) (Wong et al. 2021).

Comparison of PDTC, DHGTC and ATC

Feature Poorly differentiated thyroid carcinoma Differentiated high-grade thyroid carcinoma Anaplastic thyroid carcinoma Source
Architecture Solid, trabecular or insular Retains the architecture of PTC, FTC or oncocytic carcinoma Undifferentiated: epithelioid, spindle, giant cell, pleomorphic, small cell, squamous, rhabdoid, angiomatoid or paucicellular patterns Volante et al. 2007; Jung et al. 2022
Cytology No conventional PTC nuclei; convoluted nuclei count as a criterion PTC nuclei may be present Spindled, pleomorphic, squamoid or rhabdoid cells Volante et al. 2007; Jung et al. 2022; CAP 2023
Mitoses and necrosis ≥3 mitoses per 2 mm², necrosis or convoluted nuclei ≥5 mitoses per 2 mm² and/or necrosis No mitotic or necrosis threshold; defined by undifferentiated histology Jung et al. 2022; CAP 2023
Ki-67 10%–30% in most Not required for diagnosis Higher than PDTC CAP 2023; Jung et al. 2022
Dominant drivers RAS (Turin-defined PDTC) BRAF V600E more frequent than in Turin PDTC BRAF V600E 45%, RAS 24%, TP53 73%, TERT promoter 73% Landa et al. 2016; Xu et al. 2022b
AJCC 8th edition staging pT categories of follicular cell-derived carcinoma pT categories of follicular cell-derived carcinoma Same pT categories; always stage IV (IVA, IVB or IVC) CAP 2023; Perrier et al. 2018

Molecular pathology of poorly differentiated and anaplastic carcinoma

  • Progression model. Sequencing of 341 cancer genes in 117 PDTCs and ATCs supports origin of both from well-differentiated tumors through accumulation of additional alterations (Landa et al. 2016).
  • Driver frequencies. BRAF V600E was present in 33% of PDTCs and 45% of ATCs. NRAS, HRAS or KRAS mutations occurred in 28% of PDTCs and 24% of ATCs and were mutually exclusive with BRAF mutation and gene fusions (Landa et al. 2016).
  • RAS versus BRAF by definition. RAS mutations characterized PDTC defined by the Turin criteria, and BRAF mutations characterized PDTC defined by the Memorial Sloan Kettering criteria (Landa et al. 2016).
  • TP53. TP53 mutations were found in 73% of ATCs and 8% of PDTCs and distinguish the two tumors (Landa et al. 2016).
  • TERT promoter. TERT promoter mutation frequency rose from 9% in PTC to 40% in PDTC and 73% in ATC, and these mutations were clonal in advanced cancers (Landa et al. 2016).
  • Other alterations. EIF1AX mutations occurred in 11% of PDTCs and 9% of ATCs and co-occurred with RAS. Mutations in PI3K/AKT/mTOR effectors, SWI/SNF subunits and histone methyltransferases were more frequent in ATC (Landa et al. 2016).
  • High-grade non-anaplastic carcinoma. Across 364 tumors, BRAF, RAS, TERT, TP53 and PTEN alterations were present in 28%, 40%, 55%, 11% and 10%. TP53, PTEN and TERT alterations predicted unfavorable outcome, and BRAF V600E with TERT promoter mutation increased the risk of distant metastasis (Xu et al. 2022b).

Anaplastic thyroid carcinoma

  • Morphology. ATC is the most extreme form of tumor progression and is often lethal. It shows epithelioid, spindle cell, giant cell, pleomorphic, small cell, squamous cell, rhabdoid, angiomatoid or paucicellular patterns, and the WHO does not define subtypes by the predominant pattern (Jung et al. 2022; CAP 2023).
  • Squamous cell carcinoma pattern. Tumors with squamous cell carcinoma morphology are a pattern of ATC in the 5th edition (CAP 2023). Previous rule (WHO 2017): primary squamous cell carcinoma of the thyroid was a separate entity (Jung et al. 2022). This pattern has a higher BRAF V600E rate and more frequent PAX8 expression than other ATCs (Jung et al. 2022). PAX8 was a sensitive marker of thyroid origin in primary squamous cell carcinoma of the thyroid (Lam 2020).
  • Squamous differentiation in other tumors. Squamous differentiation also occurs in PTC, FTC, PDTC, MTC, mucoepidermoid carcinoma and intrathyroidal thymic carcinoma. Intrathyroidal thymic carcinoma has a 10-year survival above 80% and is separated from ATC with a squamous pattern (Jung et al. 2022).
  • PAX8. PAX8 was retained in 76% of ATCs and was negative in head and neck squamous cell carcinomas (Bishop et al. 2011). ATC usually lacks morphologic and immunohistochemical thyroid differentiation, which makes PAX8 the most useful marker of follicular cell origin (Bishop et al. 2011).
  • Diagnosis of exclusion. An ATC negative for both TTF-1 and PAX8 is a diagnosis of exclusion after other high-grade malignancies are ruled out, and immunohistochemistry is required in the workup (CAP 2023).
  • Mandatory BRAF testing. Reflex BRAF V600E mutation-specific VE1 immunohistochemistry and/or BRAF mutation analysis is required in every ATC because BRAF and MEK inhibitors are active against BRAF V600E-driven tumors (CAP 2023). Dabrafenib plus trametinib gave a confirmed response rate of 69% (11 of 16) in BRAF V600E-mutated ATC, with an estimated 12-month overall survival of 80% (Subbiah et al. 2018).
  • Minor anaplastic component. One series found no survival difference between tumors with a minor ATC component and conventional ATC (CAP 2023). Tumors with only focal anaplastic areas and no extrathyroidal extension are still reported separately, and the CAP protocol lists "ATC, focal or minor component without extrathyroidal extension" and "ATC, major component" (CAP 2023).
  • Angiomatoid pattern versus angiosarcoma. Thyroid angiosarcoma expresses CD31, ERG and factor VIII and often keratin. Absence of thyroid differentiation markers, including PAX8, separates angiosarcoma from angiomatoid ATC (Arcovito and Franchi 2026).

Medullary thyroid carcinoma: clinical and morphologic features

  • Origin. MTC arises from the parafollicular C cells, which are endoderm-derived (Non-neoplastic Thyroid Disease: Development, Thyroiditis, Graves Disease and Follicular Nodular Disease). The WHO places it in its own section as a C cell-derived carcinoma (Baloch et al. 2022).
  • Clinical presentation. Sporadic MTC occurs in the fourth to sixth decades. Of patients presenting with a palpable nodule, 70% have cervical nodal metastases and 10% have distant metastases. Central and lateral nodal metastases occur in 14% and 11% of T1 tumors and in 86% and 93% of T4 tumors (Wells et al. 2015). Microcarcinomas under 1.0 cm still show a 20% rate of regional spread and a 5% rate of distant metastasis (CAP 2023).
  • Gross. MTC is firm and white, tan or red. Sporadic MTC is usually solitary and unilateral. Hereditary MTC is usually multicentric and bilateral (Wells et al. 2015).
  • Microscopy. Round, polyhedral or spindle cells form sheets or nests with peripheral palisading in a vascular stroma. Amyloid is present in more than half of MTCs and is composed of full-length calcitonin (Wells et al. 2015).
  • Morphologic mimics. MTC can resemble PTC, FTC, paraganglioma, lymphoma or sarcoma, and some tumors show oncocytic change (Wells et al. 2015).
  • Subtypes. WHO 2017 listed papillary, follicular (tubular or glandular), spindle cell, giant cell, clear cell, oncocytic, melanotic, squamous, amphicrine, paraganglioma-like, angiosarcoma-like and small cell variants of MTC (Bai et al. 2020). The 2022 WHO calls these patterns subtypes (Jung et al. 2022). PAX8 reactivity with some antibody clones can lead to misclassification of a papillary MTC as a follicular cell-derived neoplasm (Cameselle-Teijeiro et al. 2020).
  • Survival by stage. Ten-year survival for stages I, II, III and IV is 100%, 93%, 71% and 21%. On multivariate analysis, only age and stage are independent prognostic factors in historical series (Wells et al. 2015).
Marker Result in MTC Comment Source
Calcitonin Positive; intensity and extent vary Absence makes the diagnosis doubtful; reduced in undifferentiated tumors Wells et al. 2015
CEA (monoclonal) Almost always strongly positive Retained when calcitonin staining is weak Wells et al. 2015; CAP 2023
Chromogranin A, synaptophysin, INSM1 Positive Neuroendocrine markers used to confirm nodal metastases Wells et al. 2015; CAP 2023
TTF-1 (NKX2-1), keratins 7 and 18 Positive TTF-1 is also used to confirm follicular cell-derived carcinoma Wells et al. 2015; CAP 2023
Thyroglobulin Negative Its absence is part of the recommended panel Wells et al. 2015
PAX8 Clone-dependent Reactivity occurs unless C-terminus-specific monoclonal antibodies are used; monoclonal clone MRQ-50 was negative in 45 MTCs CAP 2023
  • Recommended panel. A thyroid tumor with any feature of MTC is assessed for calcitonin, chromogranin and CEA and for the absence of thyroglobulin (ATA grade B recommendation) (Wells et al. 2015).

C-cell hyperplasia and the hereditary precursor of medullary carcinoma

  • Hereditary precursor. In hereditary MTC, C-cell hyperplasia (CCH) precedes carcinoma and is best shown by calcitonin immunohistochemistry. Because it is multicentric and probably clonal, the terms C-cell carcinoma in situ or C-cell neoplasia are considered more appropriate (Wells et al. 2015).
  • Criteria. Most pathologists diagnose CCH when there are more than seven C cells per cluster, complete follicles surrounded by C cells and C cells beyond their normal location at the junction of the upper third and lower two-thirds of the lateral lobes. Atypical C cells that breach the basement membrane, or a desmoplastic stromal response, indicate invasion (Wells et al. 2015).
  • Secondary (physiologic) CCH. CCH associated with hyperparathyroidism, chronic lymphocytic thyroiditis, renal insufficiency and aging is not premalignant (Wells et al. 2015).
  • Specificity. In 118 completion thyroidectomies without MTC or MEN2 risk factors, criteria for CCH were met in 4.2% to 30.5% depending on the definition, so CCH is not a specific marker of hereditary MTC (Fuchs et al. 2019).
  • Genetic triage. Patients with presumed sporadic MTC who have CCH or multifocal disease are evaluated for germline RET mutation (Wells et al. 2015).

Medullary thyroid carcinoma: molecular pathology and hereditary disease

  • Germline RET. Germline RET mutations are present in virtually all patients with MEN2A and MEN2B (Wells et al. 2015).
  • Hidden hereditary disease. Between 1% and 7% of patients with presumed sporadic MTC have hereditary disease. Every patient with a cytologic or histologic diagnosis of MTC has a physical examination, serum calcitonin and CEA and germline RET testing, and pheochromocytoma and hyperparathyroidism are excluded in hereditary cases (Wells et al. 2015).
  • Somatic alterations. About half of sporadic MTCs carry somatic RET mutations, and 18%–80% of tumors without somatic RET mutations carry somatic RAS mutations. Somatic RET M918T predicts an aggressive course (Wells et al. 2015).
  • Somatic testing. Routine testing of sporadic MTC for somatic RAS or RET M918T is not standard practice (Wells et al. 2015).
  • Serum markers. Calcitonin and CEA are the clinically useful tumor markers. Rare advanced MTCs secrete neither, which indicates dedifferentiation or misdiagnosis and carries a poor prognosis (Wells et al. 2015).

International Medullary Thyroid Carcinoma Grading System

The International Medullary Thyroid Carcinoma Grading System (IMTCGS) was developed from 327 MTCs at five centers in the United States, Europe and Australia. It unified the earlier Memorial Sloan Kettering two-tier and Sydney three-tier schemes (Xu et al. 2022a). The WHO 5th edition endorses the IMTCGS as a prognostic variable for MTC. Previous rule (WHO 2017): MTC had no grading system (CAP 2023; Jung et al. 2022).

Grade Mitotic count Ki-67 index Tumor necrosis Frequency 10-year disease-specific survival Source
Low grade <5 per 2 mm² <5% Absent 75.2% (246 of 327) 97% Xu et al. 2022a
High grade (any one feature) ≥5 per 2 mm² ≥5% Present 24.8% (81 of 327) 53% Xu et al. 2022a
  • Methods. Mitoses and Ki-67 are assessed in hotspots, mitoses per 2 mm² and Ki-67 on 500–2,000 tumor cells. Necrosis is tumor necrosis with degenerating cytoplasm and karyorrhectic debris regardless of extent. Infarct-like necrosis with fibroblastic reaction, hemorrhage or an FNA tract is excluded (Xu et al. 2022a).
  • Independent prognostic value. High grade independently predicted worse overall survival (hazard ratio 10.8), disease-specific survival (8.5), distant metastasis-free survival (2.3) and locoregional recurrence-free survival (1.9) in the Results section; the abstract gives 11.5, 8.5, 2.5 and 2.1 (Xu et al. 2022a).
  • Necrosis alone. Ten-year disease-specific survival was 95% without and 34% with tumor necrosis (Xu et al. 2022a).
  • Associations. High-grade MTCs were larger, more often in men and stage IV, and more often showed vascular invasion, microscopic extrathyroidal extension and positive margins (Xu et al. 2022a).
  • Reporting. The exact mitotic count and Ki-67 index are documented with the grade (Xu et al. 2022a). Ki-67 is required in every MTC and in the MTC component of mixed carcinomas, by manual count or image analysis. Visual estimation is not allowed (CAP 2023).

Mixed medullary and follicular cell-derived thyroid carcinoma

  • Classification. The 2022 WHO has a separate section for mixed tumors composed of C cells and any follicular cell-derived malignancy, with mixed medullary-follicular and mixed medullary-papillary carcinoma (Baloch et al. 2022; Jung et al. 2022).
  • Dual origin. Microdissection of 12 mixed medullary-follicular carcinomas showed different mutations, allelic losses and clonal composition in the two components, so they do not derive from a single progenitor cell. The follicular structures were often oligoclonal or polyclonal and hyperplastic (Volante et al. 1999).
  • Invasion in mixed tumors. In mixed-type thyroid carcinoma, only the neuroendocrine tumor cells escape the follicular basement membrane and invade, with a migratory phenotype resembling C-cell precursors (Lobo et al. 2026).
  • Collision. Coexisting PTC or FTC and MTC is considered a collision of neoplastic C cells and follicular cells. Simultaneous MTC and PTC occurred in 2.6% of 1,019 PTCs and in 3.6% of 727 MTCs in one German series (Wells et al. 2015).
  • Reporting. Each component of a mixed carcinoma is documented in its own synoptic report (CAP 2023).

Primary thyroid lymphoma

  • Types. Diffuse large B-cell lymphoma (DLBCL) was the most frequent primary thyroid lymphoma in SEER (68% of 1,408). Most (88%) were stage I–II, and median survival was 9.3 years. Age ≥80 years, advanced stage, no radiation or surgery and DLBCL or follicular histology predicted worse survival (Graff-Baker et al. 2009).
  • Hashimoto thyroiditis. In 829 patients with chronic lymphocytic thyroiditis, the relative risk of thyroid lymphoma was 67 (Holm et al. 1985).
  • Extranodal marginal zone (MALT) lymphoma. In 18 thyroid MALT lymphomas, prominent lymphoepithelial lesions including "MALT ball" lesions were present, plasmacytic differentiation occurred in 15 (extensive in 12), 14 were IgG positive and IRTA1-positive cells were present in all tested cases. IRTA1 is also present in Hashimoto thyroiditis, with a less extensive and perifollicular pattern (Carlsen et al. 2023).

Related page: Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia (extranodal marginal zone lymphoma) Related page: Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging (diffuse large B-cell lymphoma)

Rare primary thyroid tumors

Tumor WHO 2022 section Morphology Immunohistochemistry and genetics Behavior and distinction Source
Mucoepidermoid carcinoma Salivary gland-type carcinoma Epidermoid and mucous cells Thyroglobulin, PAX8, keratin 19, p63 and S100 positive; TTF-1 weak; CRTC1::MAML2 or CRTC3::MAML2 fusion Separated from SMECE by the MAML2 fusion and thyroglobulin expression Jung et al. 2022
Secretory carcinoma (formerly mammary analogue secretory carcinoma) Salivary gland-type carcinoma Papillary growth and nuclear irregularity that mimic PTC Thyroglobulin and TTF-1 negative; PAX8 negative or weak; GATA3, mammaglobin, GCDFP-15 and S100 positive; ETV6::NTRK3 fusion, a target of TRK inhibitors 13 reported cases; advanced presentation, tumor-related mortality about 30% Jung et al. 2022; Chu et al. 2024
Sclerosing mucoepidermoid carcinoma with eosinophilia Uncertain histogenesis Epidermoid and mucous cells in sclerotic stroma with eosinophils and lymphocytes, always with chronic lymphocytic thyroiditis p63 and keratin 19 positive; thyroglobulin, TTF-1 (or weak focal) and PAX8 negative; MAML2 fusion absent Age and distant metastasis are possible risk factors Jung et al. 2022; Han and Xu 2025
Cribriform-morular thyroid carcinoma Uncertain histogenesis Cribriform growth with morulae and little or no colloid; mean age 33 years, almost all female Nuclear and cytoplasmic β-catenin; TTF-1 positive in the cribriform component; thyroglobulin negative; PAX8 absent or focal; morulae keratin 5 and CD5 positive; APC or CTNNB1 alteration; estrogen and progesterone receptor positive Germline APC mutations in 12 tumors of the subset tested; association with familial adenomatous polyposis, sometimes before polyps are known; ATA 2025 conditionally recommends germline APC testing after a pathologic diagnosis of CMTC Boyraz et al. 2021; Jung et al. 2022; CAP 2023; Ringel et al. 2025
Intrathyroidal thymic carcinoma Thymic tumor within the thyroid Squamous features that mimic ATC with a squamous pattern or metastatic squamous cell carcinoma p63, high-molecular-weight keratin, CEA and CD5 positive (CD5 in 80%); TTF-1 negative; polyclonal PAX8 positive in 40% and monoclonal PAX8 negative 10-year survival above 80% Reimann et al. 2006; Suzuki et al. 2018; Jung et al. 2022
Spindle epithelial tumor with thymus-like elements (SETTLE) Thymic tumor within the thyroid Biphasic spindle cell and glandular tumor with low mitotic activity, no necrosis and no pleomorphism; median age 13.5 years High-molecular-weight keratin in 88% and keratin 7 in 88%; SS18::SSX fusion absent (separates it from synovial sarcoma) Low-grade malignancy with late lymph node and lung metastases Folpe et al. 2009
Thyroblastoma Embryonal thyroid neoplasm Primitive small cells, TTF-1 and PAX8-positive primitive follicles or tubules and immature mesenchymal stroma Somatic DICER1 hotspot mutations; SALL4 in the small cell or stromal component Highly aggressive Agaimy et al. 2020; Jung et al. 2022
Angiosarcoma Mesenchymal (standalone chapter) Large epithelioid pleomorphic cells with vascular spaces, hemosiderin and necrosis, often in long-standing goiter (Alpine regions) CD31, ERG and factor VIII positive; keratin often positive; thyroid markers including PAX8 negative Aggressive; 20% of thyroid mesenchymal tumors Arcovito and Franchi 2026
  • Solid cell nests. Shared expression of p63, CEA and high-molecular-weight keratin supports a solid cell nest origin for intrathyroidal thymic carcinoma and SMECE (Reimann et al. 2006; Jung et al. 2022).
  • Monoclonal PAX8 in thymic carcinoma. All PDTCs and 92.9% of thyroid squamous cell carcinomas were positive for polyclonal and monoclonal PAX8, and no intrathyroidal thymic carcinoma was positive for monoclonal PAX8 (Suzuki et al. 2018).

Related page: Thymoma and Thymic Carcinoma on FNA (thymic epithelial tumors)

Metastases to the thyroid

  • Frequency and primaries. Metastases account for 0.02%–1.4% of resected thyroid specimens (Nixon et al. 2011).
  • Institutional series. Of 1,939 thyroid malignancies, 31 (1.6%) were metastatic epithelial neoplasms. Clear cell renal cell carcinoma (36%), non-small cell lung carcinoma (19%), esophageal carcinoma (16%), head and neck carcinoma (16%) and melanoma (10%) were the primaries. The interval from the primary tumor was longest for clear cell renal cell carcinoma, and resection was associated with longer survival (25 versus 3.8 months) (Stergianos et al. 2021).
  • Renal cell carcinoma. Clear cell renal cell carcinoma is the most frequent metastasizing tumor in clinical series, followed by lung and breast carcinoma. Metastatic clear cell renal cell carcinoma is positive for PAX8 and carbonic anhydrase IX (CAIX) and negative for TTF-1 and thyroglobulin. Most patients have a history of goiter, the metastasis can be the first sign of the renal tumor (Queipo et al. 2019).
Immunostain Follicular cell-derived thyroid carcinoma Metastatic clear cell renal cell carcinoma Source
PAX8 Positive Positive Queipo et al. 2019; CAP 2023
TTF-1 Positive Negative Queipo et al. 2019; CAP 2023
Thyroglobulin Positive Negative Queipo et al. 2019; CAP 2023

Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (clear cell renal cell carcinoma)

AJCC 8th edition staging of anaplastic and medullary thyroid carcinoma

ATC and MTC use the AJCC 8th edition T and N definitions of differentiated thyroid carcinoma (Papillary thyroid carcinoma). Age is not used for MTC stage groups (CAP 2023).

Stage Anaplastic thyroid carcinoma (AJCC 8th edition) Medullary thyroid carcinoma (AJCC 7th and 8th editions) Source
I No ATC is assigned stage I; every ATC is stage IV T1 N0 M0 Perrier et al. 2018; Mathiesen et al. 2019
II No ATC is assigned stage II T2–T3 N0 M0 Mathiesen et al. 2019
III No ATC is assigned stage III T1–T3 N1a M0 Mathiesen et al. 2019
IVA T1–T3a N0/NX M0 (intrathyroidal tumor) T4a any N M0; T1–T3 N1b M0 Perrier et al. 2018; Wells et al. 2015
IVB T1–T3a N1 M0; T3b any N M0; T4 any N M0 T4b any N M0 Perrier et al. 2018; Wells et al. 2015
IVC Any T, any N, M1 Any T, any N, M1 Perrier et al. 2018; Wells et al. 2015
  • ATC T category. Previous rule (AJCC 7th edition): every ATC was T4, with intrathyroidal ATC T4a and ATC with gross extrathyroidal extension T4b. The 8th edition applies the differentiated carcinoma T definitions to ATC and keeps the stage groups: intrathyroidal IVA, nodal disease or gross extrathyroidal extension IVB and distant metastasis IVC (Perrier et al. 2018).
  • Distant metastasis in older patients with DTC versus ATC. In the 8th edition, distant metastasis in a patient aged 55 years or older with differentiated carcinoma is stage IVB, while distant metastasis in ATC remains stage IVC (Perrier et al. 2018).
  • Level VII nodes. Previous rule (AJCC 7th edition, as applied to MTC): superior mediastinal (level VII) nodes were N1b; the 8th edition classifies them as N1a (Wells et al. 2015; CAP 2023).
  • Minimal extrathyroidal extension. Previous rule (AJCC 7th edition, as applied to MTC): T3 included any tumor with minimal extrathyroidal extension (Wells et al. 2015). In the 8th edition, minimal extrathyroidal extension no longer changes the T category (CAP 2023).
  • Limits of TNM in MTC. TNM does not include age gradations, postoperative calcitonin or the number of involved nodes, and the ATA task force proposed nodal groups of 0, 1–10, 11–20 and >20 (Wells et al. 2015). A proposed regrouping gave better survival separation of stage I versus II and III versus IV in a Danish national cohort of 191 patients (Mathiesen et al. 2019).

CAP Thyroid 4.4.0.0 reporting elements for non-papillary carcinomas

Element Responses and rules Source
Separate reports MTC uses a separate synoptic report, and each component of a mixed medullary and follicular cell-derived carcinoma is documented separately CAP 2023
Histologic type FTC and oncocytic carcinoma as minimally invasive, encapsulated angioinvasive or widely invasive; high-grade FTC, invasive encapsulated follicular variant PTC, PTC or oncocytic carcinoma, or DHGTC NOS; PDTC NOS or oncocytic PDTC; ATC NOS, focal or minor component without extrathyroidal extension, or major component; MTC; mixed carcinomas; salivary gland-type, thymic, uncertain cytogenesis and embryonal tumors CAP 2023
Mitotic rate <3, ≥3 to <5, or ≥5 mitoses per 2 mm², with the count optional; perineural invasion optional CAP 2023
Ki-67 labeling index Required in every MTC and the MTC component of mixed carcinomas; manual count or automated image analysis CAP 2023
Tumor necrosis Not identified or present CAP 2023
Ancillary studies Reflex BRAF V600E (VE1 immunohistochemistry and/or mutation analysis) in every ATC; molecular results on the CAP Thyroid Biomarker template CAP 2023

Related page: Follicular Cell-Derived Thyroid Neoplasms: WHO 2022 Classification, Follicular and Oncocytic Adenoma and Carcinoma, Low-Risk Neoplasms and Invasion Criteria (criteria for capsular invasion and angioinvasion)

Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes

Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), classifies parathyroid proliferations as parathyroid adenoma, multiglandular parathyroid disease, atypical parathyroid tumor and parathyroid carcinoma, with secondary hyperplasia kept for glands stimulated by chronic kidney disease (Erickson et al. 2022; Uljanovs et al. 2022). Primary hyperparathyroidism is caused by a single adenoma in 80%–85% of patients, by disease of multiple glands in 10%–15% and by carcinoma in less than 1% in most series and up to 5% in others (Duan et al. 2015; Uljanovs et al. 2022). About 95% of hyperparathyroidism is sporadic and about 5% is hereditary (Duan et al. 2015). The 2022 classification adds the parafibromin-deficient parathyroid neoplasm and emphasizes morphologic and immunohistochemical clues to germline MEN1, CDKN1B, MAX and CDC73 disease (Erickson et al. 2022). No CAP cancer protocol exists for the parathyroid. The International Collaboration on Cancer Reporting (ICCR) dataset covers parathyroid carcinoma and atypical parathyroid neoplasm (Williams et al. 2021).

Related page: Calcium, Parathyroid Hormone, Vitamin D, Magnesium and Phosphate (PTH assays, hypercalcemia, FHH types 1–3, hypocalcemia and the intraoperative PTH decline criterion) Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (MEN1 diagnostic criteria and tumor frequencies, MEN2 risk categories and biochemical screening) Related page: High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging (medullary thyroid carcinoma and C-cell hyperplasia in MEN2) Related page: Medullary Thyroid Carcinoma (Cytology) (medullary thyroid carcinoma on FNA) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (duodenal gastrinoma and other digestive neuroendocrine tumors in MEN1) Related page: Pancreatic Neuroendocrine Neoplasms: Neuroendocrine Tumors, Functioning Syndromes, Neuroendocrine Carcinoma, Hereditary Syndromes and Staging (pancreatic neuroendocrine tumors in MEN1) Related page: Adrenal Cortex Pathology: Hyperplasia and Nodular Disease, Adrenalitis and Hemorrhage, Adrenal Cortical Adenoma and Carcinoma, Myelolipoma, Cysts and Metastases (adrenal cortical lesions in MEN1) Related page: Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms (pheochromocytoma in MEN2, MEN5 and other hereditary paraganglioma syndromes) Related page: Pituitary and Sellar Region Pathology: Pituitary Neuroendocrine Tumors, Hypophysitis, Craniopharyngioma, Rathke Cleft Cyst and Posterior Pituitary Tumors (pituitary tumors in MEN1 and MEN4) Related page: Non-neoplastic Thyroid Disease: Development, Thyroiditis, Graves Disease and Follicular Nodular Disease (thyroid embryology, ultimobranchial body and C cells) Related page: Follicular Cell-Derived Thyroid Neoplasms: WHO 2022 Classification, Follicular and Oncocytic Adenoma and Carcinoma, Low-Risk Neoplasms and Invasion Criteria (familial follicular cell-derived thyroid neoplasia) Related page: Neck Mass FNA and Cystic Neck Lesions (cystic neck masses on FNA)

Parathyroid embryology, anatomy and normal histology

  • Origin. In the sixth gestational week, the inferior parathyroid glands develop from the dorsal part of the third pharyngeal pouch, whose ventral part forms the thymus. The superior parathyroid glands develop from the dorsal part of the fourth pharyngeal pouch, whose ventral part forms the ultimobranchial body. The inferior glands migrate caudally with the thymus (Uludağ et al. 2019).
  • Number. In 503 autopsies, 84% had four glands, 13% had supernumerary glands (most often a fifth gland in the thymus) and 3% had only three glands found. Glands on the two sides were symmetric in about 80% (Akerström et al. 1984). A supernumerary gland weighs at least 5 mg; smaller extra glands are rudimentary or accessory glands (Uludağ et al. 2019).
  • Size and position. A normal gland measures about 5 × 3 × 1 mm and weighs 35–40 mg (range 10–78 mg). Superior glands lie at the cricothyroid junction on the posterolateral upper and middle thyroid. Inferior glands lie within 1 cm of the lower thyroid pole or in the upper thymus or thyrothymic ligament (Akerström et al. 1984; Uludağ et al. 2019).
  • Ectopic glands. Ectopic glands occur in 2%–43% of anatomic series and in up to 16% of patients with primary and 14% with secondary hyperparathyroidism. Ectopic inferior glands are found most often in the anterior mediastinum with the thymus or thyroid; ectopic superior glands are found most often in the tracheoesophageal groove and retroesophageal region (Noussios et al. 2012). In a meta-analysis, 31.4% of ectopic cervical glands were retroesophageal or paraesophageal, 20.3% intrathyroidal, 17.7% in the carotid sheath and 17% in the thyrothymic ligament. Most mediastinal glands were in the thymus (Uludağ et al. 2019).
  • Intrathyroidal glands. Intrathyroidal parathyroid glands are completely surrounded by thyroid tissue and occur in 0.2%–3.2% of autopsy and surgical series. Inferior glands are intrathyroidal more often than superior glands (Uludağ et al. 2019). Intrathyroidal parathyroid glands account for about 2% of primary hyperparathyroidism (Juhlin and Mete 2026).
  • Congenital and acquired ectopy. Congenital ectopy, from abnormal embryologic migration, affects mainly the inferior glands. Acquired ectopy, from migration of an enlarged gland, affects mainly the superior glands, which can descend along the paraesophageal and retroesophageal route into the posterior mediastinum (Uludağ et al. 2019).
  • Stromal fat. In 90 autopsied patients without parathyroid disease, stromal fat averaged 17%, almost one-third of glands had less than 10% fat and fat did not correlate with age, serum calcium or gland weight (Dufour and Wilkerson 1982). In 100 normal glands measured by image analysis, fat averaged 38% and correlated with age and body constitution with wide variation (Obara et al. 1990). Stromal fat percentage alone therefore does not separate a normal from an abnormal gland (Dufour and Wilkerson 1982; Obara et al. 1990).

Intraoperative assessment and immunohistochemical identification of parathyroid tissue

  • Frozen section and gland number. Frozen section does not reliably separate a single adenoma from involvement of several glands, and intraoperative PTH monitoring is more reliable for that question (Juhlin and Erickson 2021). The pathologist confirms that each excised nodule is parathyroid tissue and reports its weight and size (Duan et al. 2015).
  • Frozen section discrepancies. Among 1,844 head and neck frozen sections, 5 of 23 major interpretive errors concerned the distinction of parathyroid from thyroid tissue. Three microfollicular lesions were called thyroid or parathyroid when the reverse was true on permanent sections and needed immunohistochemistry, and two involved scant parathyroid tissue at the edge of the slide that was not identified (Albright et al. 2026).
  • Fat stains. Oil red O on frozen sections showed less intracellular lipid in hyperfunctioning chief cells than in suppressed parathyroid tissue and helped separate adenoma from hyperplasia (Ljungberg and Tibblin 1979). Sudan IV gave contradictory results in 2 of 13 hyperfunctioning glands and 11 of 73 normal glands, so neutral lipid stains are interpreted with caution (Dufour and Durkowski 1982).
  • Parathyroid versus thyroid. PTH and GATA3 are retained in parathyroid tumors, including water-clear cell adenoma and lipoadenoma (Juhlin and Mete 2026). TTF-1 and thyroglobulin are negative in parathyroid cells, and PTH is absent from thyroid tissue (Uljanovs et al. 2022). Monoclonal C-terminus-specific PAX8 does not stain parathyroid tissue, whereas polyclonal PAX8 can stain parathyroid tumors, so the PAX8 clone is documented (Juhlin and Mete 2026).
  • Neuroendocrine markers. Chromogranin A is positive in 98% of parathyroid lesions, synaptophysin in 11%–100% and INSM1 in none. CD56 is negative in parathyroid tissue and favors a nonparathyroid origin in a cervical neoplasm (Uljanovs et al. 2022).
  • Parathyroid versus medullary thyroid carcinoma. Medullary thyroid carcinoma is positive for chromogranin A, calcitonin and CEA, usually positive for TTF-1 and negative for PTH (Juhlin and Erickson 2021; Uljanovs et al. 2022). Calcitonin can be positive in rare parathyroid tumors, so PTH and TTF-1 form the distinguishing panel (Juhlin and Erickson 2021).
  • Parathyroid versus paraganglioma. Paraganglioma has zellballen with S100-positive sustentacular cells and lacks keratins (Uljanovs et al. 2022).
Marker Parathyroid tissue and tumors Medullary thyroid carcinoma Source
PTH Positive (almost always) Negative Uljanovs et al. 2022; Juhlin and Erickson 2021
TTF-1 Negative Positive in up to 80% Uljanovs et al. 2022
Thyroglobulin Negative Negative Uljanovs et al. 2022
Chromogranin A Positive in 98% Positive Uljanovs et al. 2022
Calcitonin Rarely positive Positive in 80% Uljanovs et al. 2022; Juhlin and Erickson 2021
PAX8 Negative with monoclonal C-terminus antibody; positive with polyclonal antibody Positive in 75%; clone dependent Uljanovs et al. 2022; Juhlin and Mete 2026

WHO 2022 classification of parathyroid proliferations

  • Multiglandular parathyroid disease. The 2022 classification no longer supports "hyperplasia" for multiglandular disease in primary hyperparathyroidism, because affected glands are usually composed of multiple clonal neoplastic proliferations. It classifies this disease (multiple parathyroid adenomas) as germline susceptibility-driven multiglandular parathyroid neoplasia (Erickson et al. 2022). Previous rule (WHO 4th edition, 2017): multiglandular disease in primary hyperparathyroidism was primary parathyroid hyperplasia (Hernandez-Prera et al. 2025; Uljanovs et al. 2022).
  • Hyperplasia. "Parathyroid hyperplasia" is now used mainly for secondary hyperplasia, most often caused by chronic renal failure (Erickson et al. 2022).
  • Atypical parathyroid tumor. The 2022 classification replaces "atypical parathyroid adenoma" with "atypical parathyroid tumor," a parathyroid neoplasm of uncertain malignant potential (Erickson et al. 2022; Gokozan and Scognamiglio 2023).
  • Parafibromin-deficient parathyroid neoplasm. A parathyroid neoplasm with complete absence of nuclear parafibromin immunoreactivity is designated parafibromin-deficient. Nucleolar loss alone is abnormal and needs molecular testing to confirm its significance (Erickson et al. 2022).
Lesion (WHO 2022) Former term Setting Glands Defining histology Behavior Source
Parathyroid adenoma Parathyroid adenoma Primary hyperparathyroidism (80%–85%) One Circumscribed chief, oncocytic, transitional or water-clear cell proliferation with reduced stromal fat; rim of residual gland in about half Benign Uljanovs et al. 2022; Juhlin and Mete 2026
Multiglandular parathyroid disease (multiglandular parathyroid neoplasia) Primary parathyroid hyperplasia Primary hyperparathyroidism (10%–15%); germline syndromes Several Clonal nodules in several glands; increased parenchyma-to-fat ratio Clonal neoplasia Erickson et al. 2022; Uljanovs et al. 2022
Secondary parathyroid hyperplasia Secondary parathyroid hyperplasia Chronic kidney disease Several Diffuse hyperplasia, then nodular hyperplasia with fibrosis and irregular contours Hyperplasia that can mimic carcinoma Duan et al. 2015; Palumbo et al. 2021; Juhlin and Mete 2026
Atypical parathyroid tumor Atypical parathyroid adenoma Primary hyperparathyroidism One Worrisome features without unequivocal invasion or metastasis Uncertain malignant potential Erickson et al. 2022; Juhlin and Mete 2026
Parathyroid carcinoma Parathyroid carcinoma Primary hyperparathyroidism (less than 1%); hyperparathyroidism-jaw tumor syndrome One Angioinvasion, lymphatic or perineural invasion, invasion of adjacent structures or metastasis Malignant Erickson et al. 2022; Juhlin and Erickson 2021

Parathyroid adenoma

  • Clinical correlation. Adenomas of 40–100 mg are associated with mild or asymptomatic disease. Adenomas larger than 1 cm are associated with higher calcium and PTH and a greater risk of skeletal involvement (Juhlin and Mete 2026).
  • Histology. An adenoma is a circumscribed, noninvasive proliferation of chief cells in micro-acinar or palisading formations, with transitional, oncocytic or water-clear cells. Stromal fat is reduced or absent. Scattered hyperchromatic, atypical or multinucleated cells can occur (Juhlin and Erickson 2021; Juhlin and Mete 2026).
  • Rim of residual gland. A rim of compressed nontumorous parathyroid tissue is present in more than half of adenomas when the gland is sectioned through the vascular hilum (Juhlin and Mete 2026). It is seen more often in small adenomas. A rim does not exclude multiglandular disease, which shows an apparent rim in up to 10% (Juhlin and Erickson 2021).
  • Proliferation and biomarkers. Adenomas have a Ki-67 labeling index below 5% and ≤5 mitoses per 10 mm². Parafibromin, APC and BCL2 are retained, and galectin-3 and PGP9.5 are negative (Juhlin and Mete 2026).
  • Somatic genetics. About 25%–40% of sporadic adenomas show loss of heterozygosity at the MEN1 locus on 11q13, and half of these carry an inactivating MEN1 mutation of the other allele (Juhlin and Erickson 2021). The pericentric 11p inversion that places CCND1 under control of the PTH gene promoter occurs in 5%–8% of adenomas, whereas cyclin D1 protein is overexpressed in about 40% (Uljanovs et al. 2022). Somatic CDC73 mutations occur in up to 6% of adenomas (Uljanovs et al. 2022).
Adenoma subtype Defining criterion Clinical association Source
Oncocytic adenoma Oncocytic (oxyphilic) cells form more than 75% of neoplastic cells, the parathyroid threshold given by Martiradonna et al. 2026 (the thyroid threshold of ≥75% is in Follicular Cell-Derived Thyroid Neoplasms: WHO 2022 Classification, Follicular and Oncocytic Adenoma and Carcinoma, Low-Risk Neoplasms and Invasion Criteria) Larger tumors; calcium and PTH can be lower than in conventional adenomas of similar size Martiradonna et al. 2026; Juhlin and Erickson 2021
Water-clear cell adenoma Composed entirely of water-clear cells, which have vacuolated cytoplasm, probably from glycogen accumulation, and hyperchromatic nuclei Higher calcium than lipoadenoma (12.1 versus 11.3 mg/dL); ultrasound positive in 97% Uljanovs et al. 2022; Martiradonna et al. 2026
Cystic adenoma Predominant cystic growth pattern Parafibromin loss occurs in a subset of sporadic cystic adenomas; cystic tumors raise the possibility of CDC73 disease Juhlin and Erickson 2021
Lipoadenoma Mature adipose tissue forms more than 50% of the glandular volume Possible association with arterial hypertension Martiradonna et al. 2026
  • Rare subtypes and localization. Sestamibi scintigraphy was positive in 61%–67% of lipoadenomas, oncocytic adenomas and water-clear cell adenomas (Martiradonna et al. 2026).

Multiglandular parathyroid disease and secondary and tertiary hyperparathyroidism

  • Multiglandular disease in primary hyperparathyroidism. Multiple adenomas are diagnosed when each nodule meets the features of adenoma (Uljanovs et al. 2022). Up to 10% of patients with primary multiglandular disease have MEN1 (Juhlin and Erickson 2021).
  • Supernumerary glands. Supernumerary and accessory glands can enlarge under continuous stimulation in MEN1 and secondary hyperparathyroidism (Uludağ et al. 2019). Wide excision of perithyroidal fat and thymectomy are recommended in uremic hyperparathyroidism and MEN syndromes because of supernumerary glands in the thymus (Akerström et al. 1984).
  • Secondary hyperparathyroidism. Secondary hyperparathyroidism usually presents with diffuse parathyroid hyperplasia (Duan et al. 2015). In chronic kidney disease, hyperphosphatemia, calcitriol deficiency and hypocalcemia stimulate PTH secretion. Hyperphosphatemia directly stimulates the parathyroid cell and produces nodular hyperplasia (Palumbo et al. 2021).
  • Carcinoma mimics in secondary disease. Long-standing secondary hyperparathyroidism produces nodular hyperplasia with irregular contours, nodules protruding through a thickened capsule, broad fibrous bands and more than 5 mitoses per 10 mm². Similar findings occur in multiglandular adenomas of MEN1 and with chronic lithium therapy (Juhlin and Mete 2026).
  • Tertiary hyperparathyroidism. Tertiary hyperparathyroidism is excess PTH secretion after long-standing secondary hyperparathyroidism. Some authorities reserve the term for secondary disease that persists after successful renal transplantation (Palumbo et al. 2021). It reflects the emergence of autonomous PTH-producing neoplasms from secondary hyperplasia (Duan et al. 2015). No carcinoma associated with tertiary hyperparathyroidism showed parafibromin loss in one series (Uljanovs et al. 2022).

Atypical parathyroid tumor

An atypical parathyroid tumor (formerly atypical parathyroid adenoma) is a noninvasive parathyroid neoplasm with worrisome features that does not meet the criteria for carcinoma after adequate sampling (Erickson et al. 2022; Uljanovs et al. 2022).

Worrisome feature of atypical parathyroid tumor Qualification Source
Trabecular or sheet-like architecture Not diagnostic of malignancy alone Uljanovs et al. 2022
Band-like fibrosis Without prior FNA; secondary and tertiary hyperparathyroidism also produce fibrous bands Uljanovs et al. 2022
Cytologic atypia with enlarged nucleoli or macronucleoli Not diagnostic of malignancy alone Uljanovs et al. 2022; Juhlin and Mete 2026
Increased mitotic activity More than 5 mitoses per 10 mm² in a noninvasive tumor without prior manipulation Juhlin and Mete 2026
Atypical mitoses Not diagnostic of malignancy alone Uljanovs et al. 2022
Coagulative necrosis Without prior FNA Uljanovs et al. 2022
Adherence to surrounding tissues Without frank invasion of those tissues Uljanovs et al. 2022
Tumor cells within the capsule Without full-thickness capsular penetration Uljanovs et al. 2022
  • Workup. Additional levels search for invasion, and a biomarker panel (parafibromin, RB, p27, APC, galectin-3, PGP9.5 and Ki-67) refines the risk. Diffuse loss of parafibromin or APC and PGP9.5 reactivity raise the suspicion of malignancy. Intact parafibromin and APC with negative PGP9.5 support a benign process (Juhlin and Mete 2026).
  • Behavior. Most atypical parathyroid tumors are indolent after complete excision, and a small subset recurs or metastasizes (Juhlin and Mete 2026; Juhlin and Erickson 2021). Atypical parathyroid tumors with parafibromin deficiency are at high risk of recurrence (Juhlin and Mete 2026).
  • Clinical correlation. Preoperative cytology, multiglandular disease, MEN1 or prior manipulation often explains fibrosis or mitoses in a parathyroid tumor (Juhlin and Mete 2026).

Parathyroid carcinoma: clinical features, diagnostic criteria and reporting

  • Frequency and demographics. Parathyroid carcinoma causes less than 1% of primary hyperparathyroidism in Western series, and surgical cohorts report 0.3%–5.2% (Uljanovs et al. 2022). The population incidence is 3.5–5.7 per 10 million (Uljanovs et al. 2022). The carcinoma affects women and men about equally or with a slight male predominance and presents most often at 45–60 years (Juhlin and Erickson 2021; Juhlin and Mete 2026).
  • Clinical clues. A firm palpable neck mass, a gland larger than 3 cm, serum calcium above 3.0 mmol/L (12 mg/dL), PTH several times the upper reference limit and intraoperative adhesion or invasion raise suspicion. None is diagnostic alone (Juhlin and Mete 2026). Adenomas can also adhere firmly to the thyroid (Juhlin and Erickson 2021).
  • Spread and outcome. In 609 SEER cases, lymph node metastases were present in 25.2% and distant metastases in 2.2% (Uljanovs et al. 2022). Ten-year survival is about 50%–70%, and death often results from hypercalcemia (Juhlin and Erickson 2021).

WHO 2022 diagnostic criteria for parathyroid carcinoma

The histologic diagnosis requires one of the following (Erickson et al. 2022):

Criterion Definition and exclusions Source
Angioinvasion (vascular invasion) Tumor invading through a vessel wall with associated thrombus, or intravascular tumor cells admixed with thrombus, in a vessel in the capsule or outside the tumor; tumor cells in an intratumoral vessel or displaced during grossing do not qualify Erickson et al. 2022; Uljanovs et al. 2022
Lymphatic invasion Retraction artifact excluded; endothelial immunostains are recommended Erickson et al. 2022; Uljanovs et al. 2022
Perineural (intraneural) invasion Tumor around or within a nerve Erickson et al. 2022; Juhlin and Mete 2026
Local invasion into adjacent structures Soft tissue, thyroid, esophagus or skeletal muscle; tumor within its capsule and intrathyroidal parathyroid location do not qualify Erickson et al. 2022; Uljanovs et al. 2022
Metastasis Histologically or cytologically documented regional or distant metastasis Erickson et al. 2022
  • Nondiagnostic features. Broad fibrous bands, coagulative necrosis, solid growth, macronucleoli and increased mitoses are common in carcinoma and are not diagnostic alone. The triad of coagulative necrosis, macronucleoli and more than 5 mitoses per 10 mm² (originally 5 per 50 high-power fields) raises suspicion for carcinoma but lacks absolute specificity (Juhlin and Mete 2026).
  • Capsule. Most parathyroid tumors are unencapsulated. Tumor extension into a capsule does not establish malignancy, and the capsular invasion criteria of encapsulated follicular thyroid tumors do not apply to parathyroid tumors (Juhlin and Mete 2026).
  • Vascular invasion search. Vascular invasion is sought at the interface of tumor and nontumorous parenchyma and beyond the tumor periphery. CD61 highlights the platelet and fibrin response of true vascular invasion, and CD31 or ERG confirm an endothelial lining (Juhlin and Mete 2026).
  • Proliferation. Mitotic count per 10 mm² and the Ki-67 labeling index are documented in parathyroid carcinoma (Erickson et al. 2022). Mean Ki-67 in carcinoma ranges from 6.1% to 13.9%, compared with 1.9%–4.3% in adenomas, and a 5% cutoff helps separate them without being a WHO diagnostic criterion (Uljanovs et al. 2022). Hotspot Ki-67 averaged 11.8% in carcinoma and 3.5% in adenoma in one series (Uljanovs et al. 2022).
  • Biomarker panel. Loss of parafibromin, RB, p27, BCL2, MDM2 and APC and overexpression of galectin-3, PGP9.5 and p53 support malignancy (Juhlin and Mete 2026). p27 was expressed in 80% of adenomas, 43% of atypical adenomas and 18% of carcinomas at a 30% cutoff (Uljanovs et al. 2022). Cyclin D1 does not separate benign from malignant parathyroid tumors (Uljanovs et al. 2022).
  • Molecular findings. Somatic CDC73 mutations are present in 60%–90.9% of carcinomas (Uljanovs et al. 2022). TERT promoter mutations are rare. Carcinomas show hypermethylation of CDKN2A, CDKN2B, WT1 and SFRP genes, and APC promoter methylation can explain APC loss without mutation (Juhlin and Mete 2026). Actionable alterations were found in about 54% of advanced carcinomas in one series (Juhlin and Mete 2026). Somatic MEN1 mutations are very infrequent in carcinoma (Juhlin and Erickson 2021).
  • Submission. Parathyroidectomy specimens with atypical features are submitted completely and examined at multiple levels with ancillary biomarkers (Erickson et al. 2022; Juhlin and Mete 2026).
  • Reporting dataset. The ICCR dataset has 16 core elements: clinical information, operative procedure, specimens submitted, tumor site, parathyroid weight, size, classification, grade for carcinoma (incorporating necrosis, mitotic count, perineural invasion and lymphovascular invasion), extent of local, regional and distant disease and pathologic stage. Ancillary studies are noncore elements (Williams et al. 2021).
  • Staging. The AJCC 8th edition stages parathyroid carcinoma (Williams et al. 2021; Akirov et al. 2019). The categories are summarized in the table below. No prognostic stage groups were defined because data on tumor characteristics and prognosis are limited (Akirov et al. 2019; Silva et al. 2026).
AJCC 8th category Definition Source
pTis Atypical parathyroid neoplasm of uncertain malignant potential Silva et al. 2026
pT1 Tumor confined to the parathyroid gland with extension limited to soft tissue Akirov et al. 2019; Silva et al. 2026
pT2 Direct invasion into the thyroid gland Akirov et al. 2019; Silva et al. 2026
pT3 Direct invasion into the recurrent laryngeal nerve, esophagus, trachea, skeletal muscle, adjacent lymph nodes or thymus Akirov et al. 2019
pT4 Direct invasion into a major blood vessel or the spine Akirov et al. 2019; Silva et al. 2026
pN1a Metastasis to level VI or VII lymph nodes Akirov et al. 2019
pN1b Metastasis to levels I, II, III, IV or V or retropharyngeal lymph nodes Akirov et al. 2019
M1 Distant metastasis Akirov et al. 2019; Silva et al. 2026

Parafibromin, CDC73 and the parafibromin-deficient parathyroid neoplasm

  • Gene and protein. CDC73 (formerly HRPT2, chromosome 1q31.2) encodes parafibromin, a 531-amino-acid nuclear tumor suppressor in the PAF transcriptional regulatory complex (Carpten et al. 2002; Bradley et al. 2005; Juhlin and Erickson 2021). Most germline and somatic mutations are truncating or affect nuclear localization, so mutant parafibromin fails to accumulate in the nucleus (Juhlin and Mete 2026).
  • Immunohistochemistry. Normal parathyroid nuclei always express parafibromin. Loss is reported in 0%–3.7% of multiglandular disease, 0%–17.6% of adenomas and 33.3%–100% of carcinomas (Uljanovs et al. 2022). Endothelial cells serve as the internal positive control. Diffuse nuclear loss prompts germline CDC73 testing, as does primary hyperparathyroidism at age 45 years or younger (Juhlin and Mete 2026).
  • Parafibromin deficiency and malignancy. Parafibromin deficiency alone does not establish malignancy because germline or somatic CDC73-driven adenomas can be parafibromin deficient (Juhlin and Mete 2026). In 43 parafibromin-negative tumors from 40 patients, 37.2% met the WHO 2017 criteria for carcinoma and 1 of 27 noninvasive tumors later metastasized (Gill et al. 2019).
  • Morphology of parafibromin-deficient tumors. Parafibromin-negative tumors show extensive sheet-like growth with little acinar architecture, eosinophilic cytoplasm, nuclear enlargement with coarse chromatin, perinuclear cytoplasmic clearing, prominent arborizing vessels and frequently a thick capsule. Microcystic change was present in 48.8%. Patients were younger (mean 36 versus 63 years) and tumors were heavier (mean 3.04 versus 0.62 g) than parafibromin-positive tumors (Gill et al. 2019).
  • Germline frequency. About 20%–30% of apparently sporadic parathyroid carcinomas are associated with a germline CDC73 mutation (Uljanovs et al. 2022).

Mimics of invasion and parathyromatosis

  • Prior manipulation. FNA, PTH washout and ethanol injection cause capsular defects, fibrosis, pigment-laden macrophages along the needle tract and displaced parathyroid cells that mimic invasion (Juhlin and Mete 2026).
  • Mechanical artifact. Crush artifact and tumor cells displaced into vessels during handling mimic vascular invasion. Intraluminal deposits without continuity with the tumor and without a fibrin reaction suggest contamination (Juhlin and Mete 2026).
  • Peliosis. Blood-filled spaces without an endothelial lining mimic vascular invasion and are separated by CD31 or ERG staining (Juhlin and Mete 2026).
  • Intrathyroidal parathyroid tumors. Expansile growth in the thyroid, especially after FNA, can mimic thyroid invasion (pT2, AJCC 8th edition). Vascular or perineural invasion and biomarker aberrations establish malignancy in this setting (Juhlin and Mete 2026).
  • Parathyromatosis. Parathyromatosis is multiple small nodules of hyperfunctioning parathyroid tissue in the neck or mediastinum, related mostly to prior parathyroidectomy and rarely to an embryologic remnant (Gheorghe et al. 2025). It results from seeding during surgery, biopsy or rupture of a cystic lesion. The nests are small, uniform and well circumscribed, without atypia, increased or atypical mitoses or desmoplasia (Juhlin and Mete 2026). Parathyroid carcinoma shows more coarse chromatin, infiltrative growth and metastasis, whereas parathyromatosis shows circumscribed expansile nests in soft tissue without tissue destruction (Juhlin and Mete 2026). In 22 reported patients, 21 had prior parathyroidectomy for primary (14) or secondary (7) hyperparathyroidism, and recurrent hyperparathyroidism was recognized 1–17 years after surgery (Gheorghe et al. 2025).

Parathyroid cysts

  • Frequency and types. Parathyroid cysts form less than 0.5% of parathyroid lesions and 1%–5% of neck masses. In 359 reported cases, 61.6% were nonfunctioning, the mean diameter was 4.88 cm and the commonest sites were the left thyroid lobe (31.6%) and superior mediastinum (19.3%) (Papavramidis et al. 2018).
  • Fluid. PTH was elevated in the cyst fluid in 97% of tested cysts. Fluid was clear and watery in 77.3%. Nonfunctioning cysts more often had clear fluid and functioning cysts more often had brown fluid (Papavramidis et al. 2018).
  • Histology. The cyst wall contained parathyroid tissue in 98.9%, with thyroid or thymic tissue in a few cases and fibrosis or hemorrhage in some (Papavramidis et al. 2018).
  • Cystic tumors and CDC73. Somatic CDC73 mutations were found in 3 of 48 parathyroid adenomas with cystic features (Carpten et al. 2002), and a cystic tumor raises the possibility of hyperparathyroidism-jaw tumor syndrome (Juhlin and Erickson 2021).

Hereditary hyperparathyroidism

  • Frequency. MEN1 is the most common syndrome, with a prevalence of 1 per 40,000 (Juhlin and Erickson 2021).
  • Morphologic clues to germline disease. The 2022 classification describes morphologic and immunohistochemical harbingers of MEN1-, CDKN1B-, MAX- and CDC73-related disease (Erickson et al. 2022). MEN1-related tumors are often multiglandular and asymmetric, lack a rim of normal parathyroid tissue and show compact sheet-like chief cells with fibrosis. No histologic feature separates an MEN1-related adenoma from a sporadic adenoma with certainty (Juhlin and Erickson 2021). Parafibromin-deficient morphology and cystic change point to CDC73 disease (Gill et al. 2019; Juhlin and Erickson 2021).
  • Menin and p27 immunohistochemistry. Menin loss is characteristic of MEN1 and reduced p27 of MEN4. Both stains are technically difficult, and p27 loss also occurs in sporadic carcinoma (Uljanovs et al. 2022). Menin immunohistochemistry is not suitable for routine screening because somatic MEN1 loss is common in sporadic adenomas (Juhlin and Erickson 2021).
Syndrome Gene and inheritance Parathyroid disease Other features Source
MEN1 MEN1 (11q13; menin, 610 amino acids); autosomal dominant Primary hyperparathyroidism in about 90%, penetrance 95% by age 50 years; multiglandular, synchronous or metachronous, often asymmetric; carcinoma exceedingly rare Pancreatic islet, duodenal, pituitary, adrenal cortical and carcinoid tumors Thakker et al. 2012; Juhlin and Erickson 2021
MEN2A RET (activating); autosomal dominant Primary hyperparathyroidism in 15%–30%; mild, one to four glands enlarged; carcinoma exceedingly rare Medullary thyroid carcinoma and pheochromocytoma Wells et al. 2015; Juhlin and Erickson 2021
MEN4 CDKN1B (p27Kip1); heterozygous germline variants Parathyroid adenomas, the most common feature; reduced p27 expression Pituitary adenomas Lee and Pellegata 2013; Uljanovs et al. 2022
MEN5 (MAX-related) MAX (loss of function) Multiglandular parathyroid adenomas in one proband Pheochromocytoma, pituitary tumors, ganglioneuroma and neuroblastoma Seabrook et al. 2021
Hyperparathyroidism-jaw tumor syndrome CDC73 (parafibromin); autosomal dominant, penetrance 65%–90% Primary hyperparathyroidism in 70%–80%; usually adenoma, sometimes cystic or multiglandular; carcinoma in 15%–37.5% of affected patients Ossifying fibromas of the jaw in 10%–30%; renal cysts, hamartomas and tumors in 10%; uterine lesions in 40% of women Uljanovs et al. 2022; Juhlin and Erickson 2021; Bradley et al. 2005
Familial isolated hyperparathyroidism MEN1, CDC73 or CASR in some families; activating GCM2 Hyperparathyroidism as the only feature; single carcinomas in some kindreds CDC73 mutation in 1 of 32 screened families Juhlin and Erickson 2021; Simonds et al. 2004
Familial hypocalciuric hypercalcemia type 1 Heterozygous inactivating CASR; autosomal dominant Hypercalcemia from altered calcium sensing Neonatal severe hyperparathyroidism with homozygous inactivating CASR Pollak et al. 1996; Juhlin and Erickson 2021
  • Other genes. Germline inactivating variants in CDKN1A, CDKN2B or CDKN2C occur in rare MEN1-like families (Juhlin and Erickson 2021). Familial hypocalciuric hypercalcemia types 2 and 3 (GNA11 and AP2S1) and FHH testing are taught in Calcium, Parathyroid Hormone, Vitamin D, Magnesium and Phosphate; type 3 is the more severe variant (Hannan et al. 2016). Familial hypercalciuric hypercalcemia is a separate hereditary cause (Duan et al. 2015).
  • HPT-JT uterine disease. Menorrhagia in the second to fourth decades with uterine tumors at hysterectomy affected women in 13 of 33 kindreds and reduced maternal transmission (Bradley et al. 2005). Reported uterine lesions include leiomyoma, adenomyosis, endometrial hyperplasia, adenofibroma and adenosarcoma (Uljanovs et al. 2022).
  • HPT-JT renal lesions. Renal cysts, hamartomas, Wilms tumor, papillary renal cell carcinoma and metanephric adenoma are reported (Uljanovs et al. 2022).

Multiple endocrine neoplasia syndromes

The 2022 classification newly defines MAFA-related familial insulinomatosis, MEN4 and MEN5 as familial endocrine syndromes and adds new pathologic findings in DICER1 syndrome (Nosé et al. 2022). Previous rule (WHO 4th edition, 2017): these three syndromes were not defined as separate familial syndromes (Nosé et al. 2022).

Syndrome Gene Endocrine, neuroendocrine and other tumors and features Source
MEN1 MEN1 Parathyroid; duodenal and pancreatic neuroendocrine tumors, most often gastrinoma, insulinoma or glucagonoma; pituitary tumors; adrenal cortical lesions (20%–45%); thymic neuroendocrine tumors (3.1%–8.2%) (Piórek et al. 2025) and other carcinoid tumors (Thakker et al. 2012); meningioma, facial angiofibroma, collagenoma and lipoma Thakker et al. 2012; Juhlin and Erickson 2021; Piórek et al. 2025
MEN2A RET Medullary thyroid carcinoma (more than 90%), pheochromocytoma (about 50%), parathyroid (15%–30%); cutaneous lichen amyloidosis, almost only with codon 634 variants; Hirschsprung disease in about 7% Wells et al. 2015; Juhlin and Erickson 2021
MEN2B RET (codon M918T in about 95%) Medullary thyroid carcinoma, pheochromocytoma (about 50%); multiple oral mucosal neuromas, generalized ganglioneuromatosis of the aerodigestive tract, marfanoid habitus, thickened everted eyelids Wells et al. 2015; Liu et al. 2026
MEN4 CDKN1B Parathyroid and pituitary adenomas (MEN1-like spectrum) Lee and Pellegata 2013
MEN5 MAX Pheochromocytoma (bilateral and metastatic), pituitary tumors, ganglioneuroma, neuroblastoma and possibly parathyroid adenoma; chondrosarcoma and lung adenocarcinoma in one proband Seabrook et al. 2021
MAFA-related familial insulinomatosis MAFA p.Ser64Phe Multiple insulin-secreting pancreatic neuroendocrine tumors; diabetes mellitus; congenital cataract or glaucoma in some carriers Iacovazzo et al. 2018
  • MEN1 thymic tumors. About 25% of thymic neuroendocrine tumors arise in MEN1, and thymic atypical carcinoids show the strongest association (Piórek et al. 2025).
  • MEN2B inheritance. At least 75% of patients with MEN2B have de novo RET variants and phenotypically normal parents (Wells et al. 2015). In 6 children with sporadic MEN2B and the de novo p.M918T variant, all had medullary thyroid carcinoma and 4 had nodal metastases at diagnosis (Liu et al. 2026).
  • MAFA. Insulinomatosis presented more often in females (8 of 10) and diabetes more often in males (12 of 16) (Iacovazzo et al. 2018).

RET risk categories in MEN2 (ATA 2015)

ATA risk category RET variants Prophylactic thyroidectomy Pheochromocytoma Hyperparathyroidism Source
Highest (ATA-HST) M918T (MEN2B) In the first year of life About 50% None Wells et al. 2015
High (ATA-H) C634 and A883F At or before age 5 years, guided by serum calcitonin About 50% 20%–30% with C634; none with A883F Wells et al. 2015
Moderate (ATA-MOD) All other codons Timed by the first elevated serum calcitonin About 10% (G533C, K666E, L790F, V804L, V804M, S891A); about 10% to 20%–30% (codons 609, 611, 618, 620, 630); about 50% (D631Y); none reported (E768D, R912P) About 10% (codons 609, 611, 618, 620, 630, V804L, V804M, S891A); none reported for the others Wells et al. 2015

Adrenal Cortex Pathology: Hyperplasia and Nodular Disease, Adrenalitis and Hemorrhage, Adrenal Cortical Adenoma and Carcinoma, Myelolipoma, Cysts and Metastases

Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), divides adrenal cortical proliferations into diffuse adrenal cortical hyperplasia, adrenal cortical nodular disease, adrenal cortical adenoma and adrenal cortical carcinoma (ACC). It adds separate chapters on adrenal ectopia, adrenal cysts and myelolipoma (Mete et al. 2022). Previous rule (4th edition, 2017): tumors of the adrenal cortex were classified as cortical carcinoma, cortical adenoma, sex cord-stromal tumors, adenomatoid tumor, mesenchymal and stromal tumors (myelolipoma and schwannoma), hematological tumors and secondary tumors, with schwannoma and hematological tumors newly listed (Lam 2017). The CAP Adrenal protocol, version 4.3.1.0 (March 2023), applies to ACC in all age groups. It does not apply to adrenal medullary tumors, adrenal cortical neoplasms of uncertain malignant potential, sarcomas or lymphomas (CAP 2023).

Related page: Adrenal FNA: Indications, Normal Cortex, Cortical Adenoma, Cortical Carcinoma and Myelolipoma (adrenal biopsy indications, incidentaloma imaging, adrenal FNA categories, the SF1 and melan-A data, and adrenal cortex versus renal cell and hepatocellular carcinoma immunohistochemistry) Related page: Pheochromocytoma, Metastases and Lymphoma in Adrenal FNA (adrenal metastases: frequency, primary sites and bilaterality; primary adrenal lymphoma on FNA) Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (Cushing syndrome testing, adrenal insufficiency testing, primary aldosteronism and the aldosterone-to-renin ratio, CAH enzyme defects and 17-hydroxyprogesterone) Related page: ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System (21-hydroxylase antibodies and autoimmune polyglandular syndromes) Related page: Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms (adrenal medulla, pheochromocytoma, ganglioneuroma and neuroblastic tumors) Related page: Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes (MEN1, MEN4 and the other multiple endocrine neoplasia syndromes) Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (renal cell carcinoma metastatic to the adrenal gland)

Adrenal development, anatomy and ectopic adrenal tissue

  • Embryology. The adrenal medulla derives from neural crest cells and the cortex from intermediate mesoderm. The fetal zone accounts for most prenatal growth of the gland, a definitive zone appears between the capsule and the fetal zone by the 8th week of gestation, and fetal zone cells undergo apoptosis and involute immediately after birth (Xing et al. 2015).
  • Zonation. The zona glomerulosa and zona fasciculata mature under angiotensin II and ACTH. The zona reticularis begins to form between the fasciculata and the medulla at 6–8 years of age in girls and 7–9 years in boys and produces the androgen precursors DHEA and androstenedione (Xing et al. 2015). Aldosterone synthase (CYP11B2) is expressed in the zona glomerulosa, and CYP11B1 marks zona fasciculata-type cells (Mete et al. 2022).
  • Gross anatomy. The cortex is lipid-rich and bright yellow, and the medulla is gray-white. The short right central vein drains into the inferior vena cava and the left central vein into the left renal vein. Regional lymph nodes are the aortic (para-aortic and peri-aortic) and retroperitoneal (perinephric and periadrenal) nodes (CAP 2023).
  • Adrenal weight. In 20 sudden-death controls at autopsy, the two adrenal glands together weighed 7.84 ± 1.63 g, against 10.38 ± 2.74 g in 100 suicides aged 15–60 years. Gland weight correlated with height and showed no significant relation to age or body weight (Chaurasia et al. 2023). In an autopsy series spanning infancy to more than 100 years, adrenal weight fell with age in men, and no age-related change was found in women (Nonaka et al. 2020). In 106 infant deaths, the median combined adrenal weight was 0.056% of body weight (5th–95th percentile 0.025%–0.23%), and adrenal weight alone was insufficient to diagnose adrenal insufficiency (Morrison et al. 2017).
  • Adrenal ectopia (2022 chapter). Adrenal ectopia is benign adrenal cortical tissue outside the orthotopic gland, most often found incidentally along the developmental tract in the kidney, spermatic cord, rete testis, epididymis and paraovarian or parasalpingeal tissue. Ectopic rests are small yellow subcentimeter nodules of bland eosinophilic or clear cells that express SF1. Adrenal cortical choristoma is cortical tissue in a site that embryogenesis does not explain, including corticotroph pituitary neuroendocrine tumors. "Adrenal rest tumor" is reserved for nodular proliferations in the gonads. Rests can mimic metastasis and can give rise to adenomas in the liver or gastric wall (Mete et al. 2022).

Congenital adrenal hyperplasia and testicular adrenal rest tumors

  • Genetics. Congenital adrenal hyperplasia (CAH) is autosomal recessive. CYP21A2 (21-hydroxylase) is mutated in 95%–99% of patients. Loss of cortisol removes feedback inhibition, raises ACTH and causes bilateral hyperplasia with androgen excess and virilization. Other enzyme defects are tabulated in Endocrine Function Tests: Thyroid, Adrenal and Pituitary (Mete et al. 2022).
  • Adrenal morphology. Glands and adrenal rests in CAH show diffuse compact cell (lipid-depleted) cortical hyperplasia. A resected CAH gland can show a multinodular cortex of zona reticularis-like cells with chronic lymphocytic infiltrates and multifocal myelolipomas (Mete et al. 2022).
  • Tumors in CAH. Adrenal cortical tumors develop in about 24% of patients with genetically confirmed CAH, and almost 40% may have adrenal myelolipoma (Mete et al. 2022). CAH was present in 10% of 440 reported myelolipomas (Decmann et al. 2018).
  • Testicular adrenal rest tumors. Prolonged ACTH stimulation can cause a hyperplasia-to-neoplasia sequence in gonadal rests. CYP11B1 and CYP21A2 immunohistochemistry, abundant DLK1 and absent INSL3 separate testicular adrenal rest tumors from Leydig cell tumors (Mete et al. 2022).

Adrenal cortical hyperplasia and nodular disease in the WHO 2022 classification

The 2022 classification restricts "adrenal cortical hyperplasia" to bilateral diffuse hyperplasia dependent on ACTH or CRH and to diffuse compact cell hyperplasia in CAH. Bilateral micronodular and macronodular disease are classified among benign adrenal cortical tumors because each nodule is an independent clonal proliferation, usually on a germline background (Mete et al. 2022).

Entity (2022 term) Definition and morphology Genetics and associations Former term Source
ACTH-dependent diffuse adrenal cortical hyperplasia, pituitary source Bilateral diffuse cortical expansion with preserved zonation and an expanded zona reticularis Corticotroph pituitary neuroendocrine tumor or hypothalamic neoplasm Diffuse adrenal cortical hyperplasia (unchanged) Mete et al. 2022
ACTH- or CRH-dependent diffuse hyperplasia, ectopic Diffuse compact cell hyperplasia without distinct zonation; lipid depletion gives a pink cortex ACTH- or CRH-producing neuroendocrine neoplasm or paraganglioma Diffuse adrenal cortical hyperplasia (unchanged) Mete et al. 2022
Sporadic nodular adrenocortical disease Non-functional cortical nodules <1 cm, solitary or multifocal, histologically similar to non-functional adenoma; likely microadenomas Etiology largely unknown; CYP11B1, CYP11B2 and CYP17 immunohistochemistry separates them from small functional adenomas Nodular adrenal cortical hyperplasia Mete et al. 2022
Bilateral micronodular adrenal cortical disease: primary pigmented nodular adrenocortical disease (PPNAD) Multiple pigmented micronodules <1 cm (often 2–5 mm) of eosinophilic CYP11B1-positive cells with internodular cortical atrophy; mainly children and young adults, mostly female Carney complex (c-PPNAD) or isolated (i-PPNAD); germline PRKAR1A most often, then PRKACA and the CNC2 locus Primary bilateral micronodular adrenocortical hyperplasia Mete et al. 2022
Bilateral micronodular adrenal cortical disease: isolated micronodular adrenocortical disease (i-MAD) Micronodules without pigment or internodular atrophy PDE11A, PDE8B or PRKACA copy number gain (protein kinase A pathway) Primary bilateral micronodular adrenocortical hyperplasia Mete et al. 2022
Bilateral macronodular adrenal cortical disease Massive bilateral enlargement by nodules >1 cm of lipid-rich clear cells with occasional eosinophilic cells; adults; hypercortisolism in >90% Germline ARMC5 in 25%–55% with a somatic second hit in each nodule; also MEN1, FH, APC, GNAS, PDE8B, PDE11A; aberrant G-protein-coupled receptor expression Primary bilateral macronodular adrenal cortical hyperplasia Mete et al. 2022
  • Frequency. Bilateral micronodular and macronodular disease together account for about 2% of patients with endogenous hypercortisolism. Patients with ARMC5 variants have larger glands and more severe hypercortisolism (Mete et al. 2022).
  • Molecular clusters of benign cortisol excess. Pan-genomic analysis separates PPNAD and cortisol-producing adenomas with protein kinase A activation, adenomas with mild autonomous cortisol secretion and Wnt activation, and ARMC5-related macronodular disease with an ovarian-type gene expression signature (Mete et al. 2022).

Primary aldosteronism: HISTALDO classification and CYP11B2 immunohistochemistry

The 2022 classification endorses the HISTALDO nomenclature and CYP11B2 immunohistochemistry on all adrenalectomy specimens from patients with primary aldosteronism. Not every radiologic nodule produces aldosterone, and microscopic clonal lesions may be invisible on imaging (Mete et al. 2022).

HISTALDO category Definition CYP11B2 pattern Source
Aldosterone-producing adrenal cortical carcinoma (APACC) ACC positive for CYP11B2; exceptionally rare Positive Mete et al. 2022
Aldosterone-producing adenoma (APA) Benign cortical neoplasm ≥1 cm of clear zona fasciculata-like and compact zona reticularis-like cells Diffuse Mete et al. 2022
Aldosterone-producing nodule (APN) Morphologically distinct nodule <1 cm Gradient from the outer to the inner front Mete et al. 2022
Aldosterone-producing micronodule (APM; formerly aldosterone-producing cell cluster) Subcapsular zona glomerulosa-like cells, often a few millimeters, hard to identify on H&E Gradient from the outer to the inner front Mete et al. 2022
Multiple APN or APM (formerly "micronodular hyperplasia") Synchronous multifocal APN and/or APM Discrete positive nodules without a continuous glomerulosa layer Mete et al. 2022
Aldosterone-producing diffuse hyperplasia (APDH) Broad, uninterrupted strip of zona glomerulosa More than 50% of glomerulosa cells positive Mete et al. 2022
  • Classic versus non-classic histology. A solitary APA or APN is classic histology. APDH and multifocal APN or APM are non-classic. Biochemical recurrence from bilateral disease occurred in about 42% of patients with non-classic histology and in less than 5% with classic histology. APDH is the most common cause of bilateral idiopathic primary aldosteronism (Mete et al. 2022).
  • Paradoxical zona glomerulosa hyperplasia. The non-lesional cortex beside an APA or APN often shows glomerulosa hyperplasia that is negative for CYP11B2 and is non-functional (Mete et al. 2022).
  • Genotype and morphology. Somatic ion channel mutations (KCNJ5, CACNA1D, CACNA1H, ATP1A1, ATP2B3) cause constitutive depolarization. They were first reported in about half of APAs and are found in 90%–96% when CYP11B2 positivity is required. KCNJ5 accounts for about 40% of APAs, favors younger women and clear zona fasciculata-like cells, and gives a canary-yellow cut surface. KCNJ5 wild-type tumors are more frequent in older men and are smaller and compact-celled. About 5% of sporadic APAs carry CTNNB1 mutations (Mete et al. 2022).
  • Spironolactone bodies. Spironolactone causes eosinophilic, concentrically laminated cytoplasmic inclusions in the tumor and the adjacent zona glomerulosa that stain with Luxol fast blue. Eplerenone does not produce them (Mete et al. 2022).
  • Familial hyperaldosteronism. Type I is caused by a germline CYP11B1/CYP11B2 chimeric gene, type II by CLCN2, type III by KCNJ5 and type IV by CACNA1H. Germline CACNA1D variants cause primary aldosteronism with seizures and neurologic abnormalities (PASNA syndrome) (Mete et al. 2022).

Adrenal insufficiency and adrenalitis in pathology specimens

Autoimmune adrenalitis causes 80%–90% of primary adrenal insufficiency in the United States and Europe. Tuberculosis was the most common cause 100 years ago, and bacterial, fungal (histoplasmosis), viral and protozoal (Plasmodium falciparum) infections can still involve the adrenals in immunocompetent and immunocompromised patients (Murray 2026). Bilateral infiltrative disease belongs in the differential diagnosis of new primary adrenal insufficiency, especially when autoimmune testing is negative; in a Mayo Clinic series, all 7 such patients had bilateral adrenal masses diagnosed histologically (Herndon et al. 2018).

Cause of primary adrenal insufficiency Pathologic findings Source
Autoimmune adrenalitis Small or unidentifiable glands at autopsy; cortical destruction by CD4 and CD8 T cells directed against 21-hydroxylase; 21-hydroxylase antibodies occur only in the autoimmune form, and tuberculosis, metastasis and other infiltrative causes enlarge the glands Kemp et al. 2016; Capalbo et al. 2024
Adrenal tuberculosis Granulomatous inflammation in 73%, caseous necrosis in 51% and Langhans giant cells in 25% of 55 cases with pathology; calcification in 50% on imaging Ye et al. 2026
Histoplasmosis and cryptococcosis Bilateral adrenal masses; diagnosis by adrenal biopsy Herndon et al. 2018
Bilateral metastases and lymphoma Lung and breast adenocarcinoma and diffuse large B-cell lymphoma in a biopsy series of bilateral infiltrative disease; 5 of 464 patients with adrenal metastases presented with adrenal insufficiency Herndon et al. 2018; Lam and Lo 2002
Erdheim–Chester disease Bilateral infiltrative adrenal disease confirmed histologically Herndon et al. 2018
Bilateral adrenal hemorrhage Acute insufficiency when hemorrhage destroys more than 90% of the cortex Aloini et al. 2023
X-linked adrenoleukodystrophy (ABCD1) Very long-chain fatty acids accumulate in the zona fasciculata and zona reticularis with relative sparing of the zona glomerulosa; electron microscopy shows lamellar (striated) lipid inclusions of cholesterol esters and gangliosides esterified with very long-chain fatty acids in adrenocortical cells, also present in Leydig cells; lesions begin in fetal adrenal tissue; adrenal insufficiency develops in 80%–86% of males, peaking at 3–10 years, usually without mineralocorticoid deficiency Kemp et al. 2026
  • Histology of autoimmune adrenalitis. A lymphoplasmacytic infiltrate accompanies destruction of the adrenal cortex, and insufficiency becomes clinically apparent only when about 90% of the cortex is destroyed. Focal lymphocytic adrenalitis is a common incidental finding in the elderly; it lacks the diffuse inflammation of autoimmune adrenalitis and causes no adrenal dysfunction (Uccella et al. 2023).
  • APS-1. Autoimmune polyendocrine syndrome type 1 (APECED) is caused by AIRE abnormalities. Its triad is mucocutaneous candidiasis (82.5%), usually the first manifestation, hypoparathyroidism (84.2%) and primary adrenal insufficiency (72.2%) (Uccella et al. 2023).
  • Geographic variation. In a Chinese referral series of 131 patients, infection caused 58.1% of adult primary adrenal insufficiency (tuberculosis in 93.0% of these) and autoimmune adrenalitis 19.0%. Genetic defects caused 52.6% of cases in adolescents, half of them NR0B1 (DAX1) deficiency (Wang et al. 2020).

Adrenal hemorrhage and Waterhouse–Friderichsen syndrome

  • Unilateral versus bilateral. Adrenal hemorrhage is most often unilateral and caused by abdominal trauma. Bilateral hemorrhage accounts for 10% of cases and follows systemic conditions: surgery, sepsis, bleeding diathesis, coagulopathy, systemic lupus erythematosus, antiphospholipid syndrome, anticoagulant therapy and pregnancy (Aloini et al. 2023).
  • Mechanism. Three adrenal arteries divide into capillaries at the zona reticularis, which drain into a single central vein. Vasoconstriction or thrombosis of the adrenal vein raises capillary pressure and causes bleeding. Heparin-induced thrombocytopenia is a frequent cause of adrenal vein thrombosis in heparin-associated hemorrhage, and antiphospholipid syndrome is one of the most common reported risk factors (Aloini et al. 2023).
  • Neonatal adrenal hemorrhage. Neonatal adrenal hemorrhage is more common in term infants and after perinatal asphyxia. It presents with prolonged jaundice, an abdominal mass, anemia, scrotal discoloration or swelling, hypotonia, lethargy or hypertension, or is found incidentally. The right gland is involved in about 70% of cases, ultrasound establishes the diagnosis and follow-up, and the hemorrhage usually resolves within 3 weeks to 6 months (Tognato et al. 2020).
  • Waterhouse–Friderichsen syndrome. Waterhouse–Friderichsen syndrome, first described in 1911, is massive thrombotic adrenal hemorrhage in meningococcal sepsis. Many other bacteria and viruses can cause it. Mortality reaches nearly 15% even with prompt treatment, and adrenal insufficiency after sepsis is often irreversible (Aloini et al. 2023).
  • Forensic autopsy pattern. In 86 autopsy-confirmed fatal cases, bilateral adrenal hemorrhage occurred within a systemic septic pattern of multiorgan congestion, hemorrhage and changes of disseminated intravascular coagulation. Culture and molecular results were often discordant (Camatti et al. 2026).

Adrenal cortical adenoma

  • Function. Adrenal cortical adenomas may be non-functional or may secrete cortisol or aldosterone, with overt or subclinical syndromes. Some patients have concurrent primary aldosteronism and Cushing syndrome. Cortisol-secreting adenomas are the most frequent cause of ACTH-independent Cushing syndrome. Sex steroid-secreting adenomas are exceptional in adults, and virilization or feminization raises the possibility of carcinoma (Mete et al. 2022).
  • Gross findings. Most adenomas are homogeneous, well delineated and yellow. Oncocytic adenomas are mahogany brown, and black adenomas contain lipofuscin. Size and weight above 5 cm and 100 g, an irregular border or a heterogeneous cut surface with necrosis, hemorrhage, fibrosis or a gelatinous appearance warrant extensive sampling or complete submission (Mete et al. 2022).
  • Atrophy of the adjacent cortex. In the absence of exogenous glucocorticoid, atrophy of the non-tumorous cortex (thickness <2 mm with a reduced or absent zona reticularis) is a hallmark of autonomous cortisol secretion. Intermittent loss of the zona reticularis can be the first sign in mild autonomous cortisol secretion. A subset of black adenomas shows mild autonomous cortisol secretion (Mete et al. 2022). Mild autonomous cortisol secretion is defined as serum cortisol >1.8 µg/dL (>50 nmol/L) after a 1-mg overnight dexamethasone test without clinical signs of overt Cushing syndrome (Fassnacht et al. 2023).
  • Histology. Adenomas contain lipid-rich clear cells mixed with compact eosinophilic cells. Vascular invasion, local invasion, necrosis unrelated to manipulation, any atypical mitotic figure, more than 5 mitoses per 10 mm² and marked reticulin loss are absent. Focal random nuclear atypia of Fuhrman grade 3 or 4 (endocrine atypia), infarct-type necrosis from involution and myelolipomatous change occur in adenomas (Mete et al. 2022).
  • Weight and size. Adrenal cortical neoplasms weighing less than 50 g are often benign, and adult carcinomas usually weigh more than 100 g. One study found that tumors larger than 6.5 cm are likely malignant (CAP 2023).
  • Oncocytic neoplasms. "Oncocytoma" is no longer a recommended term for oncocytic adrenal cortical neoplasms. Diffuse growth and macronucleoli are intrinsic to these tumors, so the Weiss system overestimates their malignancy, and other algorithms are used. Cortical origin is confirmed in all non-functional lesions and in oncocytic tumors because oncocytic adenomas are mistaken for pheochromocytoma on the basis of synaptophysin. Oncocytic cortical neoplasms are chromogranin A-negative and SF1-positive (Mete et al. 2022).
  • Molecular findings. Cortisol-producing adenomas carry PRKACA, PRKAR1A, GNAS or PRKACB mutations that activate protein kinase A. CTNNB1 mutations occur in non-functional adenomas and adenomas with mild autonomous cortisol secretion. Adenomas have few chromosomal alterations and global DNA hypermethylation (Mete et al. 2022).
  • Syndromes. Adenomas are unusual manifestations of Li–Fraumeni syndrome, MEN1, familial adenomatous polyposis, Beckwith–Wiedemann syndrome and Carney complex (Mete et al. 2022).

Adrenal cortical carcinoma: clinical features, subtypes and angioinvasion

  • Presentation. About half of adult ACCs present with hormone excess, usually glucocorticoids alone or with sex steroids, and 10%–15% are incidental. Virilization or feminization is highly worrisome for malignancy. Aldosterone-producing ACC is rare (Mete et al. 2022).
  • Hereditary ACC. About 10% of ACCs arise in a hereditary setting. Li–Fraumeni syndrome is found in 50%–80% of children and 3%–5% of adults with ACC, and about 3% of adults have Lynch syndrome. Lynch syndrome, MEN1, Beckwith–Wiedemann syndrome, Carney complex and NF1 are also overrepresented, and genetic counseling may be considered for all patients (Mete et al. 2022).
  • Angioinvasion (emphasized in 2022). Vascular invasion is assessed at the tumor–capsule interface or beyond the capsule. Microscopic angioinvasion is tumor invading through a vessel wall to form a thrombus/fibrin–tumor complex, or intravascular tumor admixed with platelet thrombus or fibrin. CD61 immunohistochemistry highlights platelets at sites of angioinvasion (Mete et al. 2022). In an adult series, microscopic angioinvasion was the best prognostic parameter, predicting adverse outcome in all ACCs and within low-grade ACCs. The WHO 5th edition requires lymphatic and vascular invasion to be reported separately and does not endorse the term "lymphovascular invasion" (CAP 2023).
  • Molecular pathology. ACCs carry mutually exclusive Wnt pathway (activating CTNNB1, inactivating ZNRF3) and p53 pathway (TP53 in 20%, RB1, MDM2, CDKN2A) alterations, with DAXX, ATRX, MEN1 and PRKAR1A in subsets. Loss of the maternal 11p15 allele with paternal duplication downregulates H19 and upregulates IGF2. ACCs are globally hypomethylated. Pan-genomic studies separate low-, intermediate- and high-risk clusters; high-risk tumors have Wnt/p53 mutations, a CpG island methylator (CIMP-high) phenotype and whole-genome doubling, and G0S2 hypermethylation is a surrogate for CIMP-high disease (Mete et al. 2022).
ACC subtype (WHO 2022) Definition and features Assessment system Source
Conventional Eosinophilic or clear cortical cells; thick fibrous bands, necrosis and prominent mitoses Weiss, modified Weiss, reticulin algorithm, Helsinki Mete et al. 2022; Lam 2021
Oncocytic Oncocytic cells in more than 90% of the tumor; tan-brown cut surface; most common subtype; alpha-inhibin in about half and melan-A in slightly more than one third; chromogranin A negative; median survival 60 months in pooled cases Lin–Weiss–Bisceglia, reticulin algorithm, Helsinki Mete et al. 2022; Lam 2021
Myxoid Prominent extracellular mucin; Weiss parameters hard to assess; tumors with a Weiss score of 1 have caused death Weiss, modified Weiss, Helsinki, reticulin algorithm Mete et al. 2022; CAP 2023
Sarcomatoid Resembles sarcomatoid carcinoma of other organs and often retains cortical differentiation; distinguished from sarcoma when no other ACC component is present Separation from sarcoma by adrenal cortical differentiation Mete et al. 2022

Previous rule (4th edition, 2017): oncocytic, myxoid and sarcomatoid ACC were listed as variants, myxoid ACC being formally labeled a variant for the first time in 2017 (Lam 2021). The 2017 classification adopted a system for separating oncocytoma from oncocytic cortical carcinoma (Lam 2017). The 2022 classification calls them subtypes and drops the term "oncocytoma" (Mete et al. 2022).

Weiss and modified Weiss criteria for adrenal cortical carcinoma

Histologic parameter Weiss score Modified Weiss score Source
High nuclear grade (Fuhrman grade 3 or 4) 1 Not scored Mete et al. 2022
Mitotic count >5 per 10 mm² (50 high-power fields) 1 2 Mete et al. 2022
Atypical mitoses 1 1 Mete et al. 2022
Necrosis 1 1 Mete et al. 2022
Diffuse architecture in >30% of tumor volume 1 Not scored Mete et al. 2022
Clear cells ≤25% of tumor volume 1 2 Mete et al. 2022
Capsular invasion 1 1 Mete et al. 2022
Venous invasion 1 Not scored Mete et al. 2022
Sinusoidal (lymphatic) invasion 1 Not scored Mete et al. 2022
Maximum score and threshold for carcinoma 9; ≥3 7; ≥3 Mete et al. 2022; CAP 2023
  • Original Weiss series. In 43 adrenocortical tumors, none of the 24 tumors with two or fewer criteria metastasized or recurred, and all but one of the 19 tumors with four or more recurred or metastasized. Mitotic activity, atypical mitoses and venous invasion correlated best with malignancy, and no single criterion sufficed (Weiss 1984).
  • Modified Weiss system. In 49 tumors, three or more Weiss criteria had 100% sensitivity and 96% specificity for malignancy, with excellent interobserver agreement (r = 0.94). The modified system keeps the five most reliable criteria, doubles the weight of mitotic rate and clear cells, and correlates with the Weiss score (r = 0.98) (Aubert et al. 2002).
  • Weiss score in oncocytic and pediatric tumors. Diffuse growth, high nuclear grade and ≤25% clear cells are intrinsic to oncocytic neoplasms, so the Weiss score is not used for them (Lam 2021). Weiss criteria overdiagnose pediatric tumors that behave benignly (Mete et al. 2022).

Reticulin algorithm, Lin–Weiss–Bisceglia system and Helsinki score

System Criteria Diagnosis Validation Source
Reticulin algorithm Altered reticulin framework (Gordon–Sweet silver stain) plus one of: >5 mitoses per 10 mm², tumor necrosis or angioinvasion Carcinoma when altered reticulin is combined with one parameter 245 tumors: 27% of Weiss-classified tumors reclassified as adenoma; complete agreement among 8 pathologists in 75% (κ = 0.702), 86% after training Duregon et al. 2013; Mete et al. 2022
Lin–Weiss–Bisceglia (pure oncocytic neoplasms) Major: >5 mitoses per 10 mm², atypical mitoses, venous invasion. Minor: size >10 cm and/or weight >200 g, necrosis, capsular invasion, sinusoidal invasion One major criterion: oncocytic ACC. One or more minor criteria only: oncocytic neoplasm of uncertain malignant potential. None: oncocytic adenoma Proposed from 10 tumors and a literature review Bisceglia et al. 2004; Mete et al. 2022
Helsinki score 3 × (mitoses >5 per 10 mm²) + 5 × (necrosis) + Ki-67 index (%) from the most proliferative area by image analysis >8.5: carcinoma; >17: adverse prognosis 177 adults: 100% sensitivity and 99.4% specificity for metastatic ACC, versus 90.2% specificity for Weiss and 96.9% for modified Weiss Pennanen et al. 2015; Mete et al. 2022
  • Reticulin pattern. Most ACCs show quantitative loss of the reticulin framework. Qualitative change (a mesh-like pericellular pattern) alone is not a feature of carcinoma because it occurs focally in adenomas with a preserved framework. Hemorrhage, degeneration and biopsy sites disrupt reticulin in benign tumors (Mete et al. 2022).
  • Oncocytic sampling. The Lin–Weiss–Bisceglia system applies only when more than 90% of an extensively sampled tumor is oncocytic. Mixed tumors are assessed with conventional criteria (Mete et al. 2022).
  • Systems by subtype (WHO 5th edition). Conventional adult ACC is diagnosed with a Weiss score ≥3, modified Weiss score ≥3, Helsinki score >8.5 or the reticulin algorithm. Oncocytic ACC is diagnosed with any Lin–Weiss–Bisceglia major criterion, a Helsinki score >8.5 or the reticulin algorithm. Pediatric ACC is diagnosed with a Wieneke score ≥4 (CAP 2023).

Mitotic grade, Ki-67 and immunohistochemistry of adrenal cortical carcinoma

  • Mitotic grade. The 2022 classification adopts the mitotic grade introduced by Weiss and colleagues: low grade ≤20 mitoses per 10 mm² and high grade >20 mitoses per 10 mm². Its prognostic value is validated in adults and not yet in children. Two series found that a cut-off of 10 mitoses per 10 mm² performed better (Mete et al. 2022). The CAP protocol requires mitotic grade for adult patients only and recommends documenting it in children (CAP 2023).
  • Counting method. The original method counted 10 high-power fields on each of 5 sections of high mitotic density (50 fields). Counting 10 mm² in hot spots across several slides is acceptable, and phosphohistone H3 immunohistochemistry helps in low-grade tumors (Mete et al. 2022).
  • Ki-67. Most ACCs have a Ki-67 index above 5%. Prognostic tiers used in large series are <10%, 10%–19% and ≥20%, or <20%, 20%–50% and >50%; pediatric series support 15%. Ki-67-based grading is not endorsed because proliferation is continuous. The numeric mitotic count and Ki-67 index are reported for every ACC, hot spots are counted manually or by image analysis, visual estimation is not used and the method is documented (Mete et al. 2022).
  • Clinical use. The European Society of Endocrinology guideline suggests expert pathology review with the Weiss score and Ki-67 index for every suspected ACC, and adjuvant mitotane after radical surgery for patients at high risk of recurrence (ENSAT stage III, R1 resection or Ki-67 >10%) (Fassnacht et al. 2018).
Marker Result in adrenal cortical carcinoma Interpretation Source
SF1 Nuclear Most reliable marker of cortical origin; also positive in gonadotroph pituitary neuroendocrine tumors, steroid cell tumor and Leydig cell tumor Mete et al. 2022
Melan-A, alpha-inhibin, calretinin, synaptophysin Variable Non-specific; panel use only. Synaptophysin and alpha-inhibin also stain pheochromocytoma, especially pseudohypoxia-pathway tumors Mete et al. 2022; CAP 2023
Chromogranin A Negative Separates oncocytic cortical neoplasms from pheochromocytoma Mete et al. 2022; Lam 2021
IGF2 Paranuclear (juxtanuclear) granular dots in about 80% of adult ACCs Best ancillary marker of malignancy, independent of grade and oncocytic morphology Mete et al. 2022
p53 and β-catenin Overexpression or global loss of p53; nuclear β-catenin Enriched in high-grade ACC and poor-prognosis molecular clusters; CAP recommends both on every ACC Mete et al. 2022; CAP 2023
ATRX and DAXX Global loss Prognostic Mete et al. 2022
MLH1, PMS2, MSH2, MSH6 Loss Screens for Lynch syndrome and informs immunotherapy trials Mete et al. 2022
CYP11B1 and CYP11B2 Zona fasciculata-type and aldosterone synthase expression Functional immunohistochemistry of cortisol- and aldosterone-producing lesions Mete et al. 2022
SDHB, APC, menin and p27 Loss Raise SDH-deficient paraganglioma syndrome, familial adenomatous polyposis, MEN1 and MEN4 Mete et al. 2022

Staging and reporting of adrenal cortical carcinoma (AJCC 8th edition and CAP Adrenal 4.3.1.0)

Category AJCC 8th edition definition Source
pT1 Tumor ≤5 cm, no extra-adrenal invasion CAP 2023
pT2 Tumor >5 cm, no extra-adrenal invasion CAP 2023
pT3 Tumor of any size with local invasion, not invading adjacent organs CAP 2023
pT4 Tumor of any size invading adjacent organs (kidney, diaphragm, pancreas, spleen or liver) or large blood vessels (renal vein or vena cava) CAP 2023
pN1 Metastasis in regional (aortic or retroperitoneal) lymph nodes CAP 2023
Stage I T1 N0 M0 Lam 2021
Stage II T2 N0 M0 Lam 2021
Stage III T1–T2 N1 M0, or T3–T4 any N M0 Lam 2021
Stage IV Any T, any N, M1 Lam 2021
  • Change from the 7th edition. The AJCC 8th edition adopted the ENSAT staging. T4 N0 M0 and T3–T4 N1 M0 tumors, which were stage IV in the 7th edition, are stage III, and tumor thrombus in the renal vein or vena cava, formerly M1, is T4. Only distant metastasis is stage IV (Lam 2021).
  • Weight. The adrenal gland weight is reported because the tumor is not dissected free and weighed separately (CAP 2023).
  • Metastatic sites. ACC metastasizes most often to liver, lung and retroperitoneum. Scalp metastasis can mimic angiosarcoma (CAP 2023).
CAP 4.3.1.0 element Responses and rules Source
Histologic subtype Conventional, oncocytic, myxoid or sarcomatoid CAP 2023
Mitotic tumor grade Low grade ≤20 or high grade >20 mitoses per 10 mm²; required for adults CAP 2023
Tumor size and adrenal gland weight Greatest dimension in centimeters; gland weight in grams CAP 2023
Direct extension Confined to cortex; into or through capsule; peri-adrenal fat; kidney, pancreas, liver, spleen, diaphragm, stomach or large vessels CAP 2023
Lymphatic and vascular invasion Large vessel invasion of renal vein or vena cava (including clinical or gross); microscopic angioinvasion; lymphatic invasion CAP 2023
Margins, lymph nodes and pTNM Closest margin; nodes examined and involved; AJCC 8th edition pT, pN and pM CAP 2023
Ki-67 labeling index Percentage; required CAP 2023
Biomarkers confirming cortical origin Required for all non-functional tumors; SF1 named as the most reliable marker CAP 2023
p53, β-catenin and reticulin (optional) Abnormal or wild-type p53; nuclear or membranous β-catenin; reticulin result CAP 2023

Pediatric adrenal cortical tumors and the Wieneke criteria

  • Epidemiology. Pediatric ACC has an annual incidence of 0.2–0.3 per million (about 25 patients per year in the United States) with peaks before 5 years and in adolescence. It is 15 times more frequent in southern Brazil because of the TP53 p.R337H founder variant (Mete et al. 2022).
  • Presentation and genetics. Androgen excess is the presenting feature in up to 80% of children and causes virilization in boys and girls; cortisol excess is less common. Germline TP53 variants are present in up to 80% of pediatric ACCs, in high-incidence regions and elsewhere. p53 loss leads to 11p15 loss of heterozygosity and IGF2 overexpression, and Beckwith–Wiedemann syndrome (11p15) also predisposes. Somatic ATRX and CTNNB1 mutations may indicate a poor outcome (Mete et al. 2022).
  • Behavior of pediatric tumors. In 83 pediatric adrenal cortical neoplasms (2–20 cm, mean 8.8 cm), only 31% of histologically malignant tumors behaved malignantly. Vena cava invasion, necrosis and >15 mitoses per 20 high-power fields independently predicted malignant behavior (Wieneke et al. 2003). The mean weight of pediatric ACC was 631 g (range 24–2260 g) (CAP 2023).
Wieneke criterion (1 point each) Threshold Source
Tumor weight >400 g Mete et al. 2022
Tumor size >10.5 cm Mete et al. 2022
Extension Into periadrenal soft tissue or adjacent organs Mete et al. 2022
Vena cava invasion Present Mete et al. 2022
Vascular invasion Present Mete et al. 2022
Capsular invasion Present Mete et al. 2022
Tumor necrosis Present Mete et al. 2022
Mitoses >15 per 20 high-power fields (4 mm²) Mete et al. 2022
Atypical mitoses Present Mete et al. 2022
Interpretation ≤2: benign behavior; 3: uncertain malignant potential; ≥4: malignant or poor outcome Mete et al. 2022; CAP 2023
  • Ki-67 in children. A Ki-67 index below 10% is associated with benign disease and above 15% with a higher risk of malignancy or poor outcome (Mete et al. 2022).
  • Prognostic factors. Meta-analyses confirm age, stage, tumor weight >200 g, extra-adrenal extension, incomplete resection, metastatic disease and cortisol secretion. Metastases favor brain, liver, lungs and bone (Mete et al. 2022).
  • Children's Oncology Group stage. Stage I is complete excision with negative margins, tumor weight <200 g and no metastasis; stage II is the same with weight >200 g; stage III is microscopic or gross incomplete resection or inoperable tumor; stage IV is hematogenous metastasis at presentation (Mete et al. 2022). Sources disagree on the stage I/II weight limit. The WHO 2022 overview tabulates COG stage I as <200 g and stage II as >200 g (Mete et al. 2022), whereas Lam describes the International Pediatric Adrenocortical Tumor Registry system validated by the COG with stage I ≤100 g or ≤200 cm³ and stage II >100 g or >200 cm³ (Lam 2021).

Adrenal myelolipoma

  • Definition. Adrenal myelolipoma is a benign neoplasm of mature adipose tissue and extramedullary hematopoiesis. It is the second most common primary adrenal incidentaloma after cortical adenoma and has a separate chapter in the 2022 classification (Decmann et al. 2018; Mete et al. 2022).
  • Clinical profile. In 440 reported and institutional cases, the mean age was 51 years with no sex difference and the mean size was 10.2 cm. CAH was associated with 10% of cases, and cortisol or aldosterone hypersecretion with 7.5%. CT and MRI usually establish the diagnosis, and an unambiguous asymptomatic, hormonally inactive myelolipoma does not require surgery (Decmann et al. 2018).
  • Differential diagnosis of myelolipoma. The histologic differential diagnosis is extramedullary hematopoiesis and well-differentiated or dedifferentiated liposarcoma. Both myelolipoma and extramedullary hematopoiesis contain trilineage hematopoietic cells, and myelolipoma forms a well-circumscribed mass in which mature fat and hematopoietic tissue are intimately admixed. In atypical lipomatous tumors, MDM2 amplification by FISH is more reliable than MDM2 immunohistochemistry (Hanaoka et al. 2026).
  • Myelolipomatous change. Foci of fat and hematopoiesis are often found in cortical adenomas, especially involuted adenomas with infarction and fibrocalcification (Mete et al. 2022).

Adrenal cysts and pseudocysts

Adrenal cysts are benign circumscribed fluid-containing masses with an incidence of 0.06%. They account for up to 4% of adrenal masses, show a slight female predominance and averaged 7.9 cm in one review. Most grossly cystic adrenal glands are cortical neoplasms or pheochromocytomas with cystic hemorrhagic degeneration, so the cyst wall is sampled extensively (Mete et al. 2022).

Cyst type Wall and contents Pathogenesis and frequency Immunohistochemistry Source
Pseudocyst No lining; thick fibrous wall with fibrinohemorrhagic contents Most common (up to 80%); follows hemorrhage or trauma, including COVID-19-related hemorrhage Not required Mete et al. 2022
Endothelial (vascular) cyst Single layer of flat endothelium, occasional intraluminal protrusions; often lymphatic Dilated and thrombosed blood or lymphatic vessels CD31, ERG, D2-40 Mete et al. 2022
Epithelial (mesothelial) cyst Flat or cuboidal mesothelial cells without atypia Mesothelial remnants Calretinin, WT1 Mete et al. 2022
Parasitic cyst Clear fluid, single or multiple spaces, fibrocalcific wall with PAS-positive laminated membranes Echinococcus infection PAS stain Mete et al. 2022
  • Pseudocyst and carcinoma. An adrenal pseudocyst can simulate a cystic primary neoplasm or ACC. Cystic change also occurs in adenoma, ACC, pheochromocytoma, hemangioma, lymphangioma, angiosarcoma, renal cell carcinoma, teratoma and metastases (Mete et al. 2022).

Metastases and other non-cortical lesions of the adrenal gland

  • Collision tumors. An adrenal collision tumor is two histologically distinct tumors coexisting in the same gland. Most are incidental. The mixed composition makes the CT washout protocol unreliable and can mimic malignancy, and the standard incidentaloma pathway identifies both a functional and a malignant component (Botros and Estafanous 2026).
  • Confirmation of cortical origin. Non-functional adrenal masses require confirmation of adrenal cortical origin because metastases and other non-cortical tumors mimic cortical neoplasms (CAP 2023; Mete et al. 2022).
Lesion Diagnostic features Source
Adenomatoid tumor Mesothelial neoplasm; 39 earlier adrenal cases in the English literature; angiomatoid, cystic and solid patterns infiltrating cortex or medulla, thread-like bridging strands and signet-ring-like cells; AE1/AE3, CK7, D2-40, calretinin and WT1 positive; Ki-67 1%–2% Guan et al. 2021
Schwannoma Fewer than 50 adrenal cases reported; can be FDG-avid on PET/CT and clinically indeterminate Fackelmayer et al. 2023
Hemangioma Thick- and thin-walled vessels with cortical elements at the periphery Toklu et al. 2022

Weiss, modified Weiss and Helsinki score calculator for adrenal cortical neoplasms

Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms

Definition and classification. Paragangliomas are non-epithelial neuroendocrine neoplasms of the adrenal medulla and extra-adrenal paraganglia that secrete mainly catecholamines. They are sympathetic or parasympathetic, and "pheochromocytoma" is reserved for the intra-adrenal paraganglioma, the classical sympathetic form. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), renames cauda equina paraganglioma as cauda equina neuroendocrine tumor and gangliocytic paraganglioma as composite gangliocytoma/neuroma and neuroendocrine tumor (CoGNET), and it includes the AJCC 8th edition staging of pheochromocytoma and extra-adrenal sympathetic paraganglioma (Mete et al. 2022). Previous rule (4th edition, 2017): the chapter on the adrenal medulla and extra-adrenal paraganglia comprised pheochromocytoma, head and neck and sympathetic paraganglioma, neuroblastic tumors (newly included), composite pheochromocytoma and composite paraganglioma (in separate sections), and "metastatic pheochromocytoma/paraganglioma" replaced "malignant pheochromocytoma/paraganglioma" (Lam 2017). The CAP Paraganglioma and Pheochromocytoma protocol, version 1.0.0.0, is a new protocol posted in March 2025 and required for accreditation from December 2025. It covers pheochromocytoma, extra-adrenal paragangliomas of all sites and composite tumors, and excludes neuroblastic tumors, peripheral nerve sheath tumors and cauda equina neuroendocrine tumor (CAP 2025a).

Related page: Pheochromocytoma, Metastases and Lymphoma in Adrenal FNA (pheochromocytoma and neuroblastic tumors on FNA, biopsy hazards and sustentacular cell immunostains) Related page: Paraganglioma and Granular Cell Tumor on Head and Neck FNA (head and neck paraganglioma classification, genetics and cytology) Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (plasma and urine metanephrines, 3-methoxytyramine, and urine VMA and HVA in neuroblastoma) Related page: Adrenal Cortex Pathology: Hyperplasia and Nodular Disease, Adrenalitis and Hemorrhage, Adrenal Cortical Adenoma and Carcinoma, Myelolipoma, Cysts and Metastases (adrenal cortex, ectopic adrenal tissue and adrenal metastases) Related page: Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes (MEN2, MEN4 and MEN5 syndrome definitions) Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (SDH-deficient and VHL-associated renal cell carcinoma) Related page: Pancreatic Neuroendocrine Neoplasms: Neuroendocrine Tumors, Functioning Syndromes, Neuroendocrine Carcinoma, Hereditary Syndromes and Staging (pancreatic G3 NET versus NEC: RB, p53, ATRX, DAXX and menin) Related page: High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging (International Medullary Thyroid Carcinoma Grading System) Related page: Pituitary and Sellar Region Pathology: Pituitary Neuroendocrine Tumors, Hypophysitis, Craniopharyngioma, Rathke Cleft Cyst and Posterior Pituitary Tumors (pituitary neuroendocrine tumor lineages) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (digestive neuroendocrine neoplasms in the WHO 6th edition, CoGNET and SDH-deficient GIST) Related page: Pediatric, Mesenchymal and Other Renal Tumors, Nephrectomy Grossing, WHO/ISUP Grading and Kidney Cancer Staging (Wilms tumor and other pediatric renal tumors in the differential of neuroblastoma)

Adrenal medulla and adrenal medullary hyperplasia

  • Normal medulla. Chromaffin cells derive from neural crest cells that migrate into the developing adrenal and coalesce after birth (Xing et al. 2015). Adrenal glucocorticoids induce phenylethanolamine N-methyltransferase (PNMT), so epinephrine is the dominant catecholamine of the postnatal medulla (Xing et al. 2015). The medulla is normally present only in the head and body of the gland, with minimal extension into the alae and none in the tail (CAP 2025a).
  • Adrenal medullary hyperplasia. Diffuse, non-nodular expansion of the medulla to more than one third of the gland thickness, or medulla in an abnormal location such as the tail, is adrenal medullary hyperplasia. It is a precursor of inherited pheochromocytoma with pathogenic RET (most common), MAX, TMEM127 and NF1 variants. The non-tumorous gland is submitted entirely, and its status is a required element for every adrenalectomy (CAP 2025a).
  • Micro-pheochromocytoma. Any distinct nodular chromaffin proliferation in the medulla, whatever its size, is a micro-pheochromocytoma (CAP 2025a). In MEN2A, intra-adrenal adrenaline-producing nodules smaller than 1 cm were formerly called adrenomedullary hyperplasia and are now recognized as micro-pheochromocytomas because they share the molecular alterations of the main tumor (Kimura 2026).
  • Cortical hyperplasia from ectopic hormone. Diffuse compact cell cortical hyperplasia beside a pheochromocytoma raises the possibility of ectopic ACTH or CRH production by the tumor (CAP 2025a).

Pheochromocytoma and paraganglioma: clinical features and morphology

  • Incidence and heredity. Pheochromocytoma and paraganglioma (PPGL) occur in about 1–2 per 100,000 people per year (Casey and Lussey-Lepoutre 2026). At least 40% of adult PPGLs are hereditary, caused by germline variants of at least 23 genes (CAP 2025a).
  • Function. Pheochromocytomas and most sympathetic paragangliomas cause symptoms of catecholamine excess, while only a small proportion of parasympathetic paragangliomas are symptomatic. Functional status is defined biochemically by the O-methylated metabolites metanephrine, normetanephrine and 3-methoxytyramine (CAP 2025a).
  • Architecture. The basic pattern resembles the adrenal medulla: nests (zellballen) of chief cells surrounded by S100-positive sustentacular cells and a rich vascular network (Kimura 2026).
  • Genotype–phenotype morphology. VHL-related tumors often have a thick vascular capsule, hyalinized vascular and myxoid stroma, small round cells among small vessels, clear or amphophilic cytoplasm and no hyaline globules. SDHx-related tumors show cytoplasmic vacuoles or oncocytic change. Expanded large confluent nests with central comedo necrosis occur in a subset of metastatic tumors (CAP 2025a).
  • Pigmented tumors. Abundant cytoplasmic neuromelanin produces the rare "black" PPGL, seen in dopamine-producing tumors (Kimura 2026).
Feature Sympathetic tumors (pheochromocytoma and thoracoabdominal paraganglioma) Parasympathetic tumors (most head and neck paragangliomas) Source
Sites Adrenal medulla; extra-adrenal sympathetic paraganglia of the thorax, abdomen and pelvis Carotid body, jugulotympanic, vagal, laryngeal and aorticopulmonary paraganglia Kimura 2026; Casey and Lussey-Lepoutre 2026
Secretion Norepinephrine, epinephrine or dopamine; RET-, NF1-, TMEM127- and MAX-related tumors are associated with epinephrine production Usually non-secretory or dopamine only; acetylcholine causes no syndrome Casey and Lussey-Lepoutre 2026; Kimura 2026; CAP 2025a
Cytology Polygonal chromaffin cells with amphophilic to basophilic cytoplasm Chief cells with clearer cytoplasm CAP 2025a
Catecholamine enzymes Tyrosine hydroxylase and dopamine β-hydroxylase positive Tyrosine hydroxylase and chromogranin A absent to reduced; choline acetyltransferase positive CAP 2025a; Kimura 2026
Typical germline association SDHB (extra-adrenal sympathetic), RET, NF1, VHL, MAX, TMEM127 SDHD (multifocal, slowly growing) Casey and Lussey-Lepoutre 2026; CAP 2025a

Immunohistochemistry of pheochromocytoma and paraganglioma

Marker Result Interpretation Source
Keratins (AE1/AE3, low molecular weight) Negative Testing is recommended for every neuroendocrine neoplasm; keratin (K8/K18) expression distinguishes epithelial NET and NEC from PPGL (Bellizzi 2020). CK7, CK20 and CK5/6 are not used for this purpose CAP 2025a; Kimura 2026
Chromogranin A, synaptophysin, INSM1 Positive General neuroendocrine markers; chromogranin A may be reduced in parasympathetic tumors Mete et al. 2022; CAP 2025a
GATA3 Positive Confirms paraganglionic origin in a keratin-negative NEN; also expressed by gonadotroph pituitary tumors CAP 2025a
Tyrosine hydroxylase Positive in most functional tumors Rate-limiting enzyme converting L-tyrosine to L-DOPA; can be negative in non-functional tumors Mete et al. 2022; Kimura 2026
Dopamine β-hydroxylase Positive in norepinephrine-producing cells Positive even in tyrosine hydroxylase-negative sympathetic tumors and well preserved after fixation Mete et al. 2022; Kimura 2026
PNMT Positive in epinephrine-producing tumors Identifies epinephrine synthesis Mete et al. 2022
PHOX2B Positive Supports paraganglionic origin and highlights ganglioneuronal elements of composite tumors CAP 2025a
S100 and SOX10 Sustentacular cell network Not specific for PPGL; reduced network is an adverse risk factor and helps separate multifocal primaries from metastases CAP 2025a
SDHB Global loss of granular cytoplasmic staining SDH deficiency from any SDHx alteration CAP 2025a
SDHA Loss Germline SDHA variant Korpershoek et al. 2011
Alpha-inhibin Positive Pseudohypoxia pathway tumors (SDHx, VHL) and noradrenergic immature secretory phenotype CAP 2025a
CAIX Membranous VHL-related tumors CAP 2025a
FH and 2SC FH loss with 2-succinocysteine positivity FH-related tumors CAP 2025a
Menin Loss MEN1-related tumors CAP 2025a
MAX Nuclear loss MAX-related tumors; experience is conflicting, and gene analysis follows a negative result CAP 2025a; Kimura 2026
ATRX and Ki-67 ATRX loss; Ki-67 often >3% Adverse parameters in risk stratification CAP 2025a
  • Germline testing. Immunohistochemistry raises the possibility of heritable disease, and germline genetic testing is offered to all patients with PPGL (CAP 2025a).
  • SDHB pitfalls. SDHB loss also occurs with SDHC promoter methylation and occasionally with VHL or NF1 mutations, so an SDHB-negative tumor proceeds to gene analysis (Kimura 2026).

Metastatic potential and risk stratification of pheochromocytoma and paraganglioma

  • No benign or malignant categories. Since the 4th edition, paragangliomas have not been classified as benign or malignant because any tumor can metastasize and no feature reliably predicts metastasis. Some tumors are lethal through local invasion of critical structures (Mete et al. 2022). PPGLs are regarded as malignant non-epithelial neuroendocrine neoplasms, and "metastatic paraganglioma or pheochromocytoma" is used for metastatic disease (CAP 2025a).
  • Definition of metastasis. Metastases are paragangliomas in sites where paraganglia do not normally exist. Lymph node and bone are the only reliable sites of unequivocal metastasis. Primary paragangliomas occur in lung, liver, prostate, kidney, bladder, heart and mesentery, so a tumor in lung or liver is not proof of metastasis, especially in a germline carrier with multifocal disease (CAP 2025a; Mete et al. 2022). Metastases tend to lack a sustentacular cell network (CAP 2025a).
  • Scoring systems. The WHO 2022 classification reviews the scoring systems and neither endorses nor discourages their use (Mete et al. 2022). The CAP protocol notes that higher scores can overestimate the risk of metastasis in some subgroups (CAP 2025a).
  • Proliferation. No formal WHO grade exists for PPGL. Ki-67 is counted in hot spots of at least 500 cells by manual count of a printed image or by image analysis, and visual estimation is not acceptable. Mitoses are reported per 2 mm² after counting at least 10 mm² (CAP 2025a). Historically, metastatic PPGLs were described as having Ki-67 >3% but usually <10%; a high Ki-67 index is not rare in metastatic PPGL and does not argue against the diagnosis (Kimura 2026).
  • Clinical and molecular risk factors. Extra-adrenal location, size above 5 cm, local invasion and germline SDHx variants, especially SDHB, increase the risk of metastasis. MAML3 fusions, ATRX mutations with alternative lengthening of telomeres, and TERT activation by promoter mutation, rearrangement or hypermethylation are associated with metastatic disease (Casey and Lussey-Lepoutre 2026).
PASS parameter Points Source
Large nests or diffuse growth 2 Thompson 2002
Focal or confluent necrosis 2 Thompson 2002
High cellularity 2 Thompson 2002
Tumor cell spindling 2 Thompson 2002
Cellular monotony 2 Thompson 2002
Mitoses >3 per 10 high-power fields 2 Thompson 2002
Atypical mitotic figures 2 Thompson 2002
Extension into periadrenal adipose tissue 2 Thompson 2002
Vascular invasion 1 Thompson 2002
Capsular invasion 1 Thompson 2002
Profound nuclear pleomorphism 1 Thompson 2002
Nuclear hyperchromasia 1 Thompson 2002
Interpretation ≥4: potential for aggressive behavior; <4: benign behavior in the original series Thompson 2002
GAPP parameter Finding and points Source
Histologic pattern Zellballen 0; large irregular nests 1; pseudorosettes (even focal) 1 Kimura 2026
Cellularity Low (<150 cells per unit) 0; moderate (150–250) 1; high (>250) 2 Kimura 2026
Comedo-type necrosis Absent 0; present 2 Kimura 2026
Capsular or vascular invasion Absent 0; present 1 Kimura 2026
Ki-67 labeling index <1% 0; 1%–3% 1; >3% 2 Kimura 2026
Catecholamine type Epinephrine type 0; norepinephrine type 1; non-functional 0 Kimura 2026
Grade 0–2 well differentiated; 3–6 moderately differentiated; 7–10 poorly differentiated Kimura et al. 2014
  • PASS performance. PASS was built from 50 histologically benign and 50 malignant adrenal pheochromocytomas (Thompson 2002). Its strength is a high negative predictive value, and its clinical use is limited by interobserver variation (Casey and Lussey-Lepoutre 2026).
  • GAPP performance. In 163 tumors including 40 metastatic tumors, mean GAPP scores were 2.08 in non-metastatic and 5.33 in metastatic tumors. Five-year survival was 100%, 66.8% and 22.4% for well, moderately and poorly differentiated tumors. SDHB was negative in 13 moderately or poorly differentiated tumors, and 10 of the 13 metastasized (Kimura et al. 2014). A modified GAPP adds SDHB immunohistochemistry (Casey and Lussey-Lepoutre 2026).
  • COPPS. The Composite Pheochromocytoma/paraganglioma Prognostic Score combines size >7 cm, necrosis, vascular invasion and loss of S100 and/or SDHB staining. A score of 3 or more predicted metastasis with 100% sensitivity and 95% specificity in the initial series (Casey and Lussey-Lepoutre 2026).

Hereditary pheochromocytoma and paraganglioma

Another 30%–40% of apparently sporadic tumors carry somatic drivers (Casey and Lussey-Lepoutre 2026). Up to 80% of pediatric PPGLs are hereditary (Casey and Lussey-Lepoutre 2026), compared with at least 40% of adult PPGLs (CAP 2025a), and germline testing is recommended for every child (Casey and Lussey-Lepoutre 2026). The SDHx genes account for about half of hereditary paragangliomas (Casey and Lussey-Lepoutre 2026).

Molecular cluster Genes Phenotype Metastatic risk Source
1, pseudohypoxia Tricarboxylic acid cycle: SDHA, SDHB, SDHC, SDHD, SDHAF2, FH, MDH2, DLST, GOT2, SLC25A11; hypoxia signaling: VHL, EGLN1, EGLN2, EPAS1 (HIF2A) HIF stabilization; noradrenergic, sometimes with increased 3-methoxytyramine Moderate to high, highest with SDHB Casey and Lussey-Lepoutre 2026
2, kinase signaling RET, NF1, TMEM127, MAX, HRAS RAS/RAF/MEK/ERK and PI3K/AKT/mTOR activation; adrenergic and/or noradrenergic; often bilateral pheochromocytoma Lower Casey and Lussey-Lepoutre 2026
3, Wnt-altered Somatic CSDE1 mutations and MAML3 fusions Sporadic tumors High Casey and Lussey-Lepoutre 2026
Gene Syndrome and typical tumors Biochemistry and morphology Immunohistochemistry Source
SDHB Mainly extra-adrenal sympathetic paraganglioma; metastatic in 30%–40% Noradrenergic and/or dopaminergic; large tumors with low tissue catecholamine content SDHB loss Casey and Lussey-Lepoutre 2026; CAP 2025a
SDHD Multifocal, slowly growing head and neck paragangliomas; metastatic in about 5% Penetrance after paternal transmission 90%–100%; maternal transmission very rarely causes tumors (genomic imprinting) SDHB loss Casey and Lussey-Lepoutre 2026; Taïeb et al. 2023
SDHAF2 Hereditary paraganglioma Tumors almost exclusively after paternal transmission SDHB loss Hoekstra et al. 2015
SDHA Apparently sporadic paraganglioma or pheochromocytoma Germline variant in at least 3% of apparently sporadic cases SDHA and SDHB loss Korpershoek et al. 2011
SDHC Hereditary paraganglioma SDHB loss also follows SDHC promoter methylation SDHB loss Kimura 2026
VHL von Hippel–Lindau disease Noradrenergic; thick vascular capsule, hyalinized stroma, clear cells, no hyaline globules CAIX membranous, alpha-inhibin positive CAP 2025a; Kimura 2026
RET MEN2; bilateral pheochromocytoma Adrenergic; adrenal medullary hyperplasia and micro-pheochromocytomas; composite tumors Not part of the CAP molecular immunohistochemistry panel CAP 2025a; Kimura 2026
NF1 Neurofibromatosis type 1 Adrenergic; composite pheochromocytoma with ganglioneuroma Neurofibromin lost in tumor cells CAP 2025a; Kimura 2026
TMEM127 Non-syndromic pheochromocytoma Adrenergic; adrenal medullary hyperplasia Not part of the CAP molecular immunohistochemistry panel CAP 2025a
MAX MEN5 (Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes) Mixed adrenergic and noradrenergic; bilateral or multiple pheochromocytomas Nuclear MAX loss in 9 of 13 pheochromocytomas in one series Kimura 2026; CAP 2025a
FH Hereditary leiomyomatosis and renal cell cancer Pseudohypoxia cluster FH loss, 2SC positive CAP 2025a
EPAS1 (HIF2A) Pseudohypoxia cluster; somatic or germline Noradrenergic Not part of the CAP molecular immunohistochemistry panel Casey and Lussey-Lepoutre 2026
  • Associated tumors. Hereditary PPGL syndromes are associated with gastrointestinal stromal tumors, renal cell carcinomas and pituitary neuroendocrine tumors (CAP 2025a). Paragangliomas in unusual sites such as the duodenum and colorectum have shown SDHB loss with confirmed SDHB mutation (Kimura 2026).
  • Multifocality. Multiple pheochromocytomas, a pheochromocytoma with an extra-adrenal paraganglioma, or multifocal extra-adrenal paragangliomas prompt genetic testing and are recorded in the synoptic report (CAP 2025a).

Composite pheochromocytoma and paraganglioma

  • Definition. A composite PPGL combines a typical PPGL with a developmentally related component: ganglioneuroma (mature or maturing), ganglioneuroblastoma (nodular or intermixed), neuroblastoma (undifferentiated, poorly differentiated or differentiating) or malignant peripheral nerve sheath tumor. The 2022 classification proposes a minimum of 5% for each element, which requires thorough sampling (CAP 2025a).
  • Diagnosis. Scattered ganglion-like cells or degenerated neuropil-like stroma do not make a tumor composite. Neuroblastic elements are classified with INPC criteria, and their extent and mitosis-karyorrhexis index can be documented. PHOX2B and S100 or SOX10 highlight ganglioneuronal elements and Schwannian stroma (CAP 2025a).
  • Genetics. Composite PPGLs occur with pathogenic RET, MAX and NF1 variants (CAP 2025a). Composite pheochromocytoma in NF1 contains ganglioneuroma with many ganglion cells and nerve bundles (Kimura 2026).

Renamed entities and paraganglioma at specific sites

  • Cauda equina neuroendocrine tumor. The tumor formerly called cauda equina paraganglioma is an epithelial neuroendocrine tumor in the 2022 classification and is not reported with the PPGL protocol (Mete et al. 2022; CAP 2025a).
  • CoGNET. Duodenal gangliocytic paraganglioma is renamed composite gangliocytoma/neuroma and neuroendocrine tumor because its neuronal and glial elements are integral and its neuroendocrine component is epithelial. Middle ear and spinal tumors have also been reclassified as epithelial NETs (Rindi et al. 2022; Mete et al. 2022).
  • Head and neck paraganglioma. Head and neck paragangliomas are classified by site as carotid body, jugulotympanic, vagal, laryngeal and aorticopulmonary paragangliomas (Kimura 2026).

Staging and reporting of pheochromocytoma and paraganglioma (AJCC 8th edition and CAP 1.0.0.0)

The AJCC 8th edition stages pheochromocytoma and extra-adrenal sympathetic paraganglioma by size, location and invasion of the primary tumor, regional nodes and the site of distant metastasis. Bone-only metastasis carries longer survival than lung or liver metastasis. No TNM classification exists for parasympathetic and composite tumors, and the CAP authors encourage applying the same template for uniform data collection (CAP 2025a).

Category Definition Source
T1 Pheochromocytoma <5 cm, no extra-adrenal invasion CAP 2025a
T2 Pheochromocytoma ≥5 cm, or sympathetic paraganglioma of any size, no extra-adrenal invasion CAP 2025a
T3 Tumor of any size invading surrounding organs or tissues (liver, pancreas, spleen, kidneys) CAP 2025a
N1 Regional lymph node metastasis CAP 2025a
M1a / M1b / M1c Bone only / distant lymph nodes, liver or lung only / bone plus multiple other sites CAP 2025a
Stage 1 T1 N0 M0 CAP 2025a
Stage 2 T2 N0 M0 CAP 2025a
Stage 3 T1–T2 N1 M0, or T3 any N M0 CAP 2025a
Stage 4 Any T, any N, M1 CAP 2025a
CAP 1.0.0.0 element Responses and rules Source
Functional status Metanephrine/adrenaline, normetanephrine/noradrenaline, 3-methoxytyramine/dopamine, non-functional or not tested CAP 2025a
Tumor number, location and size Unifocal or multifocal; intra-adrenal or extra-adrenal site; size of the dominant and second tumors CAP 2025a
Histologic type Paraganglioma; pheochromocytoma; micro-pheochromocytoma; composite paraganglioma or pheochromocytoma with the composite element named CAP 2025a
Necrosis, angioinvasion and lymphatic invasion Each reported separately; angioinvasion requires tumor through a vessel wall with tumor–thrombus complex or intravascular tumor admixed with thrombus; CD61 highlights platelets CAP 2025a
Tumor extent Confined; adrenal capsule invasion; peri-adrenal or peritumoral soft tissue; adjacent organs CAP 2025a
Proliferation Ki-67 percentage with manual or image analysis method (required); mitoses per 2 mm² (optional) CAP 2025a
Additional findings Adrenal medullary hyperplasia present or absent, required for every adrenalectomy CAP 2025a
Special studies (optional) Keratins, chromogranin A, tyrosine hydroxylase, GATA3, sustentacular network, SDHB, alpha-inhibin, CAIX, FH, 2SC, ATRX CAP 2025a

Neuroblastic tumors: neuroblastoma, ganglioneuroblastoma and ganglioneuroma

  • Sites and presentation. More than 70% of neuroblastomas arise in the abdomen, in the adrenal gland or paravertebral sympathetic chain, and the posterior mediastinum is the second most common site. Cervical tumors may cause Horner syndrome, and any neuroblastoma can extend through the spinal foramina as a dumbbell mass (CAP 2025b). About 90% take up MIBG (CAP 2025b).
  • Paraneoplastic syndromes. Opsoclonus-myoclonus ataxia syndrome occurs with 2%–4% of neuroblastic tumors, and these tumors nearly always contain extensive lymphoid infiltrates with follicles. VIP-secreting tumors cause watery diarrhea and are usually differentiating neuroblastoma or ganglioneuroblastoma with a better prognosis. ROHHAD syndrome is usually associated with ganglioneuroma (CAP 2025b).
  • Urinary catecholamines. VMA and HVA are increased and support the diagnosis, but they are no longer part of the International Neuroblastoma Response Criteria (CAP 2025b).
INPC category Schwannian stroma and composition Source
Neuroblastoma (Schwannian stroma-poor) Neuroblastic nests separated by delicate septa; Schwannian stroma <50% CAP 2025b; Shimada et al. 1999
Ganglioneuroblastoma, intermixed (Schwannian stroma-rich) Ganglioneuromatous component >50% with randomly distributed microscopic nests of neuroblasts in various stages of differentiation within neuropil; no macroscopic hemorrhagic nodules CAP 2025b
Ganglioneuroma (Schwannian stroma-dominant), maturing or mature Schwannian stroma with individual or clustered maturing and mature ganglion cells; no neuroblasts with naked neuritic processes CAP 2025b
Ganglioneuroblastoma, nodular (composite) One or more grossly visible, often hemorrhagic neuroblastoma nodules in a ganglioneuroblastoma, intermixed, or ganglioneuroma background CAP 2025b
Neuroblastoma subtype Definition Source
Undifferentiated No neuropil and no differentiation; diagnosis relies on immunohistochemistry or molecular studies; may show a starry-sky pattern CAP 2025b
Poorly differentiated Neuropil present; <5% of cells are differentiating neuroblasts CAP 2025b
Differentiating >5% differentiating neuroblasts (enlarged vesicular nucleus with a single prominent nucleolus and eosinophilic or amphophilic cytoplasm twice the nuclear diameter) CAP 2025b
Mitosis-karyorrhexis index (MKI) Mitotic and karyorrhectic cells per 5000 neuroblastic cells Source
Low <100 (<2%) CAP 2025b
Intermediate 100–200 (2%–4%) CAP 2025b
High >200 (>4%) CAP 2025b
Age Favorable histology Unfavorable histology Source
Any age Ganglioneuroma; ganglioneuroblastoma, intermixed Undifferentiated neuroblastoma (any MKI); any neuroblastoma with high MKI CAP 2025b
<18 months Poorly differentiated or differentiating neuroblastoma with low or intermediate MKI Undifferentiated or high MKI CAP 2025b
18 months to <5 years Differentiating neuroblastoma with low MKI Poorly differentiated neuroblastoma (any MKI); differentiating neuroblastoma with intermediate or high MKI CAP 2025b
≥5 years None among neuroblastomas Neuroblastoma of any subtype and any MKI CAP 2025b
Nodular ganglioneuroblastoma Nodule meets favorable criteria for age Nodule meets unfavorable criteria for age; the least favorable nodule decides CAP 2025b
  • Basis of INPC. The International Neuroblastoma Pathology Classification is an age-linked system modeled on the Shimada classification, using neuroblast differentiation, MKI and Schwannian stroma (Shimada et al. 1999). The original INPC classified all nodular ganglioneuroblastomas as unfavorable, and the 2003 revision divides them into favorable and unfavorable subsets by grading the nodules (CAP 2025b).
  • Treated tumors. INPC does not apply after chemotherapy. Treated tumors show maturation toward ganglioneuroma, necrosis with hemorrhage, calcification and fibrosis, or no effect. Once assigned before treatment, the favorable or unfavorable designation never changes (CAP 2025b).
  • Sampling. At least one section per centimeter is taken, every nodule and hemorrhagic focus is sampled, and at least 1 g of viable tumor is kept for MYCN, ploidy and segmental chromosomal studies (CAP 2025b).
  • Immunohistochemistry. PHOX2B is the most sensitive and specific marker of neuroblastoma, though it also stains all peripheral neuroblastic tumors and PPGLs. It separates neuroblastoma from Ewing sarcoma and alveolar rhabdomyosarcoma and detects marrow metastases. PGP9.5, CD56, NB84, synaptophysin and neuron-specific enolase are less specific, Schwann cells express S100, and undifferentiated cells occasionally express vimentin (CAP 2025b).
Molecular finding Significance Source
MYCN amplification (2p) Most prognostically relevant alteration; high risk; undifferentiated or poorly differentiated tumors with high MKI; double minutes or homogeneously staining regions; amplified when MYCN signals exceed chromosome 2 signals at least threefold by FISH (CAP); the INRG consensus uses a >4-fold increase over the 2q reference probe and calls lesser increases 2p24 gain (Ambros et al. 2009) CAP 2025b; Ambros et al. 2009
Genotype–phenotype discordance MYCN-amplified tumors with favorable histology lack active N-myc and bull's-eye nucleoli; non-amplified tumors with unfavorable histology often express C-myc CAP 2025b
Segmental chromosomal aberrations (1p deletion, 11q deletion, 17q gain; 14q deletion) High risk; whole-chromosome changes indicate lower risk CAP 2025b
ALK Kinase-domain mutations in 8%–10% and amplification in about 2%; germline in familial neuroblastoma; ALK immunohistochemistry does not predict mutation CAP 2025b
DNA index Hyperdiploid (near-triploid) tumors favorable; near-diploid or tetraploid unfavorable; effect limited to patients younger than 1 year CAP 2025b
ATRX, TERT ATRX mutations in 2%–3% overall but most high-stage tumors of older children and adolescents; TERT rearrangements in high-risk tumors; MYCN, ATRX and TERT groups barely overlap CAP 2025b
PHOX2B Germline mutations frequent in familial neuroblastoma, rare in sporadic tumors CAP 2025b
  • Staging and risk. The International Neuroblastoma Risk Group Staging System uses pretreatment imaging, age and clinical extent: L1 (localized without image-defined risk factors and confined to one compartment), L2 (locoregional with one or more image-defined risk factors), M (distant metastasis) and MS (metastases confined to skin, liver and/or bone marrow in children younger than 18 months). Pretreatment risk groups combine INRGSS stage, age, histologic category, MYCN status, 11q aberration and ploidy. The pathologist is not required to report stage (CAP 2025b). L1 and L2 are separated by the absence or presence of one or more of 20 image-defined risk factors, and 5-year event-free survival was 90% for L1 versus 78% for L2 in 661 European patients (Monclair et al. 2009).
CAP Neuroblastoma 5.0.0.1 element (resection) Responses Source
Treatment history and age group No preoperative therapy or therapy given; <18 months, 18 months to <5 years, ≥5 years CAP 2025b
Tumor site and size Adrenal or periadrenal, retroperitoneal, thoracic paraspinal, cervical or other CAP 2025b
Histologic type Neuroblastoma; ganglioneuroblastoma, nodular (with number of nodules) or intermixed; ganglioneuroma, maturing or mature; unclassifiable; treated neuroblastic tumor CAP 2025b
Differentiation and MKI Reported for untreated neuroblastic components CAP 2025b
INPC Favorable or unfavorable with the defining combination; not applicable after chemotherapy CAP 2025b
Lymph nodes and distant sites Nodes examined and involved CAP 2025b
MYCN status and molecular studies Required for all tumors except ganglioneuroma and post-therapy resections; segmental chromosomal aberrations and method optional CAP 2025b

Common classification framework for neuroendocrine neoplasms

The IARC–WHO common framework uses "neuroendocrine neoplasm" (NEN) for all neoplasms with predominant neuroendocrine differentiation. Epithelial NENs form two families: well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Paragangliomas, the non-epithelial NENs, form a third family (Rindi et al. 2018). The WHO 2022 endocrine classification consolidates this nomenclature (Rindi et al. 2022).

Family Epithelial Grade Defining features Source
Neuroendocrine tumor (NET) Yes G1, G2 or G3 by mitotic count and Ki-67 at most sites Well differentiated; keratin positive Rindi et al. 2018; Rindi et al. 2022; Kimura 2026
Neuroendocrine carcinoma (NEC) Yes High grade by definition; not formally graded Poorly differentiated; small cell or large cell type; TP53 and RB1 alterations; may be mixed with adenocarcinoma or squamous carcinoma Rindi et al. 2018
Paraganglioma (including pheochromocytoma) No No formal grade Keratin negative; GATA3 and catecholamine enzymes positive; sustentacular cells Rindi et al. 2018; Mete et al. 2022
  • Grading parameters. Mitoses are counted per mm², ideally in up to 10 mm² and expressed per 2 mm² in lung and pancreas. Ki-67 is counted in hot spots of at least 0.4 mm² with a validated antibody (MIB1). Necrosis is recorded as punctate or geographic. Reports state the site-specific WHO term first and the uniform framework term in brackets (Rindi et al. 2018).
  • G3 NET versus NEC. Somatostatin receptor expression and molecular immunohistochemistry separate them (Rindi et al. 2022).
  • Biomarkers. INSM1, synaptophysin, chromogranins and somatostatin receptors confirm neuroendocrine differentiation. Transcription factors identify the site of origin of a metastasis of unknown primary, and hormones, enzymes and keratins support functional and structural correlation. Mixed neuroendocrine–non-neuroendocrine neoplasms (MiNEN) and amphicrine tumors are defined in the 2022 classification (Rindi et al. 2022).
  • Site of origin of metastatic NET. A first-round panel assigns metastatic well-differentiated NETs to presumed midgut origin (CDX2-positive, ISL1- and PAX6-negative) or a pancreatic pattern (ISL1 and/or PAX6 positive), which is also typical of rectal and duodenal NETs. SATB2 is strongly positive in 96% of rectal NETs. OTP is the preferred bronchopulmonary marker and is about twice as sensitive as TTF-1 (30%–40%). ISL1 is also expressed by medullary thyroid carcinoma and PPGL (Bellizzi 2020).
Site Site-specific rule within the framework Source
Lung and thymus Typical carcinoid is NET G1 and atypical carcinoid NET G2; small cell carcinoma and large cell neuroendocrine carcinoma are NECs; G3 atypical carcinoid is not a validated pulmonary entity Rindi et al. 2018
Pancreas NET G1–G3 and NEC; G3 NETs at least as frequent as NECs Rindi et al. 2018
Pituitary Pituitary neuroendocrine tumors are NETs classified by cell lineage; NECs do not occur Rindi et al. 2018
Thyroid C cells Most medullary thyroid carcinomas are well-differentiated NETs; NECs are <1%. The WHO 5th edition grades them with the two-tier International Medullary Thyroid Carcinoma Grading System (High-Grade and Anaplastic Thyroid Carcinoma, Medullary Thyroid Carcinoma, Thyroid Lymphoma, Rare and Metastatic Tumors, and Thyroid Cancer Staging). Previous rule (2018 framework, WHO 2017): no validated grade Rindi et al. 2018; Xu et al. 2022
Parathyroid Adenomas, atypical tumors and carcinomas are parathyroid NETs; NECs are extremely unusual Rindi et al. 2018
Adrenal medulla and paraganglia Paragangliomas; NECs do not occur Rindi et al. 2018
Digestive tract Most high-grade NENs are NECs with TP53 and RB1 mutations Rindi et al. 2018

Pituitary and Sellar Region Pathology: Pituitary Neuroendocrine Tumors, Hypophysitis, Craniopharyngioma, Rathke Cleft Cyst and Posterior Pituitary Tumors

Definition and classification. The WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition (2022), separates anterior lobe (adenohypophyseal), posterior lobe (neurohypophyseal) and hypothalamic tumors. Anterior lobe tumors are pituitary neuroendocrine tumors (PitNETs; formerly pituitary adenomas), pituitary blastoma and the two types of craniopharyngioma. Routine immunohistochemistry for PIT1, TPIT, SF1, GATA3 and ERα is endorsed, the null cell tumor is reserved for PitNETs without lineage differentiation, and "metastatic PitNET" replaces "pituitary carcinoma" to avoid confusion with neuroendocrine carcinoma (Asa et al. 2022). The pituitary classification first appeared in the 5th edition CNS volume (2021) and was revised in the endocrine volume (2022) (Lopes 2025). Previous rule (4th edition, 2017): pituitary adenomas were classified by adenohypophyseal cell lineage with pituitary transcription factors, the concept of "a hormone-producing pituitary adenoma" was abandoned, null cell adenoma required negativity for transcription factors and hormones, "atypical pituitary adenoma" was no longer recommended, and routine electron microscopy was not required (Mete and Lopes 2017). The CAP Pituitary Neuroendocrine Tumor (PitNET) protocol, version 1.0.0.0, is a new protocol posted in March 2025. It is recommended for clinical care and is not required for accreditation, and no TNM staging exists for sellar tumors (CAP 2025).

Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (prolactin and macroprolactin, GH and IGF-1, Cushing syndrome testing and hypopituitarism) Related page: Intraoperative Smear Cytology of CNS Tumors, Including Meningioma (sellar lesions on intraoperative smears) Related page: Adrenal Cortex Pathology: Hyperplasia and Nodular Disease, Adrenalitis and Hemorrhage, Adrenal Cortical Adenoma and Carcinoma, Myelolipoma, Cysts and Metastases (ACTH-dependent adrenal cortical hyperplasia and adrenal cortical choristoma in corticotroph PitNETs) Related page: Pheochromocytoma, Paraganglioma, Hereditary Paraganglioma Syndromes, Neuroblastic Tumors and the Classification of Neuroendocrine Neoplasms (MAX-related MEN5 and the common classification framework for neuroendocrine neoplasms) Related page: Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes (MEN1 and MEN4) Related page: Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts (IgG4-related disease tissue thresholds)

Normal pituitary: anatomy, histology and transcription factor lineages

  • Adenohypophysis. Hormone-producing cells form acini outlined by an intact reticulin network. Folliculostellate cells are GFAP- and S100-positive sustentacular cells that surround the acini (Hacioglu et al. 2025).
  • Neurohypophysis. Pituicytes of the posterior lobe include major, dark, oncocytic, granular and ependymal types on electron microscopy, and they are the proposed normal counterpart of TTF-1-positive posterior pituitary tumors (Roncaroli and Giannini 2025).
  • Vascular vulnerability. The location of hormone-secreting cells relative to the vasculature explains why GH and prolactin secretion are lost first after ischemic necrosis, followed by FSH and LH, and then TSH and ACTH (Karaca et al. 2016).
Transcription factor lineage Cell types Hormones Cofactors Source
PIT1 Somatotroph, lactotroph, thyrotroph GH, prolactin, TSH ERα in lactotrophs (predicts dopamine agonist sensitivity); GATA3 in thyrotrophs CAP 2025; Pandit et al. 2026
TPIT Corticotroph ACTH (PAS-positive) None CAP 2025
SF1 Gonadotroph FSH, LH, alpha-subunit GATA3 and ERα CAP 2025

Pituitary neuroendocrine tumors: WHO 2022 types and subtypes

Lineage PitNET type or subtype (2022) Defining immunoprofile 2017 category Source
PIT1 Densely granulated somatotroph tumor PIT1, diffuse strong GH, alpha-subunit, perinuclear keratin Densely granulated somatotroph adenoma CAP 2025; Nasi-Kordhishti et al. 2025
PIT1 Sparsely granulated somatotroph tumor PIT1, weak GH, fibrous bodies in >70% of cells Sparsely granulated somatotroph adenoma CAP 2025; Nasi-Kordhishti et al. 2025
PIT1 Densely and sparsely granulated lactotroph tumors PIT1, ERα, prolactin Densely and sparsely granulated lactotroph adenoma CAP 2025; Nasi-Kordhishti et al. 2025
PIT1 Mammosomatotroph tumor (distinct type) PIT1, ERα, diffuse GH, less extensive prolactin, alpha-subunit, perinuclear keratin Subtype of somatotroph adenoma CAP 2025; Asa et al. 2022; Nasi-Kordhishti et al. 2025
PIT1 Mixed somatotroph and lactotroph tumor Each component subtyped Subtype of somatotroph adenoma CAP 2025; Nasi-Kordhishti et al. 2025
PIT1 Acidophil stem cell tumor (distinct type) PIT1, ERα, prolactin, weak GH, rare fibrous bodies, focal alpha-subunit Subtype of lactotroph adenoma CAP 2025; Asa et al. 2022; Nasi-Kordhishti et al. 2025
PIT1 Thyrotroph tumor PIT1, GATA3, TSH, alpha-subunit Thyrotroph adenoma CAP 2025
PIT1 Mature plurihormonal PIT1-lineage tumor PIT1, ERα, GATA3, diffuse GH, variable prolactin, TSH and alpha-subunit, perinuclear keratin Plurihormonal PIT1-positive adenoma CAP 2025; Asa et al. 2022
PIT1 Immature PIT1-lineage tumor Diffuse PIT1 with focal or patchy ER, GATA3, GH, prolactin, TSH and alpha-subunit Plurihormonal PIT1-positive adenoma (formerly silent subtype 3) CAP 2025; Asa et al. 2022
TPIT Densely granulated corticotroph tumor TPIT, diffuse strong PAS and ACTH, diffuse cytoplasmic keratin Densely granulated corticotroph adenoma CAP 2025; Nasi-Kordhishti et al. 2025
TPIT Sparsely granulated corticotroph tumor TPIT, weak and focal PAS and ACTH, diffuse cytoplasmic keratin Sparsely granulated corticotroph adenoma CAP 2025; Nasi-Kordhishti et al. 2025
TPIT Crooke cell tumor TPIT, peripheral and perinuclear PAS and ACTH, ring-like keratin Crooke cell adenoma CAP 2025; Nasi-Kordhishti et al. 2025
SF1 Gonadotroph tumor SF1, GATA3, ERα, FSH, LH, alpha-subunit Gonadotroph adenoma CAP 2025
None Null cell tumor No transcription factor or hormone; diagnosis of exclusion Null cell adenoma CAP 2025; Mete and Lopes 2017
Multiple Multilineage PitNET (plurihormonal tumor) Multiple lineages in one cell population Plurihormonal adenoma or adenoma with unusual immunohistochemical combination CAP 2025; Nasi-Kordhishti et al. 2025
  • Multiple synchronous PitNETs. About 1% of patients have two or more synchronous PitNETs, usually in one specimen. An unusual immunoprofile can reflect two discrete tumors, and each is subtyped separately (CAP 2025; Asa et al. 2022).
  • Silent corticotroph tumors. Biochemically non-functional densely and sparsely granulated corticotroph tumors were called silent corticotroph tumors types I and II. "Silent" is used only as a clinical designation (CAP 2025).
  • Shift from hormone-based classification. In 921 tumors, 35.3% were PIT1-positive, 11.9% TPIT-positive and 51.8% SF1-positive, and 0.7% lacked every transcription factor, ERα and GATA3. SF1 reclassified 377 of 397 (95%) 2004 null cell adenomas as gonadotroph tumors. Applying the 2022 criteria changed the overall distribution little; the main change was the division of plurihormonal PIT1-positive tumors into mature (11) and immature (6) types (Nasi-Kordhishti et al. 2025).
  • Keratin patterns. Low-molecular-weight keratin (CAM5.2 or CK18) is required for PIT1-lineage, TPIT-lineage and null cell tumors. Sparsely granulated somatotroph tumors are defined by fibrous bodies (CAP 2025).
  • Null cell tumor. A null cell tumor is diagnosed only after excluding other neuroendocrine neoplasms, including keratin-negative sellar paraganglioma and metastatic neuroendocrine neoplasms (CAP 2025).
  • p27 in corticotroph tumors. Glucocorticoid excess suppresses p27, so loss of nuclear p27 reflects a functioning corticotroph tumor, and clinically silent corticotroph tumors usually retain p27 (CAP 2025).
  • Molecular correlates. GNAS gain-of-function mutations are found in up to 40% of somatotroph tumors, mainly densely granulated tumors, which are smaller and respond better to somatostatin analogs. Sparsely granulated somatotroph tumors express less SSTR2 and respond poorly to first-generation somatostatin analogs. Germline AIP variants are linked to large, aggressive sparsely granulated somatotroph tumors in young patients (Pandit et al. 2026). USP8 mutations underlie densely granulated corticotroph tumors, and MEN1 mutations are not cell-type specific (Rindi et al. 2018).
  • Outcome by lineage. After complete resection, recurrence-free survival was 98.3% at 5 years and 89.9% at 10 years. Corticotroph tumors had the highest 10-year recurrence risk (38.3%) (Nasi-Kordhishti et al. 2025).

High-risk, aggressive and metastatic pituitary neuroendocrine tumors

Concept WHO 2022 Previous rule Source
High-risk subtypes Sparsely granulated somatotroph, lactotroph tumor in men, silent corticotroph, Crooke cell, immature PIT1-lineage and acidophil stem cell tumors 2017: sparsely granulated somatotroph adenoma, lactotroph adenoma in men, Crooke cell adenoma, silent corticotroph adenoma and plurihormonal PIT1-positive adenoma (silent subtype 3) Nasi-Kordhishti et al. 2025; Pandit et al. 2026; Casar-Borota et al. 2025; Mete and Lopes 2017
Proliferation-based category No grade; mitotic count and Ki-67 documented without cut-offs 2004: "atypical adenoma" (Ki-67 ≥3%, extensive p53, increased mitoses), abandoned in 2017 for low predictive value Casar-Borota et al. 2025; Nasi-Kordhishti et al. 2025; Mete and Lopes 2017
Tumor with distant spread Metastatic PitNET: metastasis to lymph nodes and distant sites, or discontinuous spread through the central nervous system Pituitary carcinoma Casar-Borota et al. 2025; Asa et al. 2022
p53 immunohistochemistry Removed as a criterion suggestive of aggressiveness Part of the 2004 atypical adenoma definition Casar-Borota et al. 2025; Nasi-Kordhishti et al. 2025
  • Aggressive PitNET. The European Society of Endocrinology defines a clinically aggressive PitNET as a radiologically invasive tumor with unusually rapid growth, or clinically relevant growth or recurrence despite optimal standard therapy (Villa et al. 2025). Functioning corticotroph tumors make up 40%–50% of aggressive tumors, and silent corticotroph and PIT1-lineage tumors are overrepresented among non-functioning ones (Casar-Borota et al. 2025).
  • Proliferation. Ki-67 >10% was found in 41% of aggressive tumors and 61% of carcinomas in the second ESE survey, and in less than 3% of non-aggressive PitNETs. Ki-67 was ≤3% at first surgery in 15% of 150 aggressive and metastatic tumors, so Ki-67 alone does not predict metastasis (Casar-Borota et al. 2025). PitNETs are not graded by Ki-67 or mitoses because cell type is more informative; Ki-67 is counted from a printed image or by image analysis in hot spots of at least 500 cells, and mitoses are reported per 2 mm² (CAP 2025).
  • Molecular findings. TP53 and ATRX mutations occur in aggressive tumors and carcinomas, especially corticotroph tumors (Casar-Borota et al. 2025). ATRX loss and p53 alterations are optional CAP elements (CAP 2025).
  • Invasion. Invasion of the cavernous or sphenoid sinus occurs in up to 40% of resections and is assessed by MRI with the Knosp system. Knosp grades cavernous sinus invasion on coronal MRI against the intracavernous internal carotid artery: 0, medial to the medial tangent; 1, up to the intercarotid line; 2, up to the lateral tangent; 3, lateral to the lateral tangent; 4, complete encasement of the artery. Grades 3 and 4 are invasive. The revised system divides grade 3 into 3A (superior cavernous sinus compartment) and 3B (inferior compartment); in 228 tumors, surgical cure was 56.0% for 3A and 30.0% for 3B, a difference that was not significant (Araujo-Castro et al. 2021). The five-tiered Trouillas classification combines invasion (grade 1 non-invasive, grade 2 invasive) with proliferation (b, at least two of Ki-67 ≥3%, mitoses >2 per 10 high-power fields and >10 strongly p53-positive nuclei per 10 high-power fields); grade 2b tumors had a recurrence or progression rate of 38%–73% across validation cohorts (Villa et al. 2025). Dura, bone, sinus mucosa and brain are the sites of invasion seen in pathology specimens (CAP 2025).
  • Metastatic sites. Metastatic PitNETs spread most often to liver, bone and brain. Discontinuous CNS spread counts as metastasis, and contiguous infiltration of the hypothalamus does not (CAP 2025).
  • ICD-O coding. The 5th edition codes all PitNETs as malignant (8272/3), a choice criticized because most PitNETs behave as benign or borderline tumors (Casar-Borota et al. 2025).
CAP PitNET 1.0.0.0 element Responses and rules Source
Procedure and specimen Transsphenoidal or transcranial resection; fresh or fixed; intact or fragmented; ectopic or teratoma-associated tumors noted CAP 2025
Tumor number Single or multiple; each tumor reported separately (up to 10) CAP 2025
Type and subtype TPIT, PIT1, SF1 lineage, no distinct lineage or NOS, with subtype CAP 2025
Proliferation Ki-67 percentage with method (required); mitoses per 2 mm² (optional) CAP 2025
Histologically confirmed invasion Dura, bone, sinus mucosa or brain CAP 2025
Immunohistochemistry TPIT, PIT1 and SF1 required; ACTH for TPIT tumors; GH, prolactin and β-TSH for PIT1 tumors; low-molecular-weight keratin extent and pattern for PIT1, TPIT and no-lineage tumors; GATA3, ERα, alpha-subunit, FSH, LH, p27, ATRX and p53 optional CAP 2025
Histochemistry (optional) Reticulin (disrupted or expanded acini); PAS CAP 2025
Non-tumorous pituitary Adenohypophysis present; Crooke hyaline change required for corticotroph tumors; hyperplasia; neurohypophysis CAP 2025
Additional findings Hypophysitis, craniopharyngioma, Rathke cleft cyst or acute hemorrhagic necrosis (apoplexy) CAP 2025

Pituitary hyperplasia

  • Reticulin. Hyperplasia expands acini that remain intact on reticulin stain, whereas a PitNET breaks down the acinar architecture (CAP 2025).
  • Lactotroph hyperplasia of pregnancy. Pituitary volume increases by 120%–136% during pregnancy, peaks in the postpartum period and returns to baseline within 6 months of delivery. The enlargement is caused mainly by estrogen-induced lactotroph hyperplasia, with a tenfold rise in prolactin (Donald et al. 2025). Serial MRI of three women showed a first-trimester dip in anterior lobe volume, a rise of about 17.5% to a peak at 34 weeks and a return to baseline about 3 months postpartum, without significant change in the posterior lobe (Picci et al. 2026). Physiologic hyperplasia can compress the optic apparatus: a pituitary 14 mm high caused visual field loss at 34 weeks and measured 11 mm one month after delivery (Peel et al. 2026).
  • Thyrotroph hyperplasia. In longstanding primary hypothyroidism, high TRH induces thyrotroph hyperplasia and also lactotroph hyperplasia with hyperprolactinemia. MRI shows a smooth projection of the midline of the gland (the "nipple sign" or dome-shaped enlargement). On follow-up MRI of 77 patients treated with levothyroxine, the enlargement regressed completely in 55 and partially in 17; persistent enlargement raises the possibility of a coexisting PitNET (Roux et al. 2024).

Pituitary apoplexy and Sheehan syndrome

  • Pituitary apoplexy. Pituitary apoplexy is an acute, potentially fatal syndrome caused by hemorrhage and/or infarction of the pituitary gland. The term was introduced in 1950 to describe sudden deaths with hemorrhagic necrosis of PitNETs at autopsy. Precipitating factors are present in up to 30% of cases and include anticoagulant and antiplatelet drugs, dopamine agonists, GnRH agonist therapy and pregnancy. Visual defects occur in up to 75% and ophthalmoplegia in 50%–70%, and about 70% develop central adrenal insufficiency (corticotropin deficiency) (Iglesias 2024).
  • Sheehan syndrome. Sheehan syndrome is hypopituitarism from necrosis of a pituitary enlarged by pregnancy after massive postpartum hemorrhage. Small sella size, vasospasm and thrombosis predispose, and autoimmunity may contribute to progressive loss. Symptoms range from failure to lactate and fatigue to severe adrenal crisis, usually appear years after delivery, and the syndrome remains an important cause of hypopituitarism in developing countries (Karaca et al. 2016).

Hypophysitis

Hypophysitis is inflammation of the pituitary and/or infundibulum. It is classified as primary or secondary and by location as adenohypophysitis, neurohypophysitis, infundibuloneurohypophysitis or panhypophysitis (Iglesias 2026). Primary hypophysitis is traditionally lymphocytic, granulomatous, necrotizing or IgG4-related, and it often mimics a PitNET and requires histologic confirmation (Turin and Kleinschmidt-DeMasters 2026).

Type Histology Clinical associations Source
Lymphocytic CD4-positive T cells with B cells and plasma cells Prototypical primary type; historically young women in pregnancy or postpartum; biopsied cases mainly lack known risk factors Iglesias 2026; Turin and Kleinschmidt-DeMasters 2026
Granulomatous Granulomas with multinucleated giant cells and variable fibrosis; may contain many IgG4-positive plasma cells Rare; secondary causes excluded first Iglesias 2026; Turin and Kleinschmidt-DeMasters 2026
Xanthomatous Foamy CD68-positive histiocytes, S100 and CD1a negative; preserved reticulin and vascular networks Mimics a neoplasm clinically and radiologically Deodhare et al. 1999
Necrotizing Less histologically uniform than lymphocytic hypophysitis; may contain many IgG4-positive plasma cells Less common than lymphocytic hypophysitis Turin and Kleinschmidt-DeMasters 2026
IgG4-related Dense IgG4-positive plasma cells and storiform fibrosis with lymphoplasmacytic inflammation Autoimmune pancreatitis, salivary or lacrimal enlargement, retroperitoneal fibrosis, pachymeningitis; IgG4-positive cells are also abundant in granulomatosis with polyangiitis Iglesias 2026; Turin and Kleinschmidt-DeMasters 2026
Immune checkpoint inhibitor-related Inflammatory infiltration with gland enlargement after CTLA-4 blockade CTLA-4 inhibitors (ipilimumab, tremelimumab): multiple axes and enlargement; PD-1/PD-L1 inhibitors: isolated ACTH deficiency with little radiologic inflammation Iglesias 2026
Anti-PIT1 hypophysitis Cytotoxic T cells targeting PIT1-expressing cells Thymoma or other malignancy; GH, prolactin and TSH deficiency Iglesias 2026
  • Secondary hypophysitis and mimics. Germ cell tumors, Langerhans cell histiocytosis, metastases, lymphoma, sarcoidosis and tuberculosis enter the differential diagnosis and may require transsphenoidal biopsy (Iglesias 2026).

Rathke cleft cyst and craniopharyngioma

  • Rathke cleft cyst. A true Rathke cleft cyst is lined by ciliated cuboidal or columnar epithelium with occasional goblet cells and squamous metaplasia, and it contains mucoid or serous fluid. A large autopsy series found Rathke cleft cysts in 11.3% of pituitaries (Hacioglu et al. 2025).
  • BRAF VE1 staining of cilia. The BRAF V600E (VE1) antibody cross-reacts with axonemal dyneins and stains cilia, so ciliated Rathke cleft cyst epithelium can stain without a BRAF mutation, and sequencing has not shown BRAF mutations in Rathke cleft cysts. CTNNB1 mutations were found in 77% of craniopharyngiomas, all adamantinomatous, and in none of 10 Rathke cleft cysts (Hacioglu et al. 2025).
  • Genetics of craniopharyngioma. Whole-exome sequencing found CTNNB1 mutations in 11 of 12 adamantinomatous craniopharyngiomas and BRAF V600E in all 3 papillary tumors. Targeted genotyping confirmed BRAF V600E in 95% (36 of 39) of papillary and CTNNB1 mutations in 96% (51 of 53) of adamantinomatous craniopharyngiomas. The mutations are clonal, mutually exclusive and the only recurrent alterations (Brastianos et al. 2014).
Feature Adamantinomatous craniopharyngioma Papillary craniopharyngioma Source
Age Bimodal, 5–14 and 50–74 years; almost all childhood craniopharyngiomas Almost exclusively adults, 40–55 years Meyer et al. 2025
Imaging Lobulated, frequent calcification Spherical, predominantly solid Meyer et al. 2025
Histology Cords, lobules and nodular whorls bordered by palisaded columnar epithelium; anucleate "ghost cells" (wet keratin); cysts with debris, fibrosis and cholesterol; finger-like invasive protrusions Monomorphic sheets of well-differentiated squamous epithelium around fibrovascular cores; may contain ciliated epithelium and PAS-positive goblet cells resembling Rathke cleft cyst Meyer et al. 2025
Driver CTNNB1 (β-catenin) mutation with nuclear β-catenin accumulation BRAF p.V600E Brastianos et al. 2014; Hacioglu et al. 2025
  • Targeted therapy. The BRAF V600E mutation of papillary craniopharyngioma allows treatment with BRAF inhibitors (dabrafenib, vemurafenib) and MEK inhibitors (Meyer et al. 2025).

Posterior pituitary tumors: the pituicyte tumor family

Tumors of the posterior pituitary and infundibulum share nuclear TTF-1 expression and lack chromogranin A, INSM1, pituitary hormones and lineage-restricted pituitary transcription factors. They account for about 0.2% of adult sellar tumors and peak at 50–60 years. The 2022 endocrine classification treats them as one entity with variants, whereas the 2021 CNS classification keeps pituicytoma, spindle cell oncocytoma and granular cell tumor as distinct tumors and omits sellar ependymoma (Roncaroli and Giannini 2025; Asa et al. 2022). Previous rule (4th edition, 2017): pituicytoma, spindle cell oncocytoma, granular cell tumor of the neurohypophysis and sellar ependymoma were a morphologic spectrum of a single TTF-1-expressing entity (Mete and Lopes 2017).

WHO 2022 name Former name Histology and immunohistochemistry Behavior Source
Pituicytoma Pituicytoma Fascicles of bipolar spindle cells; TTF-1, S100 and vimentin positive, GFAP variable Most common tumor of the group Roncaroli and Giannini 2025
Oncocytic pituicytoma Spindle cell oncocytoma Spindle or epithelioid cells with granular eosinophilic cytoplasm from abundant mitochondria; TTF-1, S100, vimentin; hypervascular, hemosiderin on MRI; MAPK alterations including HRAS and BRAF V600E Recurrence or progression in 27%; responses to MAPK inhibitors reported Roncaroli and Giannini 2025
Granular cell pituicytoma Granular cell tumor of the sellar region (neurohypophysis) Sheets of large cells with intensely eosinophilic granular PAS-positive cytoplasm; TTF-1, S100, CD68, alpha-1-antitrypsin, cathepsin B Recurrence or progression in 5% Roncaroli and Giannini 2025
Ependymal pituicytoma Sellar ependymoma Spindled to epithelioid cells with perivascular pseudorosettes, true ependymal rosettes and follicle-like structures; EMA membranous, luminal and paranuclear dot-like Very rare Roncaroli and Giannini 2025; Asa et al. 2022
  • TTF-1 in oncocytic sellar tumors. TTF-1 positivity separates oncocytic pituicytoma from an oncocytic null cell tumor or thyrotroph PitNET (Pandit et al. 2026).
  • Lesions outside the 2022 classification. Primary papillary epithelial tumor of the sella (TTF-1-positive) and sellar atypical teratoid/rhabdoid tumor are not described in the 2022 endocrine classification (Roncaroli and Giannini 2025).

Pituitary blastoma, hypothalamic tumors and other sellar lesions

  • Pituitary blastoma. Pituitary blastoma is a dysontogenetic tumor of infancy, first described in 2008 and strongly suggestive of DICER1 syndrome. In 17 children (median age 11 months, range 2–24), Cushing syndrome was the most frequent presentation (10 patients), 16 tumors were attributed to DICER1 abnormalities, 8 patients died, and extent of resection was associated with survival, whereas Ki-67 index and adjuvant therapy were not (Liu et al. 2021). DICER1 RNase IIIb hotspot mutations distort microRNA processing, PRAME is upregulated about 500-fold, the genome is otherwise quiet, and the methylation profile is distinct from other CNS tumors and pituitary adenomas (Nadaf et al. 2021).
  • Hypothalamic neuronal tumors. Tumors with hypothalamic neuronal differentiation are classified as gangliocytoma (large cells) or neurocytoma (small cells) (Asa et al. 2022).
Sellar lesion Diagnostic points Source
Metastasis to the pituitary Lung (27.7%), breast (18.7%) and renal (14.5%) primaries among 166 reported patients; diabetes insipidus in 41 and hypopituitarism in 55; median survival 9.9 months Yang et al. 2023
Germ cell tumors, Langerhans cell histiocytosis, lymphoma Differential diagnosis of hypophysitis and PitNET; biopsy may be required Iglesias 2026
Craniopharyngioma, germinoma and meningioma The common non-PitNET sellar tumors Roncaroli and Giannini 2025
Hypothalamic hamartoma Developmental lesion attached to the hypothalamus with gelastic seizures, drug-resistant epilepsy, endocrine dysfunction and developmental delay; somatic variants in Sonic hedgehog and primary cilia pathway genes in about half of nonsyndromic cases, with GLI3, OFD1 or PRKACA variants in 7 of 9 resected lesions in one cohort Jacobs and Hildebrand 2025; Sami et al. 2024
Sellar chordoma Arises from notochordal remnants, usually in bone adjacent to or above the sella; about 1% of malignant bone tumors and 0.2% of intracranial tumors; brachyury, EMA and keratin (CK8/18) positive; can coexist with a PitNET as a collision tumor Gao et al. 2025

References

  1. Agaimy A, Witkowski L, Stoehr R, et al. Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations: is the term "thyroblastoma" more appropriate? Virchows Arch. 2020;477(6):787–798. doi:10.1007/s00428-020-02853-1. PMID 32507920
  2. Akerström G, Malmaeus J, Bergström R. Surgical anatomy of human parathyroid glands. Surgery. 1984;95(1):14–21. PMID 6691181
  3. Akirov A, Asa SL, Larouche V, et al. The clinicopathological spectrum of parathyroid carcinoma. Front Endocrinol (Lausanne). 2019;10:731. doi:10.3389/fendo.2019.00731. PMID 31708875
  4. Albright S, Isaacson A, Robinson R. Discrepancies with final diagnosis in head and neck intraoperative frozen section. Head Neck Pathol. 2026;20(1):91. doi:10.1007/s12105-026-01959-3. PMID 42599558
  5. Aloini ME, Manella S, Biondo I, et al. Bilateral adrenal hemorrhage: learning notes from clinical practice and literature review. Front Endocrinol (Lausanne). 2023;14:1233710. doi:10.3389/fendo.2023.1233710. PMID 38027193
  6. Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100(9):1471–1482. doi:10.1038/sj.bjc.6605014. PMID 19401703
  7. Araujo-Castro M, Acitores Cancela A, Vior C, et al. Radiological Knosp, revised-Knosp, and Hardy–Wilson classifications for the prediction of surgical outcomes in the endoscopic endonasal surgery of pituitary adenomas: study of 228 cases. Front Oncol. 2021;11:807040. doi:10.3389/fonc.2021.807040. PMID 35127519
  8. Arcovito G, Franchi A. Thyroid angiosarcoma: a comprehensive review. Semin Diagn Pathol. 2026;43(1):150979. doi:10.1016/j.semdp.2025.150979. PMID 41418536
  9. Asa SL, Mete O, Perry A, et al. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33(1):6–26. doi:10.1007/s12022-022-09703-7. PMID 35291028 (summarizes the WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition; abstract)
  10. Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002;26(12):1612–1619. doi:10.1097/00000478-200212000-00009. PMID 12459628
  11. Bai Y, Kakudo K, Jung CK. Updates in the pathologic classification of thyroid neoplasms: a review of the World Health Organization classification. Endocrinol Metab (Seoul). 2020;35(4):696–715. doi:10.3803/EnM.2020.807. PMID 33261309
  12. Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol. 2022;33(1):27–63. doi:10.1007/s12022-022-09707-3. PMID 35288841
  13. Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol. 2020;96:8–33. doi:10.1016/j.humpath.2019.12.002. PMID 31857137
  14. Bisceglia M, Ludovico O, Di Mattia A, et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol. 2004;12(3):231–243. doi:10.1177/106689690401200304. PMID 15306935
  15. Bishop JA, Sharma R, Westra WH. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol. 2011;42(12):1873–1877. doi:10.1016/j.humpath.2011.02.004. PMID 21663937
  16. Botros MA, Estafanous LA. Adrenal collision tumors: a practical application of the existing evidence. Endocr Pract. 2026. doi:10.1016/j.eprac.2026.10.001. PMID 42906884
  17. Boyraz B, Sadow PM, Asa SL, et al. Cribriform-morular thyroid carcinoma is a distinct thyroid malignancy of uncertain cytogenesis. Endocr Pathol. 2021;32(3):327–335. doi:10.1007/s12022-021-09683-0. PMID 34019236
  18. Bradley KJ, Hobbs MR, Buley ID, et al. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med. 2005;257(1):18–26. doi:10.1111/j.1365-2796.2004.01421.x. PMID 15606373
  19. Brancatella A, Torregrossa L, Viola N, et al. In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features. J Endocrinol Invest. 2023;46(8):1695–1703. doi:10.1007/s40618-023-02044-0. PMID 36840841
  20. Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46(2):161–165. doi:10.1038/ng.2868. PMID 24413733
  21. Camatti J, Santunione AL, Cecchi R, et al. Fatal Waterhouse–Friderichsen syndrome at autopsy: a systematic review and forensic diagnostic framework. Int J Legal Med. 2026. doi:10.1007/s00414-026-03978-9. PMID 42665693
  22. Cameselle-Teijeiro JM, Eloy C, Sobrinho-Simões M. Pitfalls in challenging thyroid tumors: emphasis on differential diagnosis and ancillary biomarkers. Endocr Pathol. 2020;31(3):197–217. doi:10.1007/s12022-020-09638-x. PMID 32632840
  23. Capalbo D, Esposito A, Gaeta V, et al. The multiple faces of autoimmune Addison's disease in children. Front Endocrinol (Lausanne). 2024;15:1411774. doi:10.3389/fendo.2024.1411774. PMID 39351530
  24. Carlsen ED, Davis AR, Cook JR, et al. The distinctive nature of thyroid MALT lymphomas including IRTA1 expression. Am J Surg Pathol. 2023;47(3):370–378. doi:10.1097/PAS.0000000000002005. PMID 36729757
  25. Carney JA, Moore SB, Northcutt RC, et al. Palpation thyroiditis (multifocal granulomatous folliculitis). Am J Clin Pathol. 1975;64(5):639–647. doi:10.1093/ajcp/64.5.639. PMID 1242618
  26. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32(4):676–680. doi:10.1038/ng1048. PMID 12434154
  27. Casar-Borota O, Burman P, Lopes MB. The 2022 WHO classification of tumors of the pituitary gland: an update on aggressive and metastatic pituitary neuroendocrine tumors. Brain Pathol. 2025;35(1):e13302. doi:10.1111/bpa.13302. PMID 39218431
  28. Casey RT, Lussey-Lepoutre C. Paraganglioma and phaeochromocytoma: a review of current guidelines and new diagnostic and therapeutic approaches. Endocr Relat Cancer. 2026;33(10). doi:10.1530/ERC-26-0310. PMID 42820462
  29. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391–397. doi:10.1016/j.autrev.2014.01.007. PMID 24434360
  30. Cavarzere P, Mancioppi V, Battiston R, et al. Primary congenital hypothyroidism: a clinical review. Front Endocrinol (Lausanne). 2025;16:1592655. doi:10.3389/fendo.2025.1592655. PMID 40862110
  31. Chaurasia S, Ganvir R, Pandey RK, et al. Gross changes in adrenal glands in suicidal and sudden death cases: a postmortem study. Cureus. 2023;15(12):e51175. doi:10.7759/cureus.51175. PMID 38283486
  32. Chu YH, Kobrossy B, Schwartz D, et al. Secretory carcinoma of the thyroid: a case report and update of literature. Head Neck Pathol. 2024;18(1):84. doi:10.1007/s12105-024-01693-8. PMID 39306639
  33. Clark JR, Lai P, Hall F, et al. Variables predicting distant metastases in thyroid cancer. Laryngoscope. 2005;115(4):661–667. doi:10.1097/01.mlg.0000161337.46892.e0. PMID 15805877
  34. College of American Pathologists. Protocol for the examination of resection specimens from patients with neuroblastoma, version 5.0.0.1. Posted June 2025. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). Cited as CAP 2025b.
  35. College of American Pathologists. Protocol for the examination of specimens from patients with carcinomas of the thyroid gland, version 4.4.0.0. Posted March 2023. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). Cited as CAP 2023.
  36. Conti L, Vatrano S, Bertero L, et al. Mitochondrial DNA "common deletion" in post-fine needle aspiration infarcted oncocytic thyroid tumors. Hum Pathol. 2017;69:23–30. doi:10.1016/j.humpath.2017.09.004. PMID 28962946
  37. Cracolici V, Ritterhouse LL, Segal JP, et al. Follicular thyroid neoplasms: comparison of clinicopathologic and molecular features of atypical adenomas and follicular thyroid carcinomas. Am J Surg Pathol. 2020;44(7):881–892. doi:10.1097/PAS.0000000000001489. PMID 32282345
  38. Dahlgren M, Khosroshahi A, Nielsen GP, et al. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken). 2010;62(9):1312–1318. doi:10.1002/acr.20215. PMID 20506114
  39. Decmann Á, Perge P, Tóth M, et al. Adrenal myelolipoma: a comprehensive review. Endocrine. 2018;59(1):7–15. doi:10.1007/s12020-017-1473-4. PMID 29164520
  40. Deodhare SS, Bilbao JM, Kovacs K, et al. Xanthomatous hypophysitis: a novel entity of obscure etiology. Endocr Pathol. 1999;10(3):237–241. doi:10.1007/BF02738885. PMID 12114704
  41. Donald DM, Tomkins M, O'Reilly MW, et al. Pituitary disorders in pregnancy. Clin Med (Lond). 2025;25(5):100488. doi:10.1016/j.clinme.2025.100488. PMID 40744144
  42. Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. J Clin Pathol. 2015;68(10):771–787. doi:10.1136/jclinpath-2015-203186. PMID 26163537
  43. Dufour DR, Durkowski C. Sudan IV stain. Its limitations in evaluating parathyroid functional status. Arch Pathol Lab Med. 1982;106(5):224–227. PMID 6176209
  44. Dufour DR, Wilkerson SY. The normal parathyroid revisited: percentage of stromal fat. Hum Pathol. 1982;13(8):717–721. doi:10.1016/s0046-8177(82)80293-1. PMID 7106734
  45. Duregon E, Fassina A, Volante M, et al. The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol. 2013;37(9):1433–1440. doi:10.1097/PAS.0b013e31828d387b. PMID 23774167
  46. Erickson LA, Mete O, Juhlin CC, et al. Overview of the 2022 WHO classification of parathyroid tumors. Endocr Pathol. 2022;33(1):64–89. doi:10.1007/s12022-022-09709-1. PMID 35175514 (summarizes the WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition)
  47. Fackelmayer OJ, Rodriguez ED, Sisk AE Jr, et al. Adrenal schwannoma can be FDG-avid on PET/CT: case report and review of historic institutional pathology. Diagn Pathol. 2023;18(1):112. doi:10.1186/s13000-023-01399-5. PMID 37833805
  48. Falhammar H, Juhlin CC, Barner C, et al. Riedel's thyroiditis: clinical presentation, treatment and outcomes. Endocrine. 2018;60(1):185–192. doi:10.1007/s12020-018-1526-3. PMID 29380231
  49. Farhat NA, Onenerk AM, Krane JF, et al. Primary benign and malignant thyroid neoplasms with signet ring cells: cytologic, histologic, and molecular features. Am J Clin Pathol. 2017;148(3):251–258. doi:10.1093/ajcp/aqx074. PMID 28821194
  50. Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1–G46. doi:10.1530/EJE-18-0608. PMID 30299884
  51. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1–G42. doi:10.1093/ejendo/lvad066. PMID 37318239
  52. Fatourechi MM, Hay ID, McIver B, et al. Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976–2008. Thyroid. 2011;21(7):765–772. doi:10.1089/thy.2010.0453. PMID 21568724
  53. Fatourechi V, Aniszewski JP, Fatourechi GZ, et al. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003;88(5):2100–2105. doi:10.1210/jc.2002-021799. PMID 12727961
  54. Folpe AL, Lloyd RV, Bacchi CE, et al. Spindle epithelial tumor with thymus-like differentiation: a morphologic, immunohistochemical, and molecular genetic study of 11 cases. Am J Surg Pathol. 2009;33(8):1179–1186. doi:10.1097/PAS.0b013e31819e61c8. PMID 19417583
  55. Fuchs TL, Bell SE, Chou A, et al. Revisiting the significance of prominent C cells in the thyroid. Endocr Pathol. 2019;30(2):113–117. doi:10.1007/s12022-019-9567-6. PMID 30694510
  56. Ganly I, Makarov V, Deraje S, et al. Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes. Cancer Cell. 2018;34(2):256–270.e5. doi:10.1016/j.ccell.2018.07.002. PMID 30107176
  57. Gao S, Liu P, Yang S, et al. Case report: collision tumors of the sellar region: pituitary adenoma and chordoma coexist in the sellar region. Front Endocrinol (Lausanne). 2025;16:1605605. doi:10.3389/fendo.2025.1605605. PMID 40600012
  58. Gheorghe AM, Nistor C, Carsote M. Parathyromatosis: the pathogenic background (post-parathyroidectomy seeding or exceptional embryologic remnant) and the importance of a fine clinical index for recurrent primary hyperparathyroidism (a narrative review). J Clin Med. 2025;14(19):6937. doi:10.3390/jcm14196937. PMID 41096017
  59. Ghossein RA, Rosai J, Heffess C. Dyshormonogenetic goiter: a clinicopathologic study of 56 cases. Endocr Pathol. 1997;8(4):283–292. doi:10.1007/BF02739930. PMID 12114789
  60. Gill AJ, Lim G, Cheung VKY, et al. Parafibromin-deficient (HPT-JT type, CDC73 mutated) parathyroid tumors demonstrate distinctive morphologic features. Am J Surg Pathol. 2019;43(1):35–46. doi:10.1097/PAS.0000000000001017. PMID 29324469
  61. Gokozan HN, Scognamiglio T. Advances and updates in parathyroid pathology. Adv Anat Pathol. 2023;30(1):24–33. doi:10.1097/PAP.0000000000000379. PMID 36315270
  62. Gopal RK, Kübler K, Calvo SE, et al. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma. Cancer Cell. 2018;34(2):242–255.e5. doi:10.1016/j.ccell.2018.06.013. PMID 30107175
  63. Graff-Baker A, Roman SA, Thomas DC, et al. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases. Surgery. 2009;146(6):1105–1115. doi:10.1016/j.surg.2009.09.020. PMID 19958938
  64. Grisales J, Sanabria A. Utility of routine frozen section of thyroid nodules classified as follicular neoplasm. Am J Clin Pathol. 2020;153(2):210–220. doi:10.1093/ajcp/aqz152. PMID 31732728
  65. Guan J, Zhao C, Li H, et al. Adenomatoid tumor of the adrenal gland: report of two cases and review of the literature. Front Endocrinol (Lausanne). 2021;12:692553. doi:10.3389/fendo.2021.692553. PMID 34248850
  66. Hacioglu A, Tekiner H, Altinoz MA, et al. Rathke's cleft cyst: from history to molecular genetics. Rev Endocr Metab Disord. 2025;26(2):229–260. doi:10.1007/s11154-025-09949-6. PMID 39939491
  67. Han Q, Xu H. Sclerosing mucoepidermoid carcinoma of the thyroid with eosinophilia: a case report and review of the literature. J Med Case Rep. 2025;19(1):84. doi:10.1186/s13256-025-05096-3. PMID 40022195
  68. Hanaoka D, Shimada S, Miyaoka Y, et al. Presacral myelolipoma mimicking liposarcoma complicated by massive intraoperative hemorrhage: a case report. Surg Case Rep. 2026;12(1):26-452. doi:10.70352/scrj.cr.26-0452. PMID 42996258
  69. Hannan FM, Babinsky VN, Thakker RV. Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol. 2016;57(3):R127–R142. doi:10.1530/JME-16-0124. PMID 27647839
  70. Harach HR. Solid cell nests of the thyroid. J Pathol. 1988;155(3):191–200. doi:10.1002/path.1711550303. PMID 3045277
  71. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.0020. PMID 26462967
  72. Hernandez-Prera JC, Riddle N, Gonzalez RS, et al. Endocrine and neuroendocrine tumors: updates from the 5th edition of the World Health Organization "Blue Book". Arch Pathol Lab Med. 2025;149(12):1114–1135. doi:10.5858/arpa.2024-0315-RA. PMID 40335070
  73. Herndon J, Nadeau AM, Davidge-Pitts CJ, et al. Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine. 2018;62(3):721–728. doi:10.1007/s12020-018-1737-7. PMID 30178435
  74. Hicks DG, LiVolsi VA, Neidich JA, et al. Clonal analysis of solitary follicular nodules in the thyroid. Am J Pathol. 1990;137(3):553–562. PMID 1975986
  75. Hoekstra AS, Devilee P, Bayley JP. Models of parent-of-origin tumorigenesis in hereditary paraganglioma. Semin Cell Dev Biol. 2015;43:117–124. doi:10.1016/j.semcdb.2015.05.011. PMID 26067997
  76. Holm LE, Blomgren H, Löwhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985;312(10):601–604. doi:10.1056/NEJM198503073121001. PMID 3838363
  77. Iacovazzo D, Flanagan SE, Walker E, et al. MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proc Natl Acad Sci U S A. 2018;115(5):1027–1032. doi:10.1073/pnas.1712262115. PMID 29339498
  78. Iglesias P. Immune-mediated hypophysitis: an updated review. J Clin Med. 2026;15(9):3313. doi:10.3390/jcm15093313. PMID 42123046
  79. Iglesias P. Pituitary apoplexy: an updated review. J Clin Med. 2024;13(9):2508. doi:10.3390/jcm13092508. PMID 38731037
  80. Jacobs J, Hildebrand M. New insights to hypothalamic hamartoma syndrome. Epilepsy Behav. 2025;170:110468. doi:10.1016/j.yebeh.2025.110468. PMID 40393150
  81. Juhlin CC, Erickson LA. Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice. Endocr Pathol. 2021;32(1):17–34. doi:10.1007/s12022-020-09656-9. PMID 33269427
  82. Juhlin CC, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. 2023;30(2):e220293. doi:10.1530/ERC-22-0293. PMID 36445235
  83. Juhlin CC, Mete O. Avoiding overdiagnosis of parathyroid carcinoma. Virchows Arch. 2026;488(1):159–171. doi:10.1007/s00428-025-04274-4. PMID 41238829
  84. Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinol Metab (Seoul). 2022;37(5):703–718. doi:10.3803/EnM.2022.1553. PMID 36193717 (summarizes the WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition)
  85. Kakudo K, Bai Y, Liu Z, et al. How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules. Gland Surg. 2018;7(Suppl 1):S8–S18. doi:10.21037/gs.2017.08.02. PMID 30175059
  86. Karaca Z, Laway BA, Dokmetas HS, et al. Sheehan syndrome. Nat Rev Dis Primers. 2016;2:16092. doi:10.1038/nrdp.2016.92. PMID 28004764
  87. Kemp S, Engelen M, Jaspers YRJ. The complex lipidome as a driver of tissue-specific pathology in adrenoleukodystrophy. Mol Neurodegener. 2026;21(1):66. doi:10.1186/s13024-026-00975-9. PMID 42469918
  88. Kemp WL, Koponen MA, Meyers SE. Addison disease: the first presentation of the condition may be at autopsy. Acad Forensic Pathol. 2016;6(2):249–257. doi:10.23907/2016.026. PMID 31239896
  89. Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21(3):405–414. doi:10.1530/ERC-13-0494. PMID 24521857
  90. Kimura N. Double faces of pheochromocytoma and paraganglioma: a review of integrated pathologic diagnosis. Endocr J. 2026;73(7):799–810. doi:10.1507/endocrj.EJ25-0559. PMID 41922199
  91. Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96(9):E1472–E1476. doi:10.1210/jc.2011-1043. PMID 21752896
  92. Laamouri R, Ben Nacef I, Tbini M, et al. Amyloid goiter: a Tunisian case series. F1000Res. 2025;14:324. doi:10.12688/f1000research.162724.2. PMID 41458395
  93. Lam AK. Adrenocortical carcinoma: updates of clinical and pathological features after renewed World Health Organisation classification and pathology staging. Biomedicines. 2021;9(2):175. doi:10.3390/biomedicines9020175. PMID 33578929
  94. Lam AK. Squamous cell carcinoma of thyroid: a unique type of cancer in World Health Organization classification. Endocr Relat Cancer. 2020;27(6):R177–R192. doi:10.1530/ERC-20-0045. PMID 32252028
  95. Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol. 2017;28(3):213–227. doi:10.1007/s12022-017-9484-5. PMID 28477311 (summarizes the WHO Classification of Tumours of Endocrine Organs, 4th edition)
  96. Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol (Oxf). 2002;56(1):95–101. doi:10.1046/j.0300-0664.2001.01435.x. PMID 11849252
  97. Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–1066. doi:10.1172/JCI85271. PMID 26878173
  98. Lee M, Pellegata NS. Multiple endocrine neoplasia type 4. Front Horm Res. 2013;41:63–78. doi:10.1159/000345670. PMID 23652671
  99. Li Y, Inomata K, Nishihara E, et al. IgG4 thyroiditis in the Asian population. Gland Surg. 2020;9(5):1838–1846. doi:10.21037/gs-20-417. PMID 33224859
  100. Li Y, Zhou G, Ozaki T, et al. Distinct histopathological features of Hashimoto's thyroiditis with respect to IgG4-related disease. Mod Pathol. 2012;25(8):1086–1097. doi:10.1038/modpathol.2012.68. PMID 22555173
  101. Liu APY, Kelsey MM, Sabbaghian N, et al. Clinical outcomes and complications of pituitary blastoma. J Clin Endocrinol Metab. 2021;106(2):351–363. doi:10.1210/clinem/dgaa857. PMID 33236116
  102. Liu Y, Huang X, Hu Y, et al. Hyalinizing trabecular tumor of the thyroid: a clinicopathological analysis of four cases and review of the literature. Int J Clin Exp Pathol. 2017;10(7):7616–7626. PMID 31966606
  103. Liu Y, Liu X, Huang M, et al. The clinical consequences of diagnostic delay in sporadic pediatric MEN2B: a case series of 6 children. Eur J Pediatr. 2026;185(5):253. doi:10.1007/s00431-026-06935-1. PMID 41961175
  104. Liu Z, Zhou G, Nakamura M, et al. Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal. Cancer Sci. 2011;102(1):288–294. doi:10.1111/j.1349-7006.2010.01769.x. PMID 21070478
  105. Ljungberg O, Tibblin S. Peroperative fat staining of frozen sections in primary hyperparathyroidism. Am J Pathol. 1979;95(3):633–641. PMID 88183
  106. Lobo M, Johansson E, Kumari S, et al. Resolving thyroid lineage cell trajectories merging into a dual endocrine gland in mammals. Nat Commun. 2026;17(1):6811. doi:10.1038/s41467-026-73385-6. PMID 42185281
  107. Lopes MB. The 5th edition of the WHO classification of pituitary tumors: strengths and limitations. Brain Pathol. 2025;35(1):e13323. doi:10.1111/bpa.13323. PMID 39617421
  108. Mansour Y, Chaltiel L, Cavillon A, et al. Can we improve the diagnosis of invasion in encapsulated follicular-patterned thyroid tumors? Data from a massive international e-learning initiative. Virchows Arch. 2025;487(1):105–116. doi:10.1007/s00428-025-04045-1. PMID 39992439
  109. Martiradonna M, Mazzilli R, Zamponi V, et al. Clinical impact of rare subtypes of parathyroid adenoma: a systematic review. J Pers Med. 2026;16(4):211. doi:10.3390/jpm16040211. PMID 42042578
  110. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study. Endocr Connect. 2019;8(1):1–7. doi:10.1530/EC-18-0494. PMID 30550378
  111. Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–E765. doi:10.1210/jc.2013-3734. PMID 24476079
  112. Mete O, Asa SL, Gill AJ, et al. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33(1):90–114. doi:10.1007/s12022-022-09704-6. PMID 35285002 (summarizes the WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition; abstract)
  113. Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol. 2011;24(12):1545–1552. doi:10.1038/modpathol.2011.119. PMID 21804527
  114. Mete O, Erickson LA, Juhlin CC, et al. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol. 2022;33(1):155–196. doi:10.1007/s12022-022-09710-8. PMID 35288842 (summarizes the WHO Classification of Endocrine and Neuroendocrine Tumours, 5th edition)
  115. Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017;28(3):228–243. doi:10.1007/s12022-017-9498-z. PMID 28766057 (summarizes the WHO Classification of Tumours of Endocrine Organs, 4th edition; abstract)
  116. Meyer S, Shah SN, Dancel-Manning K, et al. A case-based review of adult-onset craniopharyngioma. Front Endocrinol (Lausanne). 2025;16:1527161. doi:10.3389/fendo.2025.1527161. PMID 40444237
  117. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298–303. doi:10.1200/JCO.2008.16.6876. PMID 19047290
  118. Morrison R, Khan J, Galloway P, et al. Use of cortisol and adrenal weight at pediatric postmortem. Fetal Pediatr Pathol. 2017;36(3):246–255. doi:10.1080/15513815.2017.1307475. PMID 28394668
  119. Murray HW. Infectious diseases targeting the adrenal glands: a review. Am J Med. 2026. doi:10.1016/j.amjmed.2026.07.022. PMID 42556495
  120. Nadaf J, de Kock L, Chong AS, et al. Molecular characterization of DICER1-mutated pituitary blastoma. Acta Neuropathol. 2021;141(6):929–944. doi:10.1007/s00401-021-02283-6. PMID 33644822
  121. Namba H, Matsuo K, Fagin JA. Clonal composition of benign and malignant human thyroid tumors. J Clin Invest. 1990;86(1):120–125. doi:10.1172/JCI114673. PMID 1973172
  122. Nasi-Kordhishti I, Hladik M, Kandilaris K, et al. Transcription factor-based classification of pituitary adenomas/PitNETs: a comparative analysis and clinical implications across WHO 2004, 2017 and 2022 in 921 cases. Acta Neuropathol Commun. 2025;13(1):135. doi:10.1186/s40478-025-02050-8. PMID 40579705
  123. Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab. 2011;96(12):E2063–E2071. doi:10.1210/jc.2011-1616. PMID 21956414
  124. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–1029. doi:10.1001/jamaoncol.2016.0386. PMID 27078145
  125. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–2326. doi:10.1210/jc.2002-021907. PMID 12727991
  126. Nikiforova MN, Nikitski AV, Panebianco F, et al. GLIS rearrangement is a genomic hallmark of hyalinizing trabecular tumor of the thyroid gland. Thyroid. 2019;29(2):161–173. doi:10.1089/thy.2018.0791. PMID 30648929
  127. Nilsson M, Mölne J, Jörtsö E, et al. Plasma membrane shedding and colloid vacuoles in hyperactive human thyroid tissue. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;56(2):85–94. doi:10.1007/BF02890006. PMID 2907207
  128. Nixon IJ, Whitcher M, Glick J, et al. Surgical management of metastases to the thyroid gland. Ann Surg Oncol. 2011;18(3):800–804. doi:10.1245/s10434-010-1408-2. PMID 21046263
  129. Nonaka K, Aida J, Takubo K, et al. Correlation between telomere attrition of zona fasciculata and adrenal weight reduction in older men. J Clin Endocrinol Metab. 2020;105(3):dgz214. doi:10.1210/clinem/dgz214. PMID 31745564
  130. Nosé V, Gill A, Teijeiro JMC, et al. Overview of the 2022 WHO classification of familial endocrine tumor syndromes. Endocr Pathol. 2022;33(1):197–227. doi:10.1007/s12022-022-09705-5. PMID 35285003
  131. Noussios G, Anagnostis P, Goulis DG, et al. Ectopic thyroid tissue: anatomical, clinical, and surgical implications of a rare entity. Eur J Endocrinol. 2011;165(3):375–382. doi:10.1530/EJE-11-0461. PMID 21715415
  132. Noussios G, Anagnostis P, Natsis K. Ectopic parathyroid glands and their anatomical, clinical and surgical implications. Exp Clin Endocrinol Diabetes. 2012;120(10):604–610. doi:10.1055/s-0032-1327628. PMID 23174995
  133. Obara T, Fujimoto Y, Aiba M. Stromal fat content of the parathyroid gland. Endocrinol Jpn. 1990;37(6):901–905. doi:10.1507/endocrj1954.37.901. PMID 2101794
  134. Oh HS, Kim SJ, Song E, et al. Modified transverse-vertical gross examination: a better method for the detection of definite capsular invasion in encapsulated follicular-patterned thyroid neoplasms. Endocr Pathol. 2019;30(2):106–112. doi:10.1007/s12022-019-9565-8. PMID 30661168
  135. Orsatti A, De Leo A, Chiarucci F, et al. Multifocal fibrosing thyroiditis: an under-recognized mimicker of papillary thyroid carcinoma. Endocr Pathol. 2022;33(3):335–345. doi:10.1007/s12022-022-09726-0. PMID 35819567
  136. Palumbo VD, Damiano G, Messina M, et al. Tertiary hyperparathyroidism: a review. Clin Ter. 2021;172(3):241–246. doi:10.7417/CT.2021.2322. PMID 33956045
  137. Pandit N, Wehbeh Y, Itani O, et al. Transcription factor-based classification of pituitary neuroendocrine tumors: practical immunohistochemical algorithms, molecular correlates, and diagnostic challenges in the 5th WHO era. Int J Mol Sci. 2026;27(5):2307. doi:10.3390/ijms27052307. PMID 41828530
  138. Papavramidis TS, Chorti A, Pliakos I, et al. Parathyroid cysts: a review of 359 patients reported in the international literature. Medicine (Baltimore). 2018;97(28):e11399. doi:10.1097/MD.0000000000011399. PMID 29995785
  139. Patel S, Bhatt AA. Thyroglossal duct pathology and mimics. Insights Imaging. 2019;10(1):12. doi:10.1186/s13244-019-0694-x. PMID 30725193
  140. Pavlidis ET, Pavlidis TE. A review of primary thyroid lymphoma: molecular factors, diagnosis and management. J Invest Surg. 2019;32(2):137–142. doi:10.1080/08941939.2017.1383536. PMID 29058491
  141. Peel A, Teasdale S, Morton A. Visual loss during pregnancy due to physiological pituitary hyperplasia. Obstet Med. 2026;19(2):133–136. doi:10.1177/1753495X251338154. PMID 40417147
  142. Peng Y, Wang HH. A meta-analysis of comparing fine-needle aspiration and frozen section for evaluating thyroid nodules. Diagn Cytopathol. 2008;36(12):916–920. doi:10.1002/dc.20943. PMID 18855886
  143. Pennanen M, Heiskanen I, Sane T, et al. Helsinki score: a novel model for prediction of metastases in adrenocortical carcinomas. Hum Pathol. 2015;46(3):404–410. doi:10.1016/j.humpath.2014.11.015. PMID 25582500
  144. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2018;68(1):55–63. doi:10.3322/caac.21439. PMID 29092098
  145. Picci G, Arora R, Grotzinger H, et al. Dense sampling for mapping pituitary growth dynamics before, during, and after pregnancy. J Neuroendocrinol. 2026;38(2):e70141. doi:10.1111/jne.70141. PMID 41644106
  146. Piórek A, Płużański A, Kowalski DM, et al. Recent clinical and molecular advances in the management of thymic carcinoids: a comprehensive review. Cancers (Basel). 2025;17(12):1975. doi:10.3390/cancers17121975. PMID 40563625
  147. Pollak MR, Seidman CE, Brown EM. Three inherited disorders of calcium sensing. Medicine (Baltimore). 1996;75(3):115–123. doi:10.1097/00005792-199605000-00001. PMID 8965680
  148. Prajapati S, Hernandez-Prera JC. Putting all the pieces together: clinical, macroscopic and microscopic characteristics of subacute thyroiditis. Head Neck Pathol. 2019;13(2):231–234. doi:10.1007/s12105-018-0890-x. PMID 29427032
  149. Queipo FJ, Panizo A, Yagüe A, et al. Metastatic clear cell renal cell carcinoma to the thyroid gland: a clinico-pathological and immunohistochemical study of 8 cases and review of the literature. Rev Esp Patol. 2019;52(2):81–86. doi:10.1016/j.patol.2018.08.004. PMID 30902382
  150. Reimann JD, Dorfman DM, Nosé V. Carcinoma showing thymus-like differentiation of the thyroid (CASTLE): a comparative study: evidence of thymic differentiation and solid cell nest origin. Am J Surg Pathol. 2006;30(8):994–1001. doi:10.1097/00000478-200608000-00010. PMID 16861971
  151. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–1786. doi:10.1038/s41379-018-0110-y. PMID 30140036
  152. Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115–154. doi:10.1007/s12022-022-09708-2. PMID 35294740 (abstract)
  153. Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35(8):841–985. doi:10.1177/10507256251363120. PMID 40844370
  154. Roncaroli F, Giannini C. Posterior pituitary tumors and other rare entities involving the pituitary gland. Brain Pathol. 2025;35(1):e13307. doi:10.1111/bpa.13307. PMID 39350562
  155. Roux A, Rosso D, Cuboni D, et al. Pituitary hyperplasia due to longstanding primary hypothyroidism: a case report and comprehensive review of the literature. Biomedicines. 2024;12(6):1368. doi:10.3390/biomedicines12061368. PMID 38927575
  156. Rutter MM, Jha P, Schultz KA, et al. DICER1 mutations and differentiated thyroid carcinoma: evidence of a direct association. J Clin Endocrinol Metab. 2016;101(1):1–5. doi:10.1210/jc.2015-2169. PMID 26555935
  157. Sami L, Chipaux M, Ferrand-Sorbets S, et al. Genetic insights into hypothalamic hamartoma: unraveling somatic variants. Neurol Genet. 2024;10(5):e200180. doi:10.1212/NXG.0000000000200180. PMID 39246740
  158. Sande CM, Tondi Resta I, LiVolsi VA. The thyroid pathologist meets therapeutic pharmacology. Endocr Pathol. 2023;34(1):48–56. doi:10.1007/s12022-023-09749-1. PMID 36723855
  159. Seabrook AJ, Harris JE, Velosa SB, et al. Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab. 2021;106(4):1163–1182. doi:10.1210/clinem/dgaa957. PMID 33367756
  160. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86(2):349–363. PMID 10421272
  161. Shimizu M, Hirokawa M, Manabe T, et al. Lithium associated autoimmune thyroiditis. J Clin Pathol. 1997;50(2):172–174. doi:10.1136/jcp.50.2.172. PMID 9155705
  162. Silva LHCD, Pontes LA, Brescia MDG, et al. Prognostic factors and survival in parathyroid carcinoma: a 50-year single-center cohort study. Arch Endocrinol Metab. 2026;70(5):e260080. doi:10.20945/2359-4292-2026-0080. PMID 42485575
  163. Simonds WF, Robbins CM, Agarwal SK, et al. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2004;89(1):96–102. doi:10.1210/jc.2003-030675. PMID 14715834
  164. Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab. 2012;97(2):334–342. doi:10.1210/jc.2011-2576. PMID 22312089
  165. Staniforth JUL, Erdirimanne S, Eslick GD. Thyroid carcinoma in Graves' disease: a meta-analysis. Int J Surg. 2016;27:118–125. doi:10.1016/j.ijsu.2015.11.027. PMID 26626367
  166. Stergianos S, Juhlin CC, Zedenius J, et al. Metastasis to the thyroid gland: characterization and survival of an institutional series spanning 28 years. Eur J Surg Oncol. 2021;47(6):1364–1369. doi:10.1016/j.ejso.2021.02.018. PMID 33642087
  167. Stoupa A, Carré A, Polak M, et al. Genetics of primary congenital hypothyroidism: three decades of discoveries and persisting etiological challenges. Eur Thyroid J. 2025;14(2). doi:10.1530/ETJ-24-0348. PMID 40100854
  168. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13. doi:10.1200/JCO.2017.73.6785. PMID 29072975
  169. Suzuki A, Hirokawa M, Takada N, et al. Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma. Endocr J. 2018;65(12):1171–1175. doi:10.1507/endocrj.EJ18-0282. PMID 30210064
  170. Taïeb D, Wanna GB, Ahmad M, et al. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol. 2023;11(5):345–361. doi:10.1016/S2213-8587(23)00038-4. PMID 37011647
  171. Takeshima K, Li Y, Kakudo K, et al. Proposal of diagnostic criteria for IgG4-related thyroid disease. Endocr J. 2021;68(1):1–6. doi:10.1507/endocrj.EJ20-0557. PMID 33311000
  172. Teixeira Mendes LS, Wotherspoon A. Marginal zone lymphoma: associated autoimmunity and auto-immune disorders. Best Pract Res Clin Haematol. 2017;30(1-2):65–76. doi:10.1016/j.beha.2016.07.006. PMID 28288719
  173. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327
  174. Thompson LD, Herrera HB, Lau SK. A clinicopathologic series of 685 thyroglossal duct remnant cysts. Head Neck Pathol. 2016;10(4):465–474. doi:10.1007/s12105-016-0724-7. PMID 27161104
  175. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551–566. doi:10.1097/00000478-200205000-00002. PMID 11979086
  176. Tognato E, Ceratto S, Enrico G, et al. Neonatal adrenal hemorrhage: a case series. Am J Perinatol. 2020;37(S 02):S57–S60. doi:10.1055/s-0040-1713407. PMID 32898884
  177. Toklu A, Mesa H, Collins K. Incidental adrenal hemangioma clinically suspicious for malignancy: diagnostic considerations and review of the literature. Int J Clin Exp Pathol. 2022;15(11):444–458. PMID 36507066
  178. Toschetti T, Parenti C, Ricci I, et al. Acute suppurative and subacute thyroiditis: from diagnosis to management. J Clin Med. 2025;14(9):3233. doi:10.3390/jcm14093233. PMID 40364264
  179. Turin CG, Kleinschmidt-DeMasters BK. Primary hypophysitis: classification review. J Neuropathol Exp Neurol. 2026;85(3):211–219. doi:10.1093/jnen/nlaf135. PMID 41317043
  180. Tzen CY, Huang YW, Fu YS. Is atypical follicular adenoma of the thyroid a preinvasive malignancy? Hum Pathol. 2003;34(7):666–669. doi:10.1016/s0046-8177(03)00241-7. PMID 12874762
  181. Uccella S, Dottermusch M, Erickson L, et al. Inflammatory and infectious disorders in endocrine pathology. Endocr Pathol. 2023;34(4):406–436. doi:10.1007/s12022-023-09771-3. PMID 37209390
  182. Uljanovs R, Sinkarevs S, Strumfs B, et al. Immunohistochemical profile of parathyroid tumours: a comprehensive review. Int J Mol Sci. 2022;23(13):6981. doi:10.3390/ijms23136981. PMID 35805976
  183. Uludağ M, Aygün N, İşgör A. Main surgical principles and methods in surgical treatment of primary hyperparathyroidism. Sisli Etfal Hastan Tip Bul. 2019;53(4):337–352. doi:10.14744/SEMB.2019.67944. PMID 32377107
  184. van Heerden JA, Hay ID, Goellner JR, et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery. 1992;112(6):1130–1138. PMID 1455315
  185. Villa C, Birtolo MF, Perez-Rivas LG, et al. Grading and staging for pituitary neuroendocrine tumors. Brain Pathol. 2025;35(1):e13299. doi:10.1111/bpa.13299. PMID 39182993
  186. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31(8):1256–1264. doi:10.1097/PAS.0b013e3180309e6a. PMID 17667551
  187. Volante M, Papotti M, Roth J, et al. Mixed medullary-follicular thyroid carcinoma: molecular evidence for a dual origin of tumor components. Am J Pathol. 1999;155(5):1499–1509. doi:10.1016/S0002-9440(10)65465-X. PMID 10550306
  188. Wallace A, Angelos P, Cipriani NA. The controversy of lateral aberrant thyroid and the use of BRAF immunostain. Int J Surg Pathol. 2022;30(2):217–220. doi:10.1177/10668969211033526. PMID 34279125
  189. Wang L, Lu L, Lu ZL, et al. [Etiology and clinical features of primary adrenal insufficiency]. Zhonghua Yi Xue Za Zhi. 2020;100(12):915–921. doi:10.3760/cma.j.cn112137-20191009-02178. PMID 32234166 (English abstract)
  190. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8(3):163–169. doi:10.1097/00000478-198403000-00001. PMID 6703192
  191. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610. doi:10.1089/thy.2014.0335. PMID 25810047
  192. Wieneke JA, Thompson LD, Heffess CS. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol. 2003;27(7):867–881. doi:10.1097/00000478-200307000-00001. PMID 12826878
  193. Williams MD, DeLellis RA, Erickson LA, et al. Pathology data set for reporting parathyroid carcinoma and atypical parathyroid neoplasm: recommendations from the International Collaboration on Cancer Reporting. Hum Pathol. 2021;110:73–82. doi:10.1016/j.humpath.2020.07.008. PMID 32687943
  194. Wong KS, Dong F, Telatar M, et al. Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma: an analysis of clinicopathologic and molecular features and outcome. Thyroid. 2021;31(6):933–940. doi:10.1089/thy.2020.0668. PMID 33143568
  195. Wong KS, Lewis JS Jr, Gottipati S, et al. Utility of birefringent crystal identification by polarized light microscopy in distinguishing thyroid from parathyroid tissue on intraoperative frozen sections. Am J Surg Pathol. 2014;38(9):1212–1219. doi:10.1097/PAS.0000000000000204. PMID 24618617
  196. Xing Y, Lerario AM, Rainey W, et al. Development of adrenal cortex zonation. Endocrinol Metab Clin North Am. 2015;44(2):243–274. doi:10.1016/j.ecl.2015.02.001. PMID 26038200
  197. Xu B, David J, Dogan S, et al. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology. 2022;80(2):322–337. doi:10.1111/his.14550. PMID 34449926. Cited as Xu et al. 2022b.
  198. Xu B, Fuchs TL, Ahmadi S, et al. International Medullary Thyroid Carcinoma Grading System: a validated grading system for medullary thyroid carcinoma. J Clin Oncol. 2022;40(1):96–104. doi:10.1200/JCO.21.01329. PMID 34731032. Cited as Xu et al. 2022a.
  199. Yang K, Begley SL, Lynch D, et al. Pituitary metastases: a case series and scoping review. Pituitary. 2023;26(5):538–550. doi:10.1007/s11102-023-01349-w. PMID 37698666
  200. Ye D, Gan N, Yang Y, et al. Clinical characteristics of nine cases of adrenal tuberculosis and literature review. Int Urol Nephrol. 2026;58(6):2207–2232. doi:10.1007/s11255-025-04897-1. PMID 41214357
  201. Zhu Y, Li Y, Jung CK, et al. Histopathologic assessment of capsular invasion in follicular thyroid neoplasms: an observer variation study. Endocr Pathol. 2020;31(2):132–140. doi:10.1007/s12022-020-09620-7. PMID 32236857